开放存取专题论文评论

# **用于调节效应子功能的Fc工程-改进用于癌症治疗的抗体**

通过 [![](../../../_resources/5995e2b1b6019c61031877ce398aa79f.png)](https://sciprofiles.com/profile/1327767)[刘瑞娜](https://sciprofiles.com/profile/1327767)

1个
葛兰素史克（GlaxoSmithKline）研发部，英国斯蒂文尼奇SG1 2NY
2
英国南安普敦大学医学院，癌症科学系，癌症免疫学中心，抗体和疫苗组，英国SO171BJ
3
英国南安普敦大学医学院，癌症科学，英国癌症研究中心，英国南安普敦SO171BJ
*
应与之联系的作者。
†
这些作者与主要作者的贡献相同。
**抗体** ****2020****，**9**（4），64; https://doi.org/10.3390/antib9040064
**收到：2020年9月2日/修订版：2020年9月28日/接受：2020年11月4日/发布：2020年11月17日**

（本文属于[癌症免疫疗法](https://www.mdpi.com/journal/antibodies/special_issues/Antibody_Engineering_Cancer_Immunotherapy)特刊[抗体工程](https://www.mdpi.com/journal/antibodies/special_issues/Antibody_Engineering_Cancer_Immunotherapy)）

[(L)](https://www.mdpi.com/2073-4468/9/4/64/pdf)[下载PDF](https://www.mdpi.com/2073-4468/9/4/64/pdf) [(L)](https://www.mdpi.com/2073-4468/9/4/64/htm "https://www.mdpi.com/2073-4468/9/4/64/htm#")[浏览图形](https://www.mdpi.com/2073-4468/9/4/64/htm "https://www.mdpi.com/2073-4468/9/4/64/htm#")

## **抽象**

大多数单克隆抗体（mAb）治疗剂具有通过其片段可结晶（Fc）结构域介导的相互作用与先天免疫效应子结合的能力。通过传递Fc-Fcγ受体（FcγR）和Fc-C1q相互作用，mAb能够将精致的特异性与强大的细胞功能和补体介导的效应子功能联系起来。Fc相互作用也可以促进增强的靶标簇，以唤起有效的受体信号传导。这些发现驱动了长达数十年的研究，以描绘Fc中引起这些各种活性，鉴定关键氨基酸残基并阐明糖基化的重要作用的特性。他们还引起了人们对Fc工程的兴趣，因此，利用这些知识来调节Fc效应子的功能以适应特定的作用机制和治疗目的。在这篇综述中，我们记录了通过研究Fc结构域产生的见解；揭示了基础结构与功能的关系，以及如何改造Fc以产生越来越多的抗体，这些抗体在临床上表现出增强的治疗癌症的能力。

**关键字：** [Fc工程](https://www.mdpi.com/search?q=Fc-engineering)；[Fcγ受体](https://www.mdpi.com/search?q=Fc%20gamma%20receptor); [抗体免疫治疗](https://www.mdpi.com/search?q=antibody%20immunotherapy); [互补](https://www.mdpi.com/search?q=complement); [抗体依赖性细胞毒性（ADCC）](https://www.mdpi.com/search?q=antibody-dependent%20cellular%20cytotoxicity%20%28ADCC%29)；[抗体依赖性细胞吞噬作用（ADCP）](https://www.mdpi.com/search?q=antibody-dependent%20cellular%20phagocytosis%20%28ADCP%29)

## **1.简介**

抗体是免疫力的重要组成部分，可预防和控制病原体扩散，同时提供长期保护，防止再次感染。经典地描述为Y形分子，抗体包含两个相同的片段抗原结合（F（ab））臂，这些臂通过铰链连接至可结晶的片段（Fc）域。所述的F（ab）臂提供特异性和介导靶抗原结合，而与Fc促进与免疫效应功能的接合（即，通过与Fc受体和补体系统的相互作用通过结合C1q的细胞免疫）\[ [1](https://www.mdpi.com/2073-4468/9/4/64/htm#B1-antibodies-09-00064)，[2](https://www.mdpi.com/2073-4468/9/4/64/htm#B2-antibodies-09-00064)，[3](https://www.mdpi.com/2073-4468/9/4/64/htm#B3-antibodies-09-00064) \]。Fc还可以通过与FcRn的相互作用来延长循环的半衰期\[ [4](https://www.mdpi.com/2073-4468/9/4/64/htm#B4-antibodies-09-00064)\]。此外，尽管F（ab）结构域可以递送治疗活性，例如通过预防导致感染的病原体：宿主结合事件，但是大多数抗体效应子功能，特别是对于IgG1，是由Fc递送的。

该知识导致在抗体领域的共同努力，以了解Fc的哪些部分调节与免疫效应系统的各个臂的结合以及随后的修饰是否可以递送增强的活性。这篇综述总结了这些努力的进展，并概述了这些努力已经到来或将要发生的地方，并被翻译成用于治疗癌症的临床研究。

随着杂交瘤技术的出现，单克隆抗体（mAb）的发展是抗体作为临床治疗手段发展的核心\[ [5](https://www.mdpi.com/2073-4468/9/4/64/htm#B5-antibodies-09-00064) \]。这一突破使得抗体的生产具有单一特异性，从而促进了通过监管机构的批准用于人类，并实现了结构：均质抗体制备的功能研究以及翻译后修饰（例如糖基化）的分析\[ [6](https://www.mdpi.com/2073-4468/9/4/64/htm#B6-antibodies-09-00064)\]。随后是分子生物学技术的爆炸式增长，此后使抗体分子的操纵达到了前所未有的程度。这些进步共同为随后的Fc工程时代铺平了道路。其中，针对癌症的抗体一直处于最前沿。

如上所述，Fc结构域的主要特性是通过与Fc受体和补体引发剂C1q的相互作用来激发免疫效应子功能。尽管现在有更多的抗体类别进入临床（请参阅本系列的其他文章），但迄今为止，几乎所有已批准的治疗性抗体都是IgG类别，因此我们对抗体效应子功能的当前了解已从他们的研究中发展而来。在下面（[第1.1节](https://www.mdpi.com/2073-4468/9/4/64/htm#sec1dot1-antibodies-09-00064)，[第1.2节](https://www.mdpi.com/2073-4468/9/4/64/htm#sec1dot2-antibodies-09-00064)和[第1.3节](https://www.mdpi.com/2073-4468/9/4/64/htm#sec1dot3-antibodies-09-00064)）中，我们总结了IgG Fc在调节抗体效应子功能和行为中介导的三个关键相互作用。

#### \*1.1。\**FcγR结合导致细胞效应子功能*

IgG分子与Fcγ受体（FcγR）结合。人类具有6个不同的FcγR：hFcγRI，hFcγRIIA，hFcγRIIB，hFcγRIIC，hFcγRIIIA和hFcγRIIIB\[ [1](https://www.mdpi.com/2073-4468/9/4/64/htm#B1-antibodies-09-00064)，[7](https://www.mdpi.com/2073-4468/9/4/64/htm#B7-antibodies-09-00064) \]，其结合的IgG在细胞表面，但具有不同的亲和性。hFcγRI包含三个细胞外免疫球蛋白结构域，并且是唯一能够结合单体IgG的高亲和力FcγR，而另一个FcγR包含两个细胞外免疫球蛋白结构域，并且具有低到中等的亲和力，仅在免疫复合物中或与病原体结合时结合IgG细胞表面。

广义上讲，FcγR在功能上分为两种主要类型：激活和抑制。活化性FcγR（hFcγRI，hFcγRIIA，hFcγRIIC，hFcγRIIIA）包含免疫酪氨酸激活基序（ITAM）或与之相关。在两个人类激活受体（hFcγRIIA和hFcγRIIC）中，ITAM包含在FcγR自身的胞质结构域内，而在其余的激活受体上，它包含在相关的FcRγ链中。在小鼠中，其含有4FcγR的，所有3个活化性FcγR的所需要的FcR的γ链表达和信令\[ [1](https://www.mdpi.com/2073-4468/9/4/64/htm#B1-antibodies-09-00064)，[8](https://www.mdpi.com/2073-4468/9/4/64/htm#B8-antibodies-09-00064)\]。相比之下，FcγRIIB包含免疫酪氨酸抑制基序（ITIM），并且是人和小鼠中唯一的抑制性FcγR。除了这些激活性和抑制性FcγR之外，还有一个GPI连接的hFcγR，它既没有ITAM也没有ITIM基序，即hFcγRIIIB。其功能尚不清楚，据报道，各种支持作用为中性或诱饵受体，调节FcγRIIA介导的中性粒细胞脱粒和ROS产生\[ [9](https://www.mdpi.com/2073-4468/9/4/64/htm#B9-antibodies-09-00064) \]。FcγRI是IgG的高亲和力受体，因此在循环中很大程度上被IgG饱和\[ [10](https://www.mdpi.com/2073-4468/9/4/64/htm#B10-antibodies-09-00064) \]。尽管有证据表明它能够在某些B16小鼠模型中介导抗肿瘤免疫治疗，但仍被认为是免疫治疗中的次要角色\[ [11](https://www.mdpi.com/2073-4468/9/4/64/htm#B11-antibodies-09-00064)\]。因此，相对较少的努力来改造与FcγRI的结合改变的抗体。尽管有hFcγRIIIB，但一般概念是在给定细胞类型（髓样细胞常见）上同时存在激活性FcγR和抑制性FcγR的情况下，整合了IgG与每种表达的FcγR的相对结合以调节细胞应答。在实践中，活化性来抑制或A：Fc和/或FcγR的细胞的表达谱的我FcγR结合比率是随后的细胞活性\[的良好估计[12](https://www.mdpi.com/2073-4468/9/4/64/htm#B12-antibodies-09-00064)，[13](https://www.mdpi.com/2073-4468/9/4/64/htm#B13-antibodies-09-00064)\]，高的A：I比率可提供可靠的响应。关键决定因素之一是抗体同种型，每种同种型提供不同的FcγR结合谱和细胞应答。例如，hIgG1与大多数FcγR和hIgG4的结合力要小得多。FcγR家族及其同种型相互作用已在其他地方进行了广泛的描述\[ [14](https://www.mdpi.com/2073-4468/9/4/64/htm#B14-antibodies-09-00064) \]，因此在本综述中仅强调特定点。

hFcγR的遗传变异也可影响表达和功能\[ [15](https://www.mdpi.com/2073-4468/9/4/64/htm#B15-antibodies-09-00064)，[16](https://www.mdpi.com/2073-4468/9/4/64/htm#B16-antibodies-09-00064) \]。特别是，某些单核苷酸多态性（SNP）影响与IgG的结合。值得注意的是，位置158上的缬氨酸（V）与苯丙氨酸（F）SNP影响FcγRIIIA与IgG1，IgG2和IgG3的结合，从而与F158相比，V158对hIgG1的亲和力增加，从而导致活化增加\[ [4](https://www.mdpi.com/2073-4468/9/4/64/htm#B4-antibodies-09-00064)，[17](https://www.mdpi.com/2073-4468/9/4/64/htm#B17-antibodies-09-00064) \]。同样，在131位的FcγRIIA中，组氨酸（H）与精氨酸（R）SNP会影响与hIgG2的结合（与hIgG1的结合程度较小），与R131相比，H131的结合增加。

FcγR显然具有影响抗癌抗体功效的潜力，尤其是通过激活Fc效应子功能，例如抗体依赖性细胞毒性（ADCC）和抗体依赖性细胞吞噬作用（ADCP）。ADCC被认为主要是由NK细胞介导的\[ [18](https://www.mdpi.com/2073-4468/9/4/64/htm#B18-antibodies-09-00064) \]。NK细胞主要通过单个激活性FcγR（FcγRIIIA）与抗体标记的肿瘤细胞的Fc结合。IgG与FcγRIIIA的结合可以激活NK细胞并刺激含有穿孔素和颗粒酶等分子的裂解颗粒的释放，最终导致靶细胞裂解\[ [19](https://www.mdpi.com/2073-4468/9/4/64/htm#B19-antibodies-09-00064) \]。已显示许多临床相关的抗癌抗体，如利妥昔单抗，赫赛汀和西妥昔单抗在体外可诱发NK介导的ADCC。

ADCP由吞噬细胞（如巨噬细胞，单核细胞和嗜中性粒细胞）介导，并在抗体与相应的活化FcγR相互作用时触发\[ [20](https://www.mdpi.com/2073-4468/9/4/64/htm#B20-antibodies-09-00064) \]。抗CD30抗体SGN-30用于治疗多种血液系统疾病，例如霍奇金病，是可以在体外刺激ADCP的抗癌抗体的一个例子\[ [21](https://www.mdpi.com/2073-4468/9/4/64/htm#B21-antibodies-09-00064) \]。利妥昔单抗和其它抗CD20抗体也已知在体外和在体内在各种动物模型\[引导学生有效的ADCP [22](https://www.mdpi.com/2073-4468/9/4/64/htm#B22-antibodies-09-00064)，[23](https://www.mdpi.com/2073-4468/9/4/64/htm#B23-antibodies-09-00064) \]。在这些系统中，巨噬细胞的去除会去除这些抗体的所有靶标缺失能力，从而突出了这种Fc介导的效应子机制的重要性。

#### \*1.2。\**C1q的参与和互补介导的效应子功能的诱导*

Fc介导的另一个重要相互作用是其与补体第一个成分C1q的结合。一旦足够的Fc分子与C1q的6个球状头部接合，它就会启动血清中补体蛋白的蛋白水解级联反应，从而导致过敏毒素（例如C3a和C5a）的释放以及在靶细胞表面形成膜攻击复合物，能够依赖补体细胞毒性（CDC）\[ [24](https://www.mdpi.com/2073-4468/9/4/64/htm#B24-antibodies-09-00064) \]。最初，通过体外研究证明了CDC在抗癌mAb效应子功能中的重要性，该研究发现肿瘤细胞过表达补体防御分子，例如CD55和CD59。并阻断它们可以增强利妥昔单抗的肿瘤杀伤能力\[ [25](https://www.mdpi.com/2073-4468/9/4/64/htm#B25-antibodies-09-00064)\]。进一步的证据表明CDC在抗癌抗体功效中发挥了作用，其中包括用利妥昔单抗治疗慢性淋巴细胞性白血病（CLL）细胞时补体成分的消耗增加；补体耗尽的CLL患者血清裂解靶细胞的能力降低\[ [26](https://www.mdpi.com/2073-4468/9/4/64/htm#B26-antibodies-09-00064) \]。在人淋巴瘤细胞异种移植实验中，利妥昔单抗在C1q缺陷型小鼠中也无效，表明补体激活是体内肿瘤清除活性所必需的\[ [27](https://www.mdpi.com/2073-4468/9/4/64/htm#B27-antibodies-09-00064) \]。然而，异种移植模型可能无法预测患者补体活性的靶细胞可能是超敏感异种补体\[ [28](https://www.mdpi.com/2073-4468/9/4/64/htm#B28-antibodies-09-00064)，[29](https://www.mdpi.com/2073-4468/9/4/64/htm#B29-antibodies-09-00064)\]。因此，同系模型（例如hCD20转基因小鼠）的实验表明，经过改造而没有补体激活功能的抗CD20抗体具有与野生型（WT）抗CD20抗体相当的B细胞耗竭能力\[ [30](https://www.mdpi.com/2073-4468/9/4/64/htm#B30-antibodies-09-00064) \]。这表明至少在小鼠中不需要补体活性。一致的是，C1q或C3的基因缺失不会明显损害具有各种抗CD20 mAb的hCD20转基因B细胞的缺失\[ [31](https://www.mdpi.com/2073-4468/9/4/64/htm#B31-antibodies-09-00064) \]。临床数据表明，在利妥昔单抗治疗后的滤泡性淋巴瘤（FL）患者中，肿瘤细胞上补体防御分子的表达不能预测临床结果，进一步表明CDC并不是利妥昔单抗治疗后成功清除肿瘤的关键因素\[ [32](https://www.mdpi.com/2073-4468/9/4/64/htm#B32-antibodies-09-00064) \]。

#### \*1.3。\**FcRn相互作用导致长的半衰期*

Fc介导的第三个主要相互作用是与参考文献\[ [4](https://www.mdpi.com/2073-4468/9/4/64/htm#B4-antibodies-09-00064) \]中所述的荆棘受体或新生儿FcR（FcRn）。该受体在结构和功能上与FcγR家族基本不同。在结构上，该受体更类似于主要组织相容性复合物（MHC）的和不包含或与能够信号转导\[的结构域缔[4](https://www.mdpi.com/2073-4468/9/4/64/htm#B4-antibodies-09-00064)，[33](https://www.mdpi.com/2073-4468/9/4/64/htm#B33-antibodies-09-00064) \]。它最初被确定为重要的IgG的运输通过胎盘由母亲传染给胎儿，但是在维持稳态的IgG其更广泛的作用，成立不久\[ [34](https://www.mdpi.com/2073-4468/9/4/64/htm#B34-antibodies-09-00064)，[35](https://www.mdpi.com/2073-4468/9/4/64/htm#B35-antibodies-09-00064)\]。不同于上文所述的直接效应物功能，这种相互作用是负责提供的抗体的半衰期长，这对于IgG的是20天以上在人类和小鼠中9天\[ [36](https://www.mdpi.com/2073-4468/9/4/64/htm#B36-antibodies-09-00064)，[37](https://www.mdpi.com/2073-4468/9/4/64/htm#B37-antibodies-09-00064) \]。血清蛋白（包括IgG）被单核细胞和内皮细胞持续内吞。FcRn能够清除内在的IgG，并将其返回循环。在此过程中，FcRn以pH依赖的方式结合Fc的CH2-CH3接口。IgG的CH2-CH3结构域中的保守组氨酸残基（H310和H435）在细胞内细胞器（如溶酶体）中存在的酸性pH（<pH6.5）下被质子化，从而使FcRn和IgG之间紧密结合并产生保护作用\[ [38](https://www.mdpi.com/2073-4468/9/4/64/htm#B38-antibodies-09-00064)，[39](https://www.mdpi.com/2073-4468/9/4/64/htm#B39-antibodies-09-00064)\]。一旦FcRn：IgG复合物再循环到细胞外环境，中性pH可使IgG重新释放到血流中。占其较长的血清半衰期。此过程的重要性在FcRn缺陷型小鼠中得到了强调，其中mIgG半衰期从9天缩短到1.4天，降低了6倍以上，这一效果可以通过引入人FcRn转基因来克服\[ [36](https://www.mdpi.com/2073-4468/9/4/64/htm#B36-antibodies-09-00064) \]。

上面讨论的所有特性和活性都是通过Fc与详细分子之间的一系列高度进化和微调的分子相互作用来传递的，这些抗体将抗体与免疫系统的强大效应子功能相接，并使其具有较长的半衰期。因此毫不奇怪，已经进行了许多尝试来增强或修改这些交互中的每一个。在随后的表和图中提供了已开发来修饰这些相互作用的抗体变体的摘要。根据变体的功能输出（效应细胞功能，补体介导的，FcγRIIB结合和半衰期延长），以下部分将对变体，其发现和主要意义进行更详细的综述，并在下面进行讨论。此外，

## **2\. Fc工程增强抗体效应细胞功能**

如上所述，FcγR对IgG效应子功能至关重要。因此，已采用Fc工程策略来增加对FcγR的亲和力，以增强Fc效应子功能，例如ADCC和ADCP，从而增加抗癌抗体的功效。这些策略已汇总在[表1中](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t001)，并在下面进行讨论。

****表1.**** 增强细胞效应子功能和FcγR结合的突变。

[(L)](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t001)

**Table 1.** Mutations augmenting cellular effector function and FcγR binding.
![](../../../_resources/a14d2a63f4d98a1990e0d54e35e2eb16.png)

|     |     |     |     |
| --- | --- | --- | --- |
|     | Magnitude of change in effector function (fold change) or binding affinity of variants were compared to WT antibodies of the same IgG isotype and F(ab) region. Each row depicts an independent experiment and often independent methods, utilizing a different IgG backbone from a particular study as referenced in the last column. NB = no detectable binding, n.d. = no data, d.n.s. = data not shown, − = no change, ↑ &lt;2 fold increase, ↑↑ 2–9.99 fold increase, ↑↑↑ 10–99.99 fold increase, ↑↑↑↑ &gt;100 fold increase, ↓↓ 2–9.99 fold decrease. **Fc****γRIIA****H** FcγRIIA-H131, **Fc****γRIIA****R** FcγRIIA-R131, **Fc****γRIIIA****F** FcγRIIIA-F158, **Fc****γRIIIA****V** FcγRIIIA-V158. |     |     |

在过去的2-3年中，已采用技术来确定与FcγR与IgG结合的氨基酸。在2001年的一项开创性研究中，Shields等人。使用丙氨酸扫描诱变\[ [40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064) \]进行高分辨率定位，以确定结合hFcγR和hFcRn所需的hIgG1中的残基（[图1](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f001) A）。hFcγRs的结合位点在hIgG1的下部铰链和CH2近端区域中发现\[ [40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064) \]。这些相互作用中涉及的关键残基随后成为突变研究的重点，并在[图1](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f001) B中突出显示。这些研究为更好地理解IgG分子如何与FcγRs相互作用铺平了道路

**![](../../../_resources/173370e987cefe0f9fe81b9c10a4e777.png)**

****图1.可**** 结晶的（Fc）修饰片段，可增强抗体效应子功能。（****甲****）事件，详细说明用于发现具有增强的效应子细胞功能的变体的技术的时间轴，并且当Fc变体首先描述\[ [40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064)，[41](https://www.mdpi.com/2073-4468/9/4/64/htm#B41-antibodies-09-00064)，[42](https://www.mdpi.com/2073-4468/9/4/64/htm#B42-antibodies-09-00064)，[43](https://www.mdpi.com/2073-4468/9/4/64/htm#B43-antibodies-09-00064)，[44](https://www.mdpi.com/2073-4468/9/4/64/htm#B44-antibodies-09-00064)，[45](https://www.mdpi.com/2073-4468/9/4/64/htm#B45-antibodies-09-00064)，[46](https://www.mdpi.com/2073-4468/9/4/64/htm#B46-antibodies-09-00064)，[47](https://www.mdpi.com/2073-4468/9/4/64/htm#B47-antibodies-09-00064)，[48](https://www.mdpi.com/2073-4468/9/4/64/htm#B48-antibodies-09-00064) \]。字母指的是在正文中讨论的引入的氨基酸取代的通用符号。（****B****）先前在Fc中鉴定的影响效应细胞功能的点突变注释在hIgG1 Fc晶体结构模型上（PDB：3AVE; \[[49](https://www.mdpi.com/2073-4468/9/4/64/htm#B49-antibodies-09-00064)，[50](https://www.mdpi.com/2073-4468/9/4/64/htm#B50-antibodies-09-00064) \]），并在详细[表1](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t001)。

#### \*2.1。\**氨基酸取代增强效应细胞功能*

在上述研究的指导下，众多研究小组随后将氨基酸取代引入抗体的Fc区，以增加A：I结合比，从而增强其hFcγR介导的效应子功能（总结于[图1](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f001) A中）。根据他们的初步观察，Shields等人。设计的变异体结合了氨基酸取代，显示出与FcγRIIIA的结合增强，但与FcγRIIB的结合降低\[ [40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064) \]。这包括所述变体S298A / E333A / K334A当被引入人源化的IgG1抗IgE单克隆抗体E27 \[其中显示了增强的ADCC与WT相比的IgG [40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064) \]。

研究小组还采用了基于计算结构的建模方法，并结合了高通量蛋白质筛选，以鉴定氨基酸取代来增强hFcγR介导的效应子功能。例如，所述抗CD52 hIgG1，阿仑珠单抗，与S239D / I332E或S239D / A330L / I332E突变被发现结合亲和力已经增加至FcγRIIIa的两种同种异型（虽然较大者为V158等位基因）和FcγRIIB的\[ [42](https://www.mdpi.com/2073-4468/9/4/64/htm#B42-antibodies-09-00064)，[51](https://www.mdpi.com/2073-4468/9/4/64/htm#B51-antibodies-09-00064) \]。因此，ADCP被证明而ADCC被略有改善由这些氨基酸引入所述抗HER2 hIgG1抗体显著增强，曲妥珠单抗\[ [42](https://www.mdpi.com/2073-4468/9/4/64/htm#B42-antibodies-09-00064)，[51](https://www.mdpi.com/2073-4468/9/4/64/htm#B51-antibodies-09-00064)\]。重要的是，尽管这两个S239D / I332E和S239D / A330L / I332E突变可成功地增强ADCC，仅S239D / I332E变体保留CDC容量而这减少了S239D / A330L / I332E，当相比于WT hIgG1 \[变体[42](https://www.mdpi.com/2073-4468/9/4/64/htm#B42-antibodies-09-00064)，[51](https://www.mdpi.com/2073-4468/9/4/64/htm#B51-antibodies-09-00064) \]。下文讨论了这种差异的潜在含义。在体内，利妥昔单抗结合在所述S239D / I332E置换结果显著降低IC50为在食蟹猴（从10微克去B细胞耗竭-1千克-1为WT利妥昔单抗以0.2微克- 1公斤-1为S239D / I332E变体）\[ [42](https://www.mdpi.com/2073-4468/9/4/64/htm#B42-antibodies-09-00064) \]。

使用类似的筛选技术，发现了与FcγRIIB相比，对FcγRIIA具有更高亲和力的其他变异体，以增强ADCP \[ [43](https://www.mdpi.com/2073-4468/9/4/64/htm#B43-antibodies-09-00064) \]。这包括G236A突变，与WT hIgG1相比，它对FcγRIIA的两种同种异型的结合提供了6-7倍的增强，而对FcγRIIB或FcγRIIIA的亲和力却没有显着改变\[ [43](https://www.mdpi.com/2073-4468/9/4/64/htm#B43-antibodies-09-00064) \]。值得注意的是，G236A变体的IIA / IIB比（Kd（FcγRIIA）/ Kd（FcγRIIB））分别为15和12（分别针对H131和R131同种异型），而WT hIgG1则为2.7和2.5 \[ [43](https://www.mdpi.com/2073-4468/9/4/64/htm#B43-antibodies-09-00064) \]。结果，该单一氨基酸突变被引入抗EpCAM hIgG1抗体中，导致ADCP适度增加，同时保持了与WT抗体相当的ADCC水平 [\[43\]](https://www.mdpi.com/2073-4468/9/4/64/htm#B43-antibodies-09-00064)\]。但是，发现G236A突变可将FcγRI亲和力降低约7倍，这可能会使该变异在治疗上欠佳\[ [43](https://www.mdpi.com/2073-4468/9/4/64/htm#B43-antibodies-09-00064) \]。因此，掺入其他突变以挽救与FcγRI的结合，包括S239突变以产生变体G236A / S239D / I332E \[ [43](https://www.mdpi.com/2073-4468/9/4/64/htm#B43-antibodies-09-00064) \]。G236A / S239D / I332E hIgG1表现出与所有FcγR的结合显着增强，对FcγRIIA-R131同种异型的结合增强了约30倍，尽管观察到ADCC和ADCP仅有少量增加（[表1](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t001)）\[ [43](https://www.mdpi.com/2073-4468/9/4/64/htm#B43-antibodies-09-00064) \]。

最近，携带G236A抗体/ A330L / I332E和G236A / S239D突变产生并评估它们增加的FcγR介导的效应子功能的能力\[/ A330L / I332E [44](https://www.mdpi.com/2073-4468/9/4/64/htm#B44-antibodies-09-00064)，[45](https://www.mdpi.com/2073-4468/9/4/64/htm#B45-antibodies-09-00064) \]。二者被发现具有增强的结合活化性FcγR的（的FcγRIIa和FcγRIIIa的）中，用G236A / A330L / I332E hIgG1也显示较低的对抑制性FcγRIIb的结合，而G236A / S239D / A330L / I332E hIgG1已增强的结合对FcγRIIb\[ [44](https://www.mdpi.com/2073-4468/9/4/64/htm#B44-antibodies-09-00064)，[45](https://www.mdpi.com/2073-4468/9/4/64/htm#B45-antibodies-09-00064) \]。在体外，与WT相比，G236A / A330L / I332E hIgG1具有更强的ADCC能力\[ [44](https://www.mdpi.com/2073-4468/9/4/64/htm#B44-antibodies-09-00064) \]。当掺入抗CD20 hIgG1中时，两个变体均显示出hCD20 +在HCD20 /hFcγR转基因小鼠的B细胞相比，WT抗CD20 hIgG1 \[ [44](https://www.mdpi.com/2073-4468/9/4/64/htm#B44-antibodies-09-00064)，[52](https://www.mdpi.com/2073-4468/9/4/64/htm#B52-antibodies-09-00064) \]。但是，与WT相比，G236A / S239D / A330L / I332E hIgG1不仅显示出降低的蛋白质热位移测量值（分别为〜55°C和〜68°C），而且在hFcγR中具有显着降低的半衰期据推测是由于转基因小鼠对FcγRs的亲和力增加而体内稳定性降低\[ [44](https://www.mdpi.com/2073-4468/9/4/64/htm#B44-antibodies-09-00064) \]。这一发现突出了Fc工程设计中的两个重要考虑因素；首先，可能存在有效增加与低亲和力hFcγRs结合的限制，其次，对其他Fc特性的意外影响。

为了鉴定与FcγRIIIA的结合增加但与FcγRIIB的结合减少的新型人IgG1 Fc区，以增强A：I比并增强Fc效应子功能，还采用了利用酵母表面展示技术进行的功能性遗传筛选（[图](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f001)1A）\[ [46](https://www.mdpi.com/2073-4468/9/4/64/htm#B46-antibodies-09-00064) \]。以这种方式发现了突变组合F243L / R292P / Y300L / V305I / P396L，与WT利妥昔单抗相比，与FcγRIIIA的结合提高了10倍，而与FcγRIIA和FcγRIIB的结合却几乎没有增强\[ [41](https://www.mdpi.com/2073-4468/9/4/64/htm#B41-antibodies-09-00064) \]。

#### \*2.2。\**糖工程增强效应细胞功能*

糖工程也被证明是修饰Fc介导的细胞效应子功能的强大工具。这如下认识，即连接在Fc的N297残基的聚糖是用于有效结合的FcγR和C1q的\[临界[53](https://www.mdpi.com/2073-4468/9/4/64/htm#B53-antibodies-09-00064)，[54](https://www.mdpi.com/2073-4468/9/4/64/htm#B54-antibodies-09-00064)，[55](https://www.mdpi.com/2073-4468/9/4/64/htm#B55-antibodies-09-00064)，[56](https://www.mdpi.com/2073-4468/9/4/64/htm#B56-antibodies-09-00064)，[57](https://www.mdpi.com/2073-4468/9/4/64/htm#B57-antibodies-09-00064) \]。尽管最初尚不清楚这些碳水化合物为何如此重要，但最近发现hIgG1 Fc N297聚糖参与了碳水化合物和氨基酸之间的分子内相互作用，从而稳定了Fc C'链和C'E环并定向了hFcγRIIIA界面以与Fc结合\[ [58](https://www.mdpi.com/2073-4468/9/4/64/htm#B58-antibodies-09-00064)\]。至于效应细胞功能，糖基化的N297网站已被发现是ADCC的诱导是关键，由于其稳定Fc区并保持它在一个“开放式”的构象的能力\[ [59](https://www.mdpi.com/2073-4468/9/4/64/htm#B59-antibodies-09-00064)，[60](https://www.mdpi.com/2073-4468/9/4/64/htm#B60-antibodies-09-00064) \]。寡糖的不同组合可以经常发生在该位点和许多的IgG通常结合的N-乙酰葡糖胺（GlcNAc的），其与其他残基的组合，形成一芯碳水化合物\[ [59](https://www.mdpi.com/2073-4468/9/4/64/htm#B59-antibodies-09-00064)，[60](https://www.mdpi.com/2073-4468/9/4/64/htm#B60-antibodies-09-00064) \]。通常是核心GlcNAc一部分的残基是岩藻糖\[ [60](https://www.mdpi.com/2073-4468/9/4/64/htm#B60-antibodies-09-00064) \]。由于空间位阻，这也妨碍岩藻糖的IgG最佳的与FcγRIIIa的\[相互作用[53](https://www.mdpi.com/2073-4468/9/4/64/htm#B53-antibodies-09-00064)，[59](https://www.mdpi.com/2073-4468/9/4/64/htm#B59-antibodies-09-00064)\]。因此，已经广泛研究了消除该位置的岩藻糖以增强与FcγRIIIA的结合并增强效应细胞功能。

在1999年，发现在CHO细胞中过表达N-乙酰氨基葡萄糖氨基转移酶III（GnTIII）酶可以产生岩藻糖基化明显降低的hIgG1抗体\[ [61](https://www.mdpi.com/2073-4468/9/4/64/htm#B61-antibodies-09-00064) \]。以这种方式工程化嵌合抗神经母细胞瘤IgG1（chCE7）导致更高的ADCC \[ [61](https://www.mdpi.com/2073-4468/9/4/64/htm#B61-antibodies-09-00064) \]。产生具有减少的岩藻糖基的抗体的这种机制被销售作为GlycoMab的®技术，由瑞士生物技术，开发Glycart，后来由Roche \[获取[62](https://www.mdpi.com/2073-4468/9/4/64/htm#B62-antibodies-09-00064) \]。

另一种产生岩藻糖基化抗体的方法源自2003年的一项研究，结果表明，与CHO细胞系产生的抗体相比，大鼠杂交瘤YB2 / 0细胞系产生的人源化抗体的ADCC活性高50倍（[图1](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f001) A）\[ [63](https://www.mdpi.com/2073-4468/9/4/64/htm#B63-antibodies-09-00064) \]。 。单糖组成和寡糖谱分析表明，与CHO细胞相比，YB2 / 0细胞系产生的抗体具有较低的岩藻糖含量\[ [63](https://www.mdpi.com/2073-4468/9/4/64/htm#B63-antibodies-09-00064) \]。这引起了对产生甚至更低的岩藻糖含量的抗体的兴趣。最值得注意的是，现在许可为POTELLIGENT的技术®从协和发酵麒麟有限公司采用FUT8敲除的CHO细胞以产生非岩藻糖化抗体\[ [64](https://www.mdpi.com/2073-4468/9/4/64/htm#B64-antibodies-09-00064)\]。最初研究以这种方式产生的岩藻糖基化抗体，与FcγRIIIA-F158的结合增加了13倍，而ADCC的结合则增加了5倍（[表1](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t001)）\[ [41](https://www.mdpi.com/2073-4468/9/4/64/htm#B41-antibodies-09-00064) \]。与WT对应物相比，发现以这种方式产生的岩藻糖基化CCR4抗体在植入人PBMC的SCID小鼠模型中以及在同基因和异种移植小鼠模型中抑制肿瘤生长方面均具有更大的效力\[ [65](https://www.mdpi.com/2073-4468/9/4/64/htm#B65-antibodies-09-00064) \]。

从那时起，已经有许多其他的努力glycoengineer抗体增强效应细胞的功能，在长度以前审查\[ [66](https://www.mdpi.com/2073-4468/9/4/64/htm#B66-antibodies-09-00064)，[67](https://www.mdpi.com/2073-4468/9/4/64/htm#B67-antibodies-09-00064) \]。然而，岩藻糖基化仍然是增强效应细胞功能的最普遍的糖工程技术，并且正在临床试验中评估掺入这些技术的抗体，其中一些现已获得批准（[表2](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t002)）。然而，重要的是要注意糖工程抗体的制备可能具有高度的异质性，这是获得监管机构批准的关键障碍。

****表2.**** 目前被批准用于临床或后期开发的Fc工程抗体。

[(L)](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t002)

**Table 2.** Fc engineered antibodies currently approved for clinical use or in late stage development.

\*2.3。\**具有增强的效应细胞功能的抗癌抗体进入临床*![](../../../_resources/cb754d454497afd8ec20b9e2833973fd.png)

#### NB: F(ab) arm exchange modified IgG4 antibodies have not been included. Antibodies engineered for increased ADCC are highlighted in red and those with Fc disabling modifications are in blue. Regulatory status obtained from The Antibody Society \[[68](https://www.mdpi.com/2073-4468/9/4/64/htm#B68-antibodies-09-00064)\] (and is correct as of 13/08/2020. * Phase 2 trial of ocaratuzumab completed in 2011 with no further information available.

目前，正在临床试验中评估许多工程改造以表现出增强的Fc效应子功能的抗体，总结了已获批准的抗体，并在[表2中](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t002)列出了晚期临床试验。由于大多数临床批准的抗癌抗体通过直接删除靶细胞群发挥作用，因此增强其效应子功能一直是mAb工程领域中取得最大临床进展的领域。批准用于癌症的第一个这样的抗体在2015年是obinutuzumab，抗CD20抗体使用Glycart GlycoMab的开发®引发低岩藻糖基化的技术。在CLL和FL键头-头研究，obinutuzumab与化疗联合改善的无进展存活（PFS）相比利妥昔单抗加化疗\[ [69](https://www.mdpi.com/2073-4468/9/4/64/htm#B69-antibodies-09-00064)，[70](https://www.mdpi.com/2073-4468/9/4/64/htm#B70-antibodies-09-00064) \]。然而，在一项针对1418名弥漫性大B细胞淋巴瘤（DLBCL）患者的研究中，obinutuzumab联合CHOP化疗没有提供优于R-CHOP的优势，这表明糖工程导致的FcγRIII结合增加可能仅对某些疾病有益\[ [71](https://www.mdpi.com/2073-4468/9/4/64/htm#B71-antibodies-09-00064)，[72](https://www.mdpi.com/2073-4468/9/4/64/htm#B72-antibodies-09-00064)\]。同样重要的是要注意，在这些试验中，利妥昔单抗和奥比妥珠单抗组的给药水平和方案不同。这些比较的另一个警告是利妥昔单抗和奥比妥单抗的作用机制有所不同。利妥昔单抗是一种I型抗CD20单克隆抗体，并且可以重新分配CD20到脂筏到诱导强CDC，而obinutuzumab是一种类型II的mAb，其缺乏这些特性，但是可以唤起直接的细胞死亡的非凋亡形式\[ [31](https://www.mdpi.com/2073-4468/9/4/64/htm#B31-antibodies-09-00064)，[73](https://www.mdpi.com/2073-4468/9/4/64/htm#B73-antibodies-09-00064) \] 。类似地，利妥昔单抗被快速从细胞表面而obinutuzumab没有，再次，由于它们各自的I / II型性质\[内在[74](https://www.mdpi.com/2073-4468/9/4/64/htm#B74-antibodies-09-00064)，[75](https://www.mdpi.com/2073-4468/9/4/64/htm#B75-antibodies-09-00064)\]。因此，难以确定功效的多少改善可归因于Fc糖工程。

乌比妥昔单抗是另一种被设计为具有低岩藻糖含量的抗CD20抗体\[ [76](https://www.mdpi.com/2073-4468/9/4/64/htm#B76-antibodies-09-00064) \]。在GENUINE高危CLL患者的第3期研究中，ublituximab成为首个为BTK抑制剂依鲁替尼提供其他患者益处的抗CD20 mAb，其总缓解率（ORR）和PFS显着改善\[ [76](https://www.mdpi.com/2073-4468/9/4/64/htm#B76-antibodies-09-00064) \]。在一项可比较的试验中，与单独使用依鲁替尼相比，利妥昔单抗联合依鲁替尼不能改善PFS，这表明增强的效应子功能可为患者带来益处\[ [77](https://www.mdpi.com/2073-4468/9/4/64/htm#B77-antibodies-09-00064) \]。此外，UNITY-CLL试验还比较了ublituximab加上PI3K抑制剂umbralisib与obinutuzumab加上苯丁酸氮芥。由于ublituximab组具有更高的疗效，该试验被提前终止\[ [78](https://www.mdpi.com/2073-4468/9/4/64/htm#B78-antibodies-09-00064)\]。然而，在两种抗体以完全不同的组合施用的情况下，不能直接评估不同抗体（更具体地说是其Fc修饰）对治疗结果的相对贡献。临床上也已经研究了另一种抗CD20抗体，含有PattI / A339Q突变以增强ADCC的ocaratuzumab \[ [79](https://www.mdpi.com/2073-4468/9/4/64/htm#B79-antibodies-09-00064) \]。但是，尽管在2011年完成了2期试验（NCT00003874），但结果尚未公布。

美国食品药品监督管理局（FDA）已批准抗CCR4 mAb莫加莫珠单抗（mogamulizumab）脱离抗CD20 mAb，用于成人T细胞白血病/淋巴瘤（ATLL）以及真菌病真菌（MF）和塞萨里综合征（Sézarysyndrome），皮肤T细胞淋巴瘤（CTCL）有2种亚型\[ [80](https://www.mdpi.com/2073-4468/9/4/64/htm#B80-antibodies-09-00064) \]。在CTCL中进行的最大试验中，与HDAC抑制剂伏立诺他（7.7 v 3.1个月）相比，mogamulizumab的PFS更高\[ [81](https://www.mdpi.com/2073-4468/9/4/64/htm#B81-antibodies-09-00064) \]。在ATLL中，莫加米单抗与研究者选择控制组相比还具有较好的ORR，但并未改善PFS \[ [82](https://www.mdpi.com/2073-4468/9/4/64/htm#B82-antibodies-09-00064) \]。这与较早但规模较小的ATLL研究相反，后者对PFS有所改善，尽管这可能反映了ATLL亚型对莫加莫珠单抗的重要性\[ [83](https://www.mdpi.com/2073-4468/9/4/64/htm#B83-antibodies-09-00064) \]。

Tafasitamab（MOR208）是FDA于2020年批准的CD19靶向抗体，可用于复发/难治性DLBCL。用S239D / I332E突变对其进行了改造，以通过增加对FcγRIIIA的亲和力来增强ADCC。在RE-MIND研究中，将接受tafasitamab与来那度胺联合治疗的DLBCL患者与仅接受来那度胺的患者的匹配历史数据进行了比较。该试验得出的结论是，与来那度胺单药治疗（34.2％）相比，联合用药的ORR（67.1％）更好\[ [84](https://www.mdpi.com/2073-4468/9/4/64/htm#B84-antibodies-09-00064) \]。遵循这些令人鼓舞的结果，在B-MIND试验中，塔法西他珠目前正在与利妥昔单抗联合苯达莫司汀直接比较\[ [85](https://www.mdpi.com/2073-4468/9/4/64/htm#B85-antibodies-09-00064)\]。预计该研究的最高结果将在2022年初开始。尽管将不同的抗原靶向利妥昔单抗，但结果可能会深入了解可通过增强FcγRIIIA结合而获得的临床结果的改善。

正如已经指出的，在WT和Fc修饰的hIgG1试剂之间缺乏直接比较，这使得很难获得Fc工程的重要性的确凿证据。实际上，除了上面详述的阳性指示外，并非为增强效应子功能而设计的所有抗体都具有预期的患者益处。例如，ocrelizumab（一种抗CD20 mAb与利妥昔单抗共享一个重叠的CD20表位）已被设计用于增强ADCC活性\[ [86](https://www.mdpi.com/2073-4468/9/4/64/htm#B86-antibodies-09-00064) \]。在先前接受利妥昔单抗治疗的FL患者的I / II期试验中，ORR达到38％\[ [87](https://www.mdpi.com/2073-4468/9/4/64/htm#B87-antibodies-09-00064) \]。然而，对利妥昔单抗治疗的患者进行的一项相似研究 [\[88\]](https://www.mdpi.com/2073-4468/9/4/64/htm#B88-antibodies-09-00064)\]。结果，用于血液恶性肿瘤的ocrelizumab的开发被暂停。尽管如此，该抗体随后已被批准用于多发性硬化症。同样，与天然抗体相比，抗EGFR mAb西妥昔单抗的岩藻糖基化形式CetuGEX无法改善PFS。而且，它的使用与输注相关事件的增加有关\[ [89](https://www.mdpi.com/2073-4468/9/4/64/htm#B89-antibodies-09-00064) \]。这项研究表明，至少对于某些靶标，增强效应细胞激活的潜在益处可能需要与增加的毒性进行权衡。

尽管存在这些并发症，但Fc增强型mAb已在实体瘤中获得成功。Macrogenics最近报道了其抗HER2抗体马格单抗的中期结果，该抗体经过工程改造以通过5个氨基酸取代（L235V / F243L / R292P / Y300L / P396L）增强FcγRIIIA的结合\[ [47](https://www.mdpi.com/2073-4468/9/4/64/htm#B47-antibodies-09-00064) \]。在直接比较中，与曲妥珠单抗加化疗相比（5.8 v 4.9个月），玛格妥昔单抗加化疗导致PFS适度改善\[ [90](https://www.mdpi.com/2073-4468/9/4/64/htm#B90-antibodies-09-00064) \]。也许最重要的是，对于携带至少1个低亲和力158FFcγRIIIA等位基因拷贝的患者，改善的反应最为明显（6.9 vs 5.1个月）。表达这种等位基因形式的FcγRIIIA的患者通常对包括曲妥珠单抗在内的许多直接靶向抗体的反应较差 [\[91\]](https://www.mdpi.com/2073-4468/9/4/64/htm#B91-antibodies-09-00064)\]。因此，通过工程化mAb增强效应细胞的功能，可以使这些反应较差的患者从mAb治疗中获得更大的收益。继这些有希望的结果之后，正在评估将马格妥昔单抗与通过抗PD1 mAb的检查点抑制剂阻断剂联合用于胃和胃食管连接癌，估计该试验将于2024年完成\[ [92](https://www.mdpi.com/2073-4468/9/4/64/htm#B92-antibodies-09-00064) \]。

最初认为靶向检查点抑制剂（例如CTLA-4）的抗体仅通过阻断T细胞上的受体即可诱导治疗反应。然而，随后的研究表明，缺失的Treg的也可有助于它们的活性，尽管这种贡献的程度是有争议的\[ [93](https://www.mdpi.com/2073-4468/9/4/64/htm#B93-antibodies-09-00064)，[94](https://www.mdpi.com/2073-4468/9/4/64/htm#B94-antibodies-09-00064) \]。Treg缺失作为抗CTLA4 mAb活性的潜在机制的出现，为开发具有增强的靶细胞缺失的抗CTLA4 mAb提供了动力。迄今为止，为增强Fc功能而设计的两种抗CTLA4抗体已进入临床。zalifrelimab（AGEN1884）和AGEN1181。体外分析表明扎利夫拉单抗可以改善Treg细胞的缺失\[ [95](https://www.mdpi.com/2073-4468/9/4/64/htm#B95-antibodies-09-00064)\]。但是，一项I期试验的中期分析表明，与抗PD1单抗组合使用时，尽管具有良好的安全性，但其反应与未经修饰的抗CTLA-4单抗伊匹木单抗相当\[ [96](https://www.mdpi.com/2073-4468/9/4/64/htm#B96-antibodies-09-00064) \]。

## **3\. Fc工程增强抗体介导的补体依赖性细胞毒性**

尽管C1q结合和CDC对WT hIgG1 mAb的治疗活性的重要性尚不清楚，但最近的研究表明，工程设计为不结合FcγR的抗体比WT IgG更能结合C1q的抗体能够结合强大的CDC并提供对肿瘤的控制。临床前模型\[ [97](https://www.mdpi.com/2073-4468/9/4/64/htm#B97-antibodies-09-00064) \]。类似地，来自Diebolder和Ugurlar开创性的研究表明，强大CDC需要在细胞表面hIgG1的高效hexamerisation，这可以通过适当的氨基酸突变在Fc \[范围内增加[3](https://www.mdpi.com/2073-4468/9/4/64/htm#B3-antibodies-09-00064)，[98](https://www.mdpi.com/2073-4468/9/4/64/htm#B98-antibodies-09-00064)\]。重要的是，有效的CDC受特定目标分子要求的约束。例如，目标表位必须相对靠近细胞膜放置，以便有效裂解，目标抗原的密度也很重要\[ [99](https://www.mdpi.com/2073-4468/9/4/64/htm#B99-antibodies-09-00064) \]。这些非常具体的目标要求的结果是，尽管CDC可能不是WT抗体针对癌细胞的功效的关键组成部分，但有可能通过这种途径提供增强的抗肿瘤功效。有先前已描述了几个CDC增强的Fc变体，在总结[图2](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f002) \[ [3](https://www.mdpi.com/2073-4468/9/4/64/htm#B3-antibodies-09-00064)，[100](https://www.mdpi.com/2073-4468/9/4/64/htm#B100-antibodies-09-00064)，[101](https://www.mdpi.com/2073-4468/9/4/64/htm#B101-antibodies-09-00064)，[102](https://www.mdpi.com/2073-4468/9/4/64/htm#B102-antibodies-09-00064) \]。由于它们一直是近期出色的评论主题\[ [103](https://www.mdpi.com/2073-4468/9/4/64/htm#B103-antibodies-09-00064)，[104](https://www.mdpi.com/2073-4468/9/4/64/htm#B104-antibodies-09-00064)，[105](https://www.mdpi.com/2073-4468/9/4/64/htm#B105-antibodies-09-00064) \]，它们将不被进一步讨论。

****图2.**** Fc修饰增加补体依赖性细胞毒性。（****甲****）在Fc内先前标识的点突变调节补体依赖性细胞毒性是在人类IgG1的Fc晶体结构模型注解（PDB：3AVE; \[ [49](https://www.mdpi.com/2073-4468/9/4/64/htm#B49-antibodies-09-00064)，[50](https://www.mdpi.com/2073-4468/9/4/64/htm#B50-antibodies-09-00064) \]）。（****B****与野生型（WT）抗体相比，补体依赖性细胞毒性（CDC）增强变体中效应子功能或对C1q的结合亲和力发生倍数变化。将效应子功能的大小或变体的结合亲和力与相同IgG同种型和F（ab）区的WT抗体进行比较。每行描绘了一个独立的实验，因此通常是独立的方法，它们利用的是上一栏中引用的来自特定研究的不同IgG骨架。NB =无可检测的结合，nd =无数据，− =无变化，↑<2倍上调，↑↑2–9.99倍上调，↑↑↑10–99.99倍上调，↓↓2–9.99倍下调。

## **4\. Fc工程增强抗体与FcγRIIB的结合**

FcγRIIB是人类和小鼠表达的唯一抑制性FcγR。对于直接靶向，缺失肿瘤的抗体，FcγRIIB的表达与功效降低相关。例如，从肿瘤细胞表面利妥昔单抗内化已经与体外FcγRIIB的表达相关联，并且高FcγRIIB的已减少的利妥昔单抗的体内活性，推测是由于它的能力有关，以减少ADCP \[ [75](https://www.mdpi.com/2073-4468/9/4/64/htm#B75-antibodies-09-00064)，[106](https://www.mdpi.com/2073-4468/9/4/64/htm#B106-antibodies-09-00064) \]。通过诸如Clynes和综述参见Ravetch开创性的研究还表明，小鼠FcγRIIb损害了乳腺癌抗体曲妥单抗\[活性[106](https://www.mdpi.com/2073-4468/9/4/64/htm#B106-antibodies-09-00064)，[107](https://www.mdpi.com/2073-4468/9/4/64/htm#B107-antibodies-09-00064)\]。然而，相比之下，已显示FcγRIIB通过更有效的mAb靶受体簇有效地调节免疫调节激动抗体的活性\[ [108](https://www.mdpi.com/2073-4468/9/4/64/htm#B108-antibodies-09-00064) \]。最初报道这种激动性抗DR5抗体，需要通过FcγRIIB交联才能成功引发肿瘤控制，但现在已经显示出它具有多个肿瘤坏死因子受体超家族（TNFRSF）成员，例如CD40、4-1BB和OX40，至少在临床前模型中\[ [109](https://www.mdpi.com/2073-4468/9/4/64/htm#B109-antibodies-09-00064)，[110](https://www.mdpi.com/2073-4468/9/4/64/htm#B110-antibodies-09-00064)，[111](https://www.mdpi.com/2073-4468/9/4/64/htm#B111-antibodies-09-00064)，[112](https://www.mdpi.com/2073-4468/9/4/64/htm#B112-antibodies-09-00064)，[113](https://www.mdpi.com/2073-4468/9/4/64/htm#B113-antibodies-09-00064)，[114](https://www.mdpi.com/2073-4468/9/4/64/htm#B114-antibodies-09-00064)\]。因此，针对激动性抗癌抗体，特别关注工程化抗体以增强与FcγRIIB的结合。这些研究的数据总结在[图3中，](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f003)并在[4.1节](https://www.mdpi.com/2073-4468/9/4/64/htm#sec4dot1-antibodies-09-00064)中进行了详细描述。

[(L)](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f003)

****图3.**** 增强与FcγRIIB结合的Fc修饰。（****甲****）以前鉴定在Fc内点突变影响结合对FcγRIIb上的hIgG1 Fc结构的晶体结构模型注解（PDB：3AVE; \[ [49](https://www.mdpi.com/2073-4468/9/4/64/htm#B49-antibodies-09-00064)，[50](https://www.mdpi.com/2073-4468/9/4/64/htm#B50-antibodies-09-00064) \]）。（****B****）将变体的结合亲和力的大小与相同IgG同种型和F（ab）区域的WT抗体进行比较。每行描绘了一个独立的实验，因此通常是独立的方法，它们利用的是上一栏中引用的来自特定研究的不同IgG骨架。NB =无可检测结合，nd =无数据，− =无变化，↑&lt;2倍上调，↑↑2–9.99倍上调，↑↑↑↑&gt; 100倍上调，↓↓2–9.99倍下调，↓↓↓下调10–99.99倍，****的Fc**** **γRIIA** **ħ**的FcγRIIa-H131，****FC**** **γRIIA** **ř**的FcγRIIa-R131，****FC**** **γRIIIA** **˚F** FcγRIIIa的-F158，****FC**** **γRIIIA** **V** FcγRIIIa的-V158。

#### \*4.1。\**设计用于增强FcγRIIB结合的氨基酸取代*

Chu等人将基于计算结构的建模与高通量蛋白质筛选相结合。筛选了900多个变体，以发现具有最佳FcγR结合图谱的抗体Fc结构域用于免疫刺激，即显示低的A：I比\[ [115](https://www.mdpi.com/2073-4468/9/4/64/htm#B115-antibodies-09-00064) \]。通过该筛选策略，该小组发现了氨基酸取代S267E / L328F，该氨基酸取代引入hIgG1后，与FcγRIIB的结合亲和力增加了430倍，与FcγRI和FcγRIIA-H131的结合变化最小，并且消除了与FcγRIIIA-V158的结合WT hIgG1 \[ [115](https://www.mdpi.com/2073-4468/9/4/64/htm#B115-antibodies-09-00064) \]。据报道，S267E / L328F突变可促进工程化的抗OX40抗体与FcγRIIB的结合，并在体外提高2倍以上的激动性\[ [116](https://www.mdpi.com/2073-4468/9/4/64/htm#B116-antibodies-09-00064)\]。在体内，与野生型hIgG1或hIgG2变体相比，S267E / L328F修饰的抗CD40 hIgG2抗体在hFcγR/ hCD40转基因小鼠中激活T细胞的能力增强\[ [117](https://www.mdpi.com/2073-4468/9/4/64/htm#B117-antibodies-09-00064) \]。

在这种方法的一种变体中，Mimoto等人。筛选了超过500种hIgG1变体，用其他氨基酸替换了下部铰链和CH2区的约30个残基\[ [118](https://www.mdpi.com/2073-4468/9/4/64/htm#B118-antibodies-09-00064) \]。通过该过程，他们发现了突变P238D，与野生型hIgG1相比，突变P238D增强了与FcγRIIB的结合，同时完全消除了或严重降低了与活化FcγRs（FcγRI，FcγRIIA-H131，FcγRIIIA-V131）的结合\[ [118](https://www.mdpi.com/2073-4468/9/4/64/htm#B118-antibodies-09-00064) \]。然后该小组向P238添加了更多的氨基酸改变，以增强与FcγRIIB的结合，包括突变：G237D / H268D / P271G / A330R（称为V11），与WT IgG1相比，其与FcγRIIB的结合提高了40倍\[ [118](https://www.mdpi.com/2073-4468/9/4/64/htm#B118-antibodies-09-00064)\]。然而，与WT IgG1相比，它是6个氨基酸取代的组合E233D / G237D / P238D / H268D / P271G / A330R（称为V12），与FcγRIIB的结合增强最高，约为217倍\[ [118](https://www.mdpi.com/2073-4468/9/4/64/htm#B118-antibodies-09-00064) \]。V12也与FcγRIIIA的同种异型均无可检测的结合。与WT hIgG1相比，与FcγRI和FcγRIIA-H131的结合减少，而与FcγRIIA-R131的结合仅轻微增强\[ [118](https://www.mdpi.com/2073-4468/9/4/64/htm#B118-antibodies-09-00064) \]。这些V12突变被引入抗OX40抗体中，并通过NF-κB报告基因检测证明，其体外激动作用增加了> 2倍\[ [48](https://www.mdpi.com/2073-4468/9/4/64/htm#B48-antibodies-09-00064)\]。自从发现增强与FcγRIIB结合的突变以来，已经有多种抗癌抗体已将其掺入其中，并且正在如[第4.2节](https://www.mdpi.com/2073-4468/9/4/64/htm#sec4dot2-antibodies-09-00064)中所述的临床试验中进行评估。

#### \*4.2。\**具有增强的FcγRIIB结合力的抗癌抗体进入临床*

如上所讨论的，有越来越多的证据表明，免疫刺激性抗体，特别是那些靶向TNFRSF成员可进一步交联通过FcγRIIB的，以增强受体成簇和提供有效的激动作用\[ [110](https://www.mdpi.com/2073-4468/9/4/64/htm#B110-antibodies-09-00064)，[112](https://www.mdpi.com/2073-4468/9/4/64/htm#B112-antibodies-09-00064) \]。当然，对于抗CD40 mAb已经显示出这一点，尽管重要的是要认识到这会根据特异性mAb和靶向CD40的表位而变化 [\[119\]。](https://www.mdpi.com/2073-4468/9/4/64/htm#B119-antibodies-09-00064)\]。因此，尽管尚未公开进行确切修饰的细节，但已对Lyvgen Biopharma开发的LVGN7408进行工程改造以增加FcγRIIB的结合。当前数据有限，但将密切监测其进展，特别是由于通过FcγRIIB介导的激动作用增加通常与毒性增加相关，并且临床前数据表明，优化后，不同的抗CD40 mAb需要进行肿瘤内给药通过V11（G237D / P238D / H268D / P271G / A330R）突变参与FcγRIIB的研究\[ [120](https://www.mdpi.com/2073-4468/9/4/64/htm#B120-antibodies-09-00064) \]。

4-1BB（CD137）是另一个TNFRSF成员，是有吸引力的治疗靶标。像CD40一样，它可以更有效地被与FcγRIIB结合的mAb交联和拮抗\[ [121](https://www.mdpi.com/2073-4468/9/4/64/htm#B121-antibodies-09-00064) \]，但是像CTLA-4一样，其在Treg上的高相对表达使其更难以靶向治疗。例如，抗4-1BB mAb与活化FcγR的相互作用会导致Treg缺失，而有效共刺激CD8 +效应物需要通过FcγRIIB交联，这两种机制均在临床前模型中提供了抗肿瘤活性\[ [121](https://www.mdpi.com/2073-4468/9/4/64/htm#B121-antibodies-09-00064) \]。确实，在含有hIgG2铰链的mIgG2a抗体的小鼠中观察到了最佳的抗肿瘤活性，在提供最佳交联的同时提供了有效的缺失 [\[121\]](https://www.mdpi.com/2073-4468/9/4/64/htm#B121-antibodies-09-00064)\]。目前正在研究抗41BB mAb LVGN6051与pembrolizumab的组合。该抗体已针对FcγRIIB相互作用进行了优化，发现可诱导有效的T细胞活化，而没有通常观察到的肝毒性 [\[122\]](https://www.mdpi.com/2073-4468/9/4/64/htm#B122-antibodies-09-00064)\]。但是，已经取消了激活性FcγR的参与，从而防止了Treg缺失作为一种作用机制。该抗体具有单一作用方式的功效尚待观察，并可能为后续的抗41BB mAb提供其他有用的作用机理数据。克服4-1BB簇中FcγRIIB参与的需求的一种有趣的替代方法是通过开发双特异性抗体。在罗氏开发的一种格式中，一根F（ab）臂靶向4-1BB，而另一根靶向在特定肿瘤的微环境中高表达的抗原，例如CD19或成纤维细胞活化蛋白（FAP）\[ [123](https://www.mdpi.com/2073-4468/9/4/64/htm#B123-antibodies-09-00064) \]。据报道，这不需要FcγRIIB参与即可促进有效的受体簇集。

## **5\. Fc工程来生产没有Fc功能的抗体**

在上文中，已经描述了设计用于增强Fc效应子功能的多种方法。但是，通过FcγR和补体相互作用参与免疫效应可能对某些mAb作用机理有害，因此可能需要Fc无效或沉默的抗体。例如，对于旨在阻断细胞表面受体或细胞因子的抗体，Fc效应子功能不是必需的，甚至可能有害 [\[105\]](https://www.mdpi.com/2073-4468/9/4/64/htm#B105-antibodies-09-00064)\]。对于抗癌抗体，这在不需要目标细胞耗尽的免疫检查点抑制剂抗体中尤为重要，并且已经选择了许多临床批准的具有天然低Fc效应子功能同种型的抗癌检查点抑制剂，或者正在设计无Fc的抗体或Fc沉默格式，如本评论后面所述。Fc沉默技术总结在[表3中](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t003)，关键残基在[图4](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f004) B中突出显示。

![](../../../_resources/3b8b6f447f14beffa2dd0128701cca12.png)

[(L)](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f004)

****图4.**** 减少抗体效应子功能和/或FcγR结合的Fc修饰。（****甲****）事件的细节重大发现的时间轴中，技术用于发现具有沉默的Fc区和变体当Fc变体在文献\[首先描述[57](https://www.mdpi.com/2073-4468/9/4/64/htm#B57-antibodies-09-00064)，[115](https://www.mdpi.com/2073-4468/9/4/64/htm#B115-antibodies-09-00064)，[124](https://www.mdpi.com/2073-4468/9/4/64/htm#B124-antibodies-09-00064)，[127](https://www.mdpi.com/2073-4468/9/4/64/htm#B127-antibodies-09-00064)，[128](https://www.mdpi.com/2073-4468/9/4/64/htm#B128-antibodies-09-00064)，[129](https://www.mdpi.com/2073-4468/9/4/64/htm#B129-antibodies-09-00064)，[130](https://www.mdpi.com/2073-4468/9/4/64/htm#B130-antibodies-09-00064)，[132](https://www.mdpi.com/2073-4468/9/4/64/htm#B132-antibodies-09-00064)，[133](https://www.mdpi.com/2073-4468/9/4/64/htm#B133-antibodies-09-00064)，[134](https://www.mdpi.com/2073-4468/9/4/64/htm#B134-antibodies-09-00064)，[135](https://www.mdpi.com/2073-4468/9/4/64/htm#B135-antibodies-09-00064)，[136](https://www.mdpi.com/2073-4468/9/4/64/htm#B136-antibodies-09-00064) \]。字母指的是在正文中讨论的引入的氨基酸取代的通用符号。（****B****）在Fc内的先前识别的点突变，其注释上的hIgG1 Fc结构的晶体结构模型（PDB沉默的Fc功能：3AVE; \[ [49](https://www.mdpi.com/2073-4468/9/4/64/htm#B49-antibodies-09-00064)，[50](https://www.mdpi.com/2073-4468/9/4/64/htm#B50-antibodies-09-00064) \]），并在详细[表3](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t003)。

****表3。**** 与WT抗体相比，Fc沉默的变体中效应子功能或对FcγR的结合亲和力降低。

[(L)](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t003)

#### *![](../../../_resources/ce3f31fcc7664cc8341ecb5ced565c70.png)*

#### \*5.1。\**氨基酸取代，降低效应子功能*

在鉴定了hIgG中FcγR和C1q结合位点后\[ [137](https://www.mdpi.com/2073-4468/9/4/64/htm#B137-antibodies-09-00064) \]，各个小组使用了定点诱变，以产生效应子功能降低的变体（[图4](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f004)）。1995年，L235A / G237A / E318A hIgG1抗体无法与表达FcγR的人细胞系结合，与WT hIgG相比，ADCC降低了近4倍\[ [127](https://www.mdpi.com/2073-4468/9/4/64/htm#B127-antibodies-09-00064) \]。在2000年，通过使用C1q结合位点的定点诱变，以**类似的方式发现了L234A / L235A Fc致残突变[\*\* \[128\]](https://www.mdpi.com/2073-4468/9/4/64/htm#B128-antibodies-09-00064)**\]。****带有hIgG1和hIgG4 L234A / L235A Fc域的OKT3抗体与低亲和力FcγRs和C1q没有可检测的结合，并且与FcγRI的结合大大减少，与WT hIgG1或IgG4相比，ADCC和CDC显着降低**\[ [128](https://www.mdpi.com/2073-4468/9/4/64/htm#B128-antibodies-09-00064) \]。

随后在已知与FcγR和C1q相互作用的hIgG1的特定残基处引入突变（参见[图4](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f004) B）\[ [129](https://www.mdpi.com/2073-4468/9/4/64/htm#B129-antibodies-09-00064) \]。这些研究确定了氨基酸取代L234F / L235E / P331S，导致与低亲和力FcγRs的结合减少（未评估FcγRIIB和FcγRIIIA-F158），并且未检测到与FcγRI的结合\[ [129](https://www.mdpi.com/2073-4468/9/4/64/htm#B129-antibodies-09-00064) \]。同年，基于计算结构的蛋白质设计和对900多个变体的高通量蛋白质筛选相结合，导致了G236R / L328R突变对的发现\[ [115](https://www.mdpi.com/2073-4468/9/4/64/htm#B115-antibodies-09-00064) \]。这些突变导致与测量的FcγR的结合减少或完全消除（未评估FcγRIIA-R131和FcγRIIIA-F158同种异型）\[ [115](https://www.mdpi.com/2073-4468/9/4/64/htm#B115-antibodies-09-00064)\]。这项研究还发现了S267E取代，降低了对所有低亲和力hFcγRs的结合（注意：研究的FcγRIIA等位基因是H131；研究的FcγRIIIA等位基因是V158）\[ [115](https://www.mdpi.com/2073-4468/9/4/64/htm#B115-antibodies-09-00064) \]。在随后的研究中，S267K取代用一系列突变在hIgG2的下铰链（E233P / L234V / L235A突变和残余物G236的缺失）被发现和并入hIgG1背景\[即组合[133](https://www.mdpi.com/2073-4468/9/4/64/htm#B133-antibodies-09-00064)，[138](https://www.mdpi.com/2073-4468/9/4/64/htm#B138-antibodies-09-00064) \]。产生的抗体水平不高的结合所有hFcγR调查（hFcγRIIIA-F158未评估）和这些突变成为其Xencor的XmAb骨干®产生双特异性抗体平台\[ [133](https://www.mdpi.com/2073-4468/9/4/64/htm#B133-antibodies-09-00064)\]。此外，通过分析hFc-hFcγR界面，Schlothauer等人（英文）。鉴定出一种新的突变P329G，该突变能够破坏hIgG和hFcγR之间的相互作用。偶联至L234A / L235A突变，从而产生三重突变L234A / L235A / P329G，他们产生了一个与C1q或FcγRs不可检测结合的变体，当引入hIgG1抗EGFR抗体时，ADCC被废除\[ [130](https://www.mdpi.com/2073-4468/9/4/64/htm#B130-antibodies-09-00064) \]。

Engelberts等人（1987年）的许多研究在相似位置引入了氨基酸取代。结合了先前发现的一些点突变（N297Q，L234F，L235E，D265A，P331S）以消除Fc功能\[ [135](https://www.mdpi.com/2073-4468/9/4/64/htm#B135-antibodies-09-00064) \]，并在抗CD3-hIgG1中对其进行了评估。他们发现L234F / L235E / D265A的组合最有效地沉默Fc区，这是由于未检测到与FcyRI的结合，与低亲和力的FcyRs的结合减少以及与C1q的结合减少所证明的\[ [135](https://www.mdpi.com/2073-4468/9/4/64/htm#B135-antibodies-09-00064) \]。

在替代方法中，使用IgG1 Fc：FcγRIII复合物的晶体结构，Sazinsky等人。发现与IgG1的CH2结构域建立了广泛的联系，特别是在Fc C'/ E环中\[ [124](https://www.mdpi.com/2073-4468/9/4/64/htm#B124-antibodies-09-00064) \]。因此，该小组创建了以Fc C'/ E环为中心的位点饱和诱变文库，理论上编码了hIgG1中第296-299、297-299和297-300位的所有氨基酸组合。随后产生了一系列突变体，并通过流式细胞术筛选了减少的FcγR结合\[ [124](https://www.mdpi.com/2073-4468/9/4/64/htm#B124-antibodies-09-00064) \]，表明S298G / T299A突变消除或显着降低了与FcγR和除FcγRIIA-R131和FcγRIIB之外的大多数FcγR的结合\[ [124](https://www.mdpi.com/2073-4468/9/4/64/htm#B124-antibodies-09-00064) \]。

#### \*5.2。\**糖工程化以减少效应子功能*

糖工程技术也已用于产生效应子功能降低的抗体。例如，在1989年，在衣霉素的存在下产生了抗体，以产生无糖基化的抗体\[ [57](https://www.mdpi.com/2073-4468/9/4/64/htm#B57-antibodies-09-00064) \]。这些无糖基化的抗体与FcγRI的结合力显着降低（与野生型IgG1相比，对RBC玫瑰结的抑制作用低约35倍）和FcγRII\[ [57](https://www.mdpi.com/2073-4468/9/4/64/htm#B57-antibodies-09-00064) \]。随后，产生了通过特定氨基酸取代靶向的无糖基化变体，以产生Fc沉默抗体（请参[见图4](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f004) B和[表3）](https://www.mdpi.com/2073-4468/9/4/64/htm#table_body_display_antibodies-09-00064-t003)）。如前所述，N297聚糖是hIgG1与FcγR和C1q之间结合的核心，结构数据证明了hIgG1 Fc N297-聚糖和FcγRIIIA之间的相互作用如何得以维持\[ [139](https://www.mdpi.com/2073-4468/9/4/64/htm#B139-antibodies-09-00064) \]。此外，还提出了以相同的方式介导不同的hFcγR，C1q和其他hIgG同种型之间的相互作用\[ [58](https://www.mdpi.com/2073-4468/9/4/64/htm#B58-antibodies-09-00064) \]。由于N297聚糖对于FcγR和C1q结合的重要性，已显示该位点的氨基酸突变（包括去除该聚糖的N297A，N297Q和N297G）会减少与所有FcγR和C1q的结合，从而导致ADCC降低和CDC \[ [124](https://www.mdpi.com/2073-4468/9/4/64/htm#B124-antibodies-09-00064)，[125](https://www.mdpi.com/2073-4468/9/4/64/htm#B125-antibodies-09-00064)，[126](https://www.mdpi.com/2073-4468/9/4/64/htm#B126-antibodies-09-00064)\]。关于这些Fc修饰中的任何一个被沉默的程度，应该注意的是，许多前述研究使用流式细胞术和/或表面等离振子共振（SPR）来评估FcγR结合。这些方法通常依赖于这些抗体的可溶或单体形式，但是，2009年表明，应考虑更多生理相关的免疫复合物来确定与hIgG同种型的FcγR结合 [\[140\]。](https://www.mdpi.com/2073-4468/9/4/64/htm#B140-antibodies-09-00064)免疫复合物比单体形式显示出更高的亲和力介导的结合。勒克斯等。然后通过生成抗原：Fc沉默的抗体复合物（在这种情况下为抗TNP：TNP复合物）并观察与在CHO细胞，人B细胞系或CHO细胞上稳定表达的hFcγR的结合，来扩展此SPR评估以评估各种Fc沉默的抗体形式。外周血单个核细胞\[ [141](https://www.mdpi.com/2073-4468/9/4/64/htm#B141-antibodies-09-00064) \]。他们发现，非糖基化hIgG1 / 2/3的抗体，呈现为大的免疫复合物保留结合的FcγRIIa-131R \[WT水平[141](https://www.mdpi.com/2073-4468/9/4/64/htm#B141-antibodies-09-00064) \]，当使用单体以往的研究，非糖基化hIgG1 / 3显示没有可检测的结合\[ [57](https://www.mdpi.com/2073-4468/9/4/64/htm#B57-antibodies-09-00064)，[124](https://www.mdpi.com/2073-4468/9/4/64/htm#B124-antibodies-09-00064)\]。此外，他们表明，hIgG1-N297A或酶促去糖基化的hIgG1保持与高亲和力FcγRI的结合，而与免疫复合物的大小无关\[ [141](https://www.mdpi.com/2073-4468/9/4/64/htm#B141-antibodies-09-00064) \]，这又与先前评估单体Fc工程抗体的报道相反\[ [57](https://www.mdpi.com/2073-4468/9/4/64/htm#B57-antibodies-09-00064) \]。这突显了在解释使用Fc沉默技术从单体抗体：FcγR结合研究获得的数据时可能要采取的谨慎态度，也许还可能从整体上整合了Fc工程策略的抗体也应注意这一点。

#### \*5.3。\**hIgG4和hIgG4 Fc工程化以减少效应子功能*

降低的Fc效应子功能的最简单指数可能是使用hIgG4作为同种型的选择。尽管未Fc的工程*本身*，人们早就知道，不同的hIgG同种型表达的效应子功能\[变化水平的[142](https://www.mdpi.com/2073-4468/9/4/64/htm#B142-antibodies-09-00064)以后被归因于他们的差分结合FcγR的和补体C1q \[\] [140](https://www.mdpi.com/2073-4468/9/4/64/htm#B140-antibodies-09-00064)，[143](https://www.mdpi.com/2073-4468/9/4/64/htm#B143-antibodies-09-00064)，[144](https://www.mdpi.com/2073-4468/9/4/64/htm#B144-antibodies-09-00064) \]。尤其是，已知hIgG4同种型对除FcγRI以外的所有FcγR均具有低亲和力，并且历史上一直被认为有助于开发Fc惰性抗体 [\[144\]](https://www.mdpi.com/2073-4468/9/4/64/htm#B144-antibodies-09-00064)\]。实际上，hIgG4抗体是仅次于hIgG1的第二大类抗体产品。对于抗癌抗体，hIgG4类通常用于检查点抑制剂抗体，例如靶向PD-1的抗体。这是由于hIgG4抗体相对无法刺激ADCC或CDC，这是针对靶向引发抗肿瘤免疫所需的重要适应性免疫细胞的抗体的理想属性\[ [142](https://www.mdpi.com/2073-4468/9/4/64/htm#B142-antibodies-09-00064) \]。

然而，尽管这些Fc效应子功能降低了，但hIgG4抗体仍遭受F（ab）臂交换的现象，因此需要特定的氨基酸取代来防止这种情况。F（ab）臂交换涉及形成由一条重链和一条轻链组成的半抗体分子，它们可以与其他半分子（例如在血清中）重组形成未知特异性的单价双特异性抗体\[ [144](https://www.mdpi.com/2073-4468/9/4/64/htm#B144-antibodies-09-00064) \]。发现在228位的丝氨酸在该现象中起关键作用，通过使重链间二硫键更易于还原，刺激半分子之间的共价键断裂，因此是F（ab）的先决条件。手臂交换\[ [145](https://www.mdpi.com/2073-4468/9/4/64/htm#B145-antibodies-09-00064)\]。当通过SDS-PAGE分析显示S228P取代可提供均质的hIgG4时，证实了228位丝氨酸的重要性。这种替代在治疗性抗体hIgG4通常引入到防止的F（ab）臂交换\[ [144](https://www.mdpi.com/2073-4468/9/4/64/htm#B144-antibodies-09-00064)，[146](https://www.mdpi.com/2073-4468/9/4/64/htm#B146-antibodies-09-00064) \]。

基于其固有的缺乏效应子功能，人γ4恒定区已成为各种Fc沉默方法的主题。在2001年，一个小组通过将人γ1区域与人γ4区域交换，重新配置了嵌合（灵长类/人）IgG1抗CD4抗体kiliximab，这导致效应子功能降低\[ [136](https://www.mdpi.com/2073-4468/9/4/64/htm#B136-antibodies-09-00064) \]。为了进一步减少残留的FcγR结合，他们将hIgG同种型的序列与同样具有低FcγR结合活性的鼠IgG2b同种型进行了比较，后者在235位发现了与hIgG4序列不同的氨基酸\[ [136](https://www.mdpi.com/2073-4468/9/4/64/htm#B136-antibodies-09-00064) \]。在此位置将小鼠IgG2b残基（谷氨酸）整合到hIgG4抗体中，进一步降低了Fc效应子的功能\[ [136](https://www.mdpi.com/2073-4468/9/4/64/htm#B136-antibodies-09-00064)\]。发现具有S228P / L235E突变的所得抗体没有或基本上没有还原，与所有FcγR和C1q结合，导致无法测量ADCC \[ [130](https://www.mdpi.com/2073-4468/9/4/64/htm#B130-antibodies-09-00064) \]。在黑猩猩中，与WT hIgG4相比，S228P / L235E抗CD4抗体（clenoliximab）未能耗尽CD4 T细胞\[ [136](https://www.mdpi.com/2073-4468/9/4/64/htm#B136-antibodies-09-00064) \]。

各个小组随后没有使用如上所述的hIgG4替换hIgG1的整个恒定区，而是使用了定点诱变，将人γ4的特定氨基酸引入其他IgG同种型的抗体中。例如，An等。他们发现了源自hIgG4的氨基酸突变H268Q / V309L / A330S / P331S（IgG2m4）的组合\[ [132](https://www.mdpi.com/2073-4468/9/4/64/htm#B132-antibodies-09-00064) \]。将这些突变引入hIgG2骨架后，无法检测到与hFcγRI，hFcγRIIIA或C1q的结合。与WT hIgG2抗体相比，与hFcγRIIB的结合减少，与FcγRIIA-H131的结合没有变化\[ [132](https://www.mdpi.com/2073-4468/9/4/64/htm#B132-antibodies-09-00064) \]。

使用基于hIgG4的设计减少效应子功能的另一个例子是V234A / G237A / P238S / H268A / V309L / A330S / P331S（IgG2c4d）突变，其中hIgG2恒定区中的多个残基被IgG4残基取代\[ [134](https://www.mdpi.com/2073-4468/9/4/64/htm#B134-antibodies-09-00064) \]。与WT hIgG2对应物相比，引入这些IgG2c4d突变导致无法检测到与任何FcγRs或C1q的结合，并且没有可测量的ADCC，ADCP或CDC \[ [134](https://www.mdpi.com/2073-4468/9/4/64/htm#B134-antibodies-09-00064) \]。

尽管选择了hIgG4作为Fc惰性同种型，但新兴证据表明，残留FcγR结合仍然有效。例如，对于抗PD1抗体，髓样效应物已将残留的FcγR结合与从靶细胞中去除抗PD1 mAb有关\[ [147](https://www.mdpi.com/2073-4468/9/4/64/htm#B147-antibodies-09-00064) \]。这表明额外的工程设计可通过减少任何剩余的FcγR相互作用进一步提高抗PD1 mAb的活性。为此，正在接近诊所的试剂中发生了一些其他突变（请参见[第5.4节](https://www.mdpi.com/2073-4468/9/4/64/htm#sec5dot4-antibodies-09-00064)）。

#### \*5.4。\**效应子功能降低的抗癌抗体进入临床*

进入临床而效应功能降低的药物可能是针对检查点分子的最大一类药物，而针对PD1：PDL-1轴的药物最为突出。它们的作用是阻断效应T细胞上的PD1与抗原呈递细胞或肿瘤上的PDL-1之间的相互作用，从而使肿瘤特异性T细胞重新活化\[ [148](https://www.mdpi.com/2073-4468/9/4/64/htm#B148-antibodies-09-00064) \]。因此，重要的是，靶向PD1的抗体不会导致有益的肿瘤反应性T细胞缺失。因此，迄今批准的所有抗PD1 mAb（卡美珠单抗，pembrolizumab，nivolumab，cemiplimab）以及其他许多接受临床评估的药物（dostarlimab，spartalizumab和tislelizumab）均为hIgG4，并包含S228P突变以预防F（ab）臂交换\[ [149](https://www.mdpi.com/2073-4468/9/4/64/htm#B149-antibodies-09-00064) \]。

Tislelizumab被进一步改造为hIgG4抗PD1 mAb，具有许多其他突变（E233P / F234V / L235A / D265A / R409K），以更充分地消除FcγR相互作用\[ [150](https://www.mdpi.com/2073-4468/9/4/64/htm#B150-antibodies-09-00064) \]。在经典型霍奇金淋巴瘤Ⅱ期临床试验，tislelizumab达到87％的ORR，相比于在相同疾病的单独试验71％为pembrolizumab \[ [151](https://www.mdpi.com/2073-4468/9/4/64/htm#B151-antibodies-09-00064)，[152](https://www.mdpi.com/2073-4468/9/4/64/htm#B152-antibodies-09-00064)\]。尽管应谨慎比较各个试验的结果，但这提示工程化抗PD1 mAb去除FcγR相互作用可能会为临床带来更多益处。Tislelizumab，pembrolizumab和nivolumab均已在鳞状NSCLC中进行了评估。用于与化疗与在其各自的研究单独化疗抗体PFS是：tislelizumab 7.6与5.5个月，pembrolizumab 6.4与4.8个月和nivolumab 7.1与4.4个月\[ [153](https://www.mdpi.com/2073-4468/9/4/64/htm#B153-antibodies-09-00064)，[154](https://www.mdpi.com/2073-4468/9/4/64/htm#B154-antibodies-09-00064)，[155](https://www.mdpi.com/2073-4468/9/4/64/htm#B155-antibodies-09-00064) \]，尽管后者未能满足其的改进的主要终点整体生存率（OS）。随着更多数据的获得，Fc工程抗PD1抗体的真正优势将变得更加清晰。

关于Fc工程，PD1：PD-L1轴的另一端也引起了人们的兴趣，目前已批准了三种靶向PD-L1的抗体：avelumab，atezolizumab和durvalumab。后两个工程被设计为减少FcγR相互作用，目的是在不删除表达APC或PD-L1的T细胞的情况下增强对PD1：PDL1相互作用的阻断\[ [156](https://www.mdpi.com/2073-4468/9/4/64/htm#B156-antibodies-09-00064) \]。Atezolizumab是包含N297A突变糖基化除去废除除了结合FcγRI的所有FcγR的\[A hIgG1 [40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064)，[157](https://www.mdpi.com/2073-4468/9/4/64/htm#B157-antibodies-09-00064) \]。Durvalumab同时包含三重突变（L234F / L235E / P331S），其中结合被输给所有FcγR的\[ [131](https://www.mdpi.com/2073-4468/9/4/64/htm#B131-antibodies-09-00064)，[158](https://www.mdpi.com/2073-4468/9/4/64/htm#B158-antibodies-09-00064)\]都atezolizumab和durvalumab（分别为12.3 10.3对13.0和10.3与月，）导致OS适度增加时，在相对于单独的化疗单独SCLC试验联合化疗\[ [159](https://www.mdpi.com/2073-4468/9/4/64/htm#B159-antibodies-09-00064)，[160](https://www.mdpi.com/2073-4468/9/4/64/htm#B160-antibodies-09-00064) \]。如上所述，在没有进行并排比较的情况下，难以评价Fc修饰的效果。所有三种mAb均已获准用于多种恶性肿瘤，但是，值得注意的是，两种修饰抗体（atezolizumab和durvalumab）均已获准在NSCLC中使用，而使用avelumab进行相同适应症的试验并未显示OS改善\[ [156](https://www.mdpi.com/2073-4468/9/4/64/htm#B156-antibodies-09-00064)，[161](https://www.mdpi.com/2073-4468/9/4/64/htm#B161-antibodies-09-00064)\]。这些抗体目前正在其他一系列肿瘤中进行评估，这可能有助于就靶向PD-L1时Fc沉默的重要性建立更好的认识。

在PD1：PDL-1之外，使用Fc沉默也被视为开发针对新兴检查点分子TIM-3的试剂的有吸引力的策略。目前正在招募两种此类试剂，即Beigene BGB-A425和Five Prime Therapeutics / BMS BMS-986258，以进行早期试验。

除了调节的效应子功能，各种团体也试图理解和操纵抗体\[的半衰期[40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064)，[162](https://www.mdpi.com/2073-4468/9/4/64/htm#B162-antibodies-09-00064)，[163](https://www.mdpi.com/2073-4468/9/4/64/htm#B163-antibodies-09-00064)，[164](https://www.mdpi.com/2073-4468/9/4/64/htm#B164-antibodies-09-00064)，[165](https://www.mdpi.com/2073-4468/9/4/64/htm#B165-antibodies-09-00064)，[166](https://www.mdpi.com/2073-4468/9/4/64/htm#B166-antibodies-09-00064)，[167](https://www.mdpi.com/2073-4468/9/4/64/htm#B167-antibodies-09-00064)，[168](https://www.mdpi.com/2073-4468/9/4/64/htm#B168-antibodies-09-00064)，[169](https://www.mdpi.com/2073-4468/9/4/64/htm#B169-antibodies-09-00064)，[170](https://www.mdpi.com/2073-4468/9/4/64/htm#B170-antibodies-09-00064)，[171](https://www.mdpi.com/2073-4468/9/4/64/htm#B171-antibodies-09-00064)，[172](https://www.mdpi.com/2073-4468/9/4/64/htm#B172-antibodies-09-00064) \]。

## **6\. Fc工程技术可延长抗体的半衰期**

在各种治疗和诊断方案中，对Fc修饰以调节IgG与FcRn的结合亲和力，从而调节IgG半衰期非常感兴趣。可能与癌症最相关的是Fc修饰，可提高IgG回收效率，延长半衰期并允许长期抑制治疗靶标，同时降低所需的给药频率。例如，通过维护策略使用抗CD20单克隆抗体延长治疗方案有助于延长在某些淋巴瘤的缓解，因此可以从较长的半衰期\[中获益[173](https://www.mdpi.com/2073-4468/9/4/64/htm#B173-antibodies-09-00064)，[174](https://www.mdpi.com/2073-4468/9/4/64/htm#B174-antibodies-09-00064) \]。这些修改的示例已汇总在[图5中](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f005)。然而，很明显，半衰期延长可能不适用于可能难以控制不良事件（例如细胞因子风暴反应）的所有抗癌抗体，例如免疫刺激性单克隆抗体（例如TGN1412）\[ [175](https://www.mdpi.com/2073-4468/9/4/64/htm#B175-antibodies-09-00064) \]。但是，某些免疫检查点抑制剂抗体（例如ipilimumab和avelumab）已显示出显着的正暴露-疗效关系，且清除率降低与有益的治疗反应相关\[ [176](https://www.mdpi.com/2073-4468/9/4/64/htm#B176-antibodies-09-00064) \]。然而，重要的是要注意，对于某些免疫检查点抑制剂，也报告了显着的暴露-安全关系，这通过暴露增加与不良事件风险增加相关联证明 [\[176\]。](https://www.mdpi.com/2073-4468/9/4/64/htm#B176-antibodies-09-00064)\]。因此，在考虑延长半衰期之前，必须仔细评估这些目标的风险：利益关系。也许由于这些原因，迄今为止，有限数量的临床相关抗癌抗体已采用半衰期延长技术，如[第6.1节所述](https://www.mdpi.com/2073-4468/9/4/64/htm#sec6dot1-antibodies-09-00064)。

![](../../../_resources/1a6f4c07d8f8ea0fad88a36fb5107434.png)

[(L)](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f005)

****图5.**** 改善半衰期的Fc修饰。（****甲****）的事件时主要发现是关于的Fc制成详细的时间表：IgG的相互作用，技术用于发现具有增强的半衰期变体和当所述Fc变体在文献\[首先描述[40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064)，[162](https://www.mdpi.com/2073-4468/9/4/64/htm#B162-antibodies-09-00064)，[163](https://www.mdpi.com/2073-4468/9/4/64/htm#B163-antibodies-09-00064)，[164](https://www.mdpi.com/2073-4468/9/4/64/htm#B164-antibodies-09-00064)，[165](https://www.mdpi.com/2073-4468/9/4/64/htm#B165-antibodies-09-00064)，[166](https://www.mdpi.com/2073-4468/9/4/64/htm#B166-antibodies-09-00064)，[167](https://www.mdpi.com/2073-4468/9/4/64/htm#B167-antibodies-09-00064)，[168](https://www.mdpi.com/2073-4468/9/4/64/htm#B168-antibodies-09-00064)，[169](https://www.mdpi.com/2073-4468/9/4/64/htm#B169-antibodies-09-00064)，[170](https://www.mdpi.com/2073-4468/9/4/64/htm#B170-antibodies-09-00064)，[171](https://www.mdpi.com/2073-4468/9/4/64/htm#B171-antibodies-09-00064)，[172](https://www.mdpi.com/2073-4468/9/4/64/htm#B172-antibodies-09-00064)，[177](https://www.mdpi.com/2073-4468/9/4/64/htm#B177-antibodies-09-00064) \]。字母指的是在正文中讨论的引入的氨基酸取代的通用符号。（****B****）在Fc内的先前识别的点突变，该突变影响的效应细胞功能注释上的hIgG1 Fc结构晶体结构模型（PDB：3AVE; \[ [49](https://www.mdpi.com/2073-4468/9/4/64/htm#B49-antibodies-09-00064)，[50](https://www.mdpi.com/2073-4468/9/4/64/htm#B50-antibodies-09-00064) \]），并在表中详述如下。（****C****）将变体的FcRn的半衰期变化或结合亲和力的大小与相同IgG同种型和F（ab）区域的WT抗体进行比较。每行描绘了一个独立的实验，因此通常是独立的方法，它们利用的是上一栏中引用的来自特定研究的不同IgG骨架。NB-无可检测的结合，nd-无数据，−无变化，↑&lt;2倍上调，↑↑2–9.99倍上调，↑↑↑10–99.99倍上调，↑↑↑↑&gt; 100倍上调。

#### \*6.1。\**导致半衰期延长的氨基酸取代。*

对FcRn hIgG1结合位点被定位在人类中在1999年和2年后，所述共晶体结构已得到解决暗指的pH依赖性通过残基H310和H435 \[的质子结合机构[39](https://www.mdpi.com/2073-4468/9/4/64/htm#B39-antibodies-09-00064)，[178](https://www.mdpi.com/2073-4468/9/4/64/htm#B178-antibodies-09-00064) \]。使用该数据，各组具有工程改造的抗体变体，这些变体显示出与FcRn的亲和力更高，并且显示了延长的半衰期（[图5](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f005)）。为了延长mAb的半衰期，试剂需要在酸性pH下具有对FcRn的增加的亲和力，同时在中性pH下仍能有效地解离，这种机制对抗体工程提出了独特的挑战。

如前所述，在2001年，对hIgG1与FcyRs和FcRn的结合位点的分析导致了许多具有不同属性的hIgG1变体的设计，包括与FcRn的结合增强（[图5](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f005) A）\[ [40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064) \]。与WT hIgG1相比，三重突变T307A / E380A / N434A在内体pH值下显示出FcRn结合增加了11.8倍，同时保留了与低亲和力FcγR的等效结合\[ [40](https://www.mdpi.com/2073-4468/9/4/64/htm#B40-antibodies-09-00064) \]。在随后的研究中，发现不仅在内体pH下与FcRn的结合增强，在细胞外pH下与FcRn的结合也增加了2.4倍\[ [177](https://www.mdpi.com/2073-4468/9/4/64/htm#B177-antibodies-09-00064) \]。在体内，与WT hIgG1抗体相比，T307A / E380A / N434A突变体在hFcRn转基因小鼠模型中的半衰期延长了2.5倍\[[177](https://www.mdpi.com/2073-4468/9/4/64/htm#B177-antibodies-09-00064) \]。

Dall'Acqua等。利用该知识合理设计了噬菌体展示库，以鉴定对FcRn具有增强结合亲和力的其他变体（[图5](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f005) A）\[ [162](https://www.mdpi.com/2073-4468/9/4/64/htm#B162-antibodies-09-00064) \]。在体pH他们确定了三重突变M252Y / S254T / T256E该增强的FcRn通过结合11倍，而不会改变在细胞外pH对FcRn的结合\[ [162](https://www.mdpi.com/2073-4468/9/4/64/htm#B162-antibodies-09-00064)，[163](https://www.mdpi.com/2073-4468/9/4/64/htm#B163-antibodies-09-00064) \]。突变的后续晶体结构分析表明，hIgG1中的T256E突变导致在Fc-YTE的256E残基与FcRn的β2m亚基的Gln2残基之间形成2个新的盐桥，这被认为是与FcRn结合增强的原因\[ [179](https://www.mdpi.com/2073-4468/9/4/64/htm#B179-antibodies-09-00064)\]。Dall'Alcqua等。食蟹猴研究表明，M252Y / S254T / T256E IgG1的半衰期比WT抗体高4倍，并且当初始剂量为30 mg / kg时，到55天仍未检测到WT抗体，而约60μg在相同的时间点在血清中检测到/ mL的M252Y / S254T / T256E IgG1 \[ [163](https://www.mdpi.com/2073-4468/9/4/64/htm#B163-antibodies-09-00064) \]。但是，引入M252Y / S254T / T256E突变会减少与FcyR的结合，并降低其ADCC的能力。此外，发现具有M252Y / S254T / T256E突变的IgG通过-8℃相比于WT hIgG1，这可能影响抗体的溶解度和聚集，对于治疗性抗体\[既不利的性质时具有较低的热稳定性[162](https://www.mdpi.com/2073-4468/9/4/64/htm#B162-antibodies-09-00064)，[180](https://www.mdpi.com/2073-4468/9/4/64/htm#B180-antibodies-09-00064) \]。

通过合理设计**和高通量筛选发现的其他延长半衰期的变体包括M428L / N434S突变\[** **[168](https://www.mdpi.com/2073-4468/9/4/64/htm#B168-antibodies-09-00064) ****\]。在体外，与WT hIgG1相比，发现M428L / N434S hIgG1在pH 6下与FcRn的结合亲和力增强11倍，在细胞外pH下与FcRn的结合没有变化**\[ [168](https://www.mdpi.com/2073-4468/9/4/64/htm#B168-antibodies-09-00064) \]。随后的分析表明，**Fc中的N434残基与FcRn的L135残基发生不利的相互作用，并且该残基（N434S）的突变允许与FcRn的羰基形成另外的氢键\[** **[179](https://www.mdpi.com/2073-4468/9/4/64/htm#B179-antibodies-09-00064) \]。在体内，M428L / N434S hIgG1抗VEGF抗体在hFcRn转基因小鼠中的半衰期延长了3.2倍，在食蟹猴中的半衰期延长了3倍\[** [168](https://www.mdpi.com/2073-4468/9/4/64/htm#B168-antibodies-09-00064)\]。

基于对FcRn的IgG结合位点的了解，各小组还使用了定点诱变进行更多的靶向突变（[图5](https://www.mdpi.com/2073-4468/9/4/64/htm#fig_body_display_antibodies-09-00064-f005) A）。结合hFc：FcRn复杂晶体结构的分子模型分析，Hinton等人。鉴定了T250Q / M428L氨基酸取代，导致内体pH下与FcRn的结合增加了28倍，而在细胞外pH下不影响与FcRn的结合\[ [164](https://www.mdpi.com/2073-4468/9/4/64/htm#B164-antibodies-09-00064) \]。在体内，与WT人源化IgG4相比，T250Q / M428L人源化IgG4在恒河猴中的半衰期延长了1.9倍，单位时间内清除的抗体的血清量低2.8倍\[ [164](https://www.mdpi.com/2073-4468/9/4/64/htm#B164-antibodies-09-00064)\]。将单突变V308P引入hIgG1还证明在内体pH值下与FcRn的结合显着增强（超过43倍），在细胞外pH值下与FcRn的结合无变化，在灵长类中增强半衰期（食蟹猴增加2.4倍）猴）与野生型hIgG1相比\[ [169](https://www.mdpi.com/2073-4468/9/4/64/htm#B169-antibodies-09-00064) \]。

假设可以增强与FcRn的结合的其他残基组合包括两个残基H433和N434，它们与已知在人FcRn-IgG相互作用中起关键作用的氨基酸非常接近\[ [167](https://www.mdpi.com/2073-4468/9/4/64/htm#B167-antibodies-09-00064) \]。因此，双突变体H433K / N434F评估并且发现其具有16倍的增强，同时最小化在细胞外pH变化的结合FcRn的在体pH对FcRn的结合相比于WT \[当[167](https://www.mdpi.com/2073-4468/9/4/64/htm#B167-antibodies-09-00064) \]。

Booth等人使用结构模型和蛋白质残基网络来了解Fc与FcRn在不同pH下的相互作用。我们寻求的变体特别关注在pH 6时降低Fc：FcRn相互作用的k off，同时保持与FcγRs的结合\[ [171](https://www.mdpi.com/2073-4468/9/4/64/htm#B171-antibodies-09-00064) \]。通过他们的框架，他们鉴定了一个三突变体H285D / T307Q / A378V，在hFcRn转基因小鼠中，其内体pH值与FcRn的结合增强了13倍以上，半衰期增强了8倍以上，同时增强了与所有FcyR和C1q和与WT相比，可增强相关的Fc效应子功能（ADCC和CDC）\[ [171](https://www.mdpi.com/2073-4468/9/4/64/htm#B171-antibodies-09-00064) \]。

延长抗体半衰期的另一种机制是设计抗体变体，该抗体变体在内体pH值下具有增强的FcRn结合力，而在细胞外pH值下则取消结合。残留在pH 7.4的IgG结合已经显示出血浆的回收和循环的持久性\[负面影响[172](https://www.mdpi.com/2073-4468/9/4/64/htm#B172-antibodies-09-00064)，[181](https://www.mdpi.com/2073-4468/9/4/64/htm#B181-antibodies-09-00064) \]。对于需要释放到血浆中并在其中持久存在的抗体，例如，靶向细胞结合靶标的抗体，以及在细胞外pH去除任何残留的IgG结合可能是有利的抗体，这种方法将是有益的\[ [97](https://www.mdpi.com/2073-4468/9/4/64/htm#B97-antibodies-09-00064) \]。Lee等。合理设计的库用于在大肠杆菌中进行高通量筛选，以鉴定在pH 5.8而非pH 7.4时选择性结合FcRn的hIgG1 Fc突变\[ [172](https://www.mdpi.com/2073-4468/9/4/64/htm#B172-antibodies-09-00064)\]。通过这些筛选策略，他们发现三重突变体L309D / Q311H / N434S在内体pH值下与FcRn的结合增强了5倍，而在细胞外pH值下与FcRn的结合与WT hIgG1无关\[ [172](https://www.mdpi.com/2073-4468/9/4/64/htm#B172-antibodies-09-00064) \]。在体内，与WT hIgG1相比，在hFcRn /hβ2m/hFcγR/ hIgG1，κ小鼠中L309D / Q311H / N434S hIgG1的半衰期延长了4倍以上\[ [172](https://www.mdpi.com/2073-4468/9/4/64/htm#B172-antibodies-09-00064) \]。与M252Y / S254T / T256E三重突变不同，具有L309D / Q311H / N434S突变的抗体保留了FcyR结合和ADCC能力\[ [172](https://www.mdpi.com/2073-4468/9/4/64/htm#B172-antibodies-09-00064) \]。

通过专注于在内体pH下增强与FcRn的结合而不改变或最小化细胞外pH结合的改变的研究发现了上述Fc变异体，但是，也可以设计变异体以调节细胞外pH的结合。鉴定在细胞外pH下与FcRn具有差异结合的抗体变异体的一种原理是生成所谓的“清扫抗体”以清除可溶性靶标。靶向使用抗体的可溶性抗原的不希望的反响是，它可以矛盾导致抗原\[A> 1000倍的增加[182](https://www.mdpi.com/2073-4468/9/4/64/htm#B182-antibodies-09-00064)，[183](https://www.mdpi.com/2073-4468/9/4/64/htm#B183-antibodies-09-00064)\]。这是由于IgG的半衰期比结合的抗原的半衰期长得多，从而允许抗体-抗原复合物的积累，并由于清除率的降低而增加血浆抗原的存在\[ [170](https://www.mdpi.com/2073-4468/9/4/64/htm#B170-antibodies-09-00064) \]。为了抵消这一点，工程改造了抗体，以在内体和细胞外pH值下增强与FcRn的结合。在pH 7.4时，与FcRn的结合增加会阻止抗体释放到血浆中，从而使其与可溶性抗原形成复合物\[ [170](https://www.mdpi.com/2073-4468/9/4/64/htm#B170-antibodies-09-00064) \]。取而代之的是，抗体与内体膜紧密结合，并与细胞表面的配体结合\[ [170](https://www.mdpi.com/2073-4468/9/4/64/htm#B170-antibodies-09-00064)\]。由于这些抗体仍然保持与细胞表面的结合，因此抗体：抗原复合物可以快速内化到细胞中。清除抗体通常经过工程改造，一旦内化在核内体中就能够从抗原上解离，从而将抗原单独靶向溶酶体降解\[ [184](https://www.mdpi.com/2073-4468/9/4/64/htm#B184-antibodies-09-00064) \]。由于抗体在细胞外pH时由于与FcRn的结合增强而保留在细胞表面，而由于在内体pH时与FcRn的强结合而保留在内体中，因此清扫抗体不会释放到血浆中形成抗体-抗原复合物或在溶酶体中降解并在细胞内不断循环\[ [184](https://www.mdpi.com/2073-4468/9/4/64/htm#B184-antibodies-09-00064)\]。因此，这些抗体在清除与延长的半衰期相关的可溶性靶标方面非常有效。关于抗癌抗体，这些广泛的抗体在靶向免疫抑制细胞因子（例如TGF-β）方面可能是有价值的\[ [185](https://www.mdpi.com/2073-4468/9/4/64/htm#B185-antibodies-09-00064) \]。例如，已证明针对这些细胞因子的抗体与免疫检查点抑制剂（例如抗PD-1 / PD-L1抗体）配对可增强抗肿瘤活性\[ [185](https://www.mdpi.com/2073-4468/9/4/64/htm#B185-antibodies-09-00064) \]。清除抗体可以更有效地清除这些可溶性靶标，从而逆转免疫抑制。尽管尚未将清除抗体用于癌症治疗，但在下面描述了产生这些试剂的Fc修饰，可以在将来实现。

使用分子建模，将hIgG1 Fc中靠近FcRn结合位点的残基鉴定为突变候选者，以改变与FcRn的结合。发现产生的突变M252Y / S254T / T256E + H433K / N434F（称为YTE-KF或MST-HN或Abdeg）在内体和细胞外pH值下与FcRn的结合增加20倍\[ [165](https://www.mdpi.com/2073-4468/9/4/64/htm#B165-antibodies-09-00064) \]。

能够在内体和细胞外pH值下增强与FcRn结合的hIgG1突变的另一个实例包括M252Y / V308P / N343Y突变。Igawa等人发现了M252Y / V308P / N343Y突变。与野生型hIgG1相比，在内体pH值下，与FcRn的结合增强了> 400倍，在细胞外pH值下，与FcRn的结合> 2500倍。在体内，与hFcRn转基因小鼠中的WT hIgG1抗体相比，具有M252Y / V308P / N343Y突变的hIgG1抗IL-6R抗体与血浆中的总人类可溶性IL-6R相比降低了1000倍\[ [170](https://www.mdpi.com/2073-4468/9/4/64/htm#B170-antibodies-09-00064) \]。

#### \*6.2。\**半衰期延长的抗癌抗体进入临床*

如上所述，用于改善半衰期的Fc工程技术将使mAb具有延长的生物利用度和潜在的治疗效果，同时降低给药频率要求。在临床前研究中，与未修饰的mAb相比，使用Xencor Xtend技术改造的西妥昔单抗和贝伐单抗的半衰期得到了显着改善，后者可转化为更长的肿瘤控制时间\[ [168](https://www.mdpi.com/2073-4468/9/4/64/htm#B168-antibodies-09-00064) \]。迄今为止，FDA仅批准了一种延长的半衰期抗体。Ravulizumab是依库丽单抗的工程化版本，靶向C5，用于阵发性夜间血红蛋白尿和非典型溶血性尿毒症综合征\[ [186](https://www.mdpi.com/2073-4468/9/4/64/htm#B186-antibodies-09-00064)\]。引入的氨基酸取代（VH\_Y27H，VH\_S57H，M428L，N434S）导致半衰期延长了4倍，使剂量从每2周减少到每8周，同时保持了疗效\[ [187](https://www.mdpi.com/2073-4468/9/4/64/htm#B187-antibodies-09-00064)\]。迄今为止，抗癌剂的Fc增强技术仅限于针对Xencor使用Xtend技术生成的针对双特异性mAb的检查点封锁（Xmab23104：PD-1 x LAG3，XmAb22841：CTLA-4 x LAG3和XmAb20717：PD-1 x CTLA-4），并且没有完整的IgG分子进展。对延长的癌症半衰期抗体的这种有限兴趣可能是由于在大多数情况下，例如在将mAb用作化学免疫疗法方案的一部分时，自然的半衰期（〜21天）就足够了。但是，在某些情况下，例如在维护制度中，增加暴露可能会特别有益。

## **7.结论**

迄今为止，临床上最先进的Fc工程化mAb是设计为具有增强的效应子功能的抗体，主要是通过增强与激活性FcγR的结合来实现的。临床上最先进的分子依靠糖基修饰，通过去除核心岩藻糖残基来增强效应细胞功能。尽管这并未导致治疗结果发生较大的变化，但成功的药物（如奥比妥珠单抗，莫加莫珠单抗和马格妥昔单抗）已提供了重要的概念证明，即Fc改造的mAb可引起患者受益。正在开发的其他mAb可能会以此成功为基础，特别是基于S239D / I332E突变的抗体的开发，发现该突变提供了ADCP和ADCC的最大增强。FcγR参与对靶向检查点抑制受体PD-1的mAb活性的有害作用似乎很明显，并且经过适当工程改造的Fc沉默试剂已获得批准。总的来说，这依赖于在临床上使用掺入S228P突变的IgG4同型突变，以防止F（ab）臂与所有IgG4 mAb交换。重要的是要了解，相对于将沉默突变引入更广泛使用的IgG1同种型，将额外的Fc沉默突变引入IgG4 mAb是否将提供强大的临床益处。抗体工程学的剩余挑战之一是要了解抗体活性的提高与有害毒性之间的平衡。对于免疫刺激抗体或半衰期延长的抗体而言，这可能是最严重的问题。

## **作者贡献**

RL制作图形，编写和编辑手稿，RJO编写和编辑手稿，ET解释结构数据并生成图形，MSC编写和编辑手稿，SAB编写和编辑手稿。所有作者均已阅读并同意该手稿的发行版本。

## **资金**

这项工作得到了MSC和SAB授予CRUK计划的资助（授予号：A24721）。CRUK赠款A20537和A25139提供了额外的支持。

## **致谢**

我们要感谢抗体和疫苗小组的成员进行了有益的讨论，并对由于篇幅和内容限制而未被引用的那些作者致歉。

## **利益冲突**

RL是GSK的员工。MSC是BioInvent International的全职顾问，并曾在罗氏（Roche），勃林格殷格翰（Boehringer Ingelheim），Baxalta，Merck KGaA和GLG担任教育和咨询职务。他已获得Bioinvent，Roche，Gilead，iTeos，UCB和GSK的研究资助。SAB曾担任BioInvent的顾问，并已获得有关资助和专利的机构支持。

## **参考文献**

1.Nimmerjahn，F。Ravetch，合资公司的Fcγ受体可调节免疫反应。*纳特* *免疫牧师* ****2008年****，*8*，34-47。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=Fcgamma+receptors+as+regulators+of+immune+responses&author=Nimmerjahn,+F.&author=Ravetch,+J.V.&publication_year=2008&journal=Nat.+Rev.+Immunol.&volume=8&pages=34%E2%80%9347&doi=10.1038/nri2206)\] \[ [CrossRef](https://dx.doi.org/10.1038/nri2206) \]

2.陈HT 休斯D. 法语，RR；阿拉巴马州图特; 加州沃尔什；特林，JL；M.Glennie；Cragg，MS CD20诱导的淋巴瘤细胞死亡与半胱天冬酶及其重新分布在Triton X-100不溶性膜筏中无关。*癌症研究。* ****2003****，*63*，5480-5489。\[ [Google Scholar](https://scholar.google.com/scholar_lookup?title=CD20-induced+lymphoma+cell+death+is+independent+of+both+caspases+and+its+redistribution+into+triton+X-100+insoluble+membrane+rafts&author=Chan,+H.T.&author=Hughes,+D.&author=French,+R.R.&author=Tutt,+A.L.&author=Walshe,+C.A.&author=Teeling,+J.L.&author=Glennie,+M.&author=Cragg,+M.S.&publication_year=2003&journal=Cancer+Res.&volume=63&pages=5480%E2%80%935489) \]

3.加利福尼亚迪博德；FJ，伯尔斯肯斯；RN de Jong；RI，Koning；K.Strumane；马萨诸塞州林多佛; 马萨诸塞州沃霍尔斯特；Ugurlar，D。Rosati，S .; 赫克，AJR；等。补体被组装在细胞表面的IgG六聚体激活。*科学* ****2014****，*343*，1260至1263年。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=Complement+is+activated+by+IgG+hexamers+assembled+at+the+cell+surface&author=Diebolder,+C.A.&author=Beurskens,+F.J.&author=de+Jong,+R.N.&author=Koning,+R.I.&author=Strumane,+K.&author=Lindorfer,+M.A.&author=Voorhorst,+M.&author=Ugurlar,+D.&author=Rosati,+S.&author=Heck,+A.J.R.&publication_year=2014&journal=Science&volume=343&pages=1260%E2%80%931263&doi=10.1126/science.1248943)\] \[ [CrossRef](https://dx.doi.org/10.1126/science.1248943) \]

4.哥伦比亚Roopenian；Akilesh，S. FcRn：新生儿Fc受体已经成熟。*纳特* *免疫牧师* ****2007年****，*7*，715-725。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=FcRn:+The+neonatal+Fc+receptor+comes+of+age&author=Roopenian,+D.C.&author=Akilesh,+S.&publication_year=2007&journal=Nat.+Rev.+Immunol.&volume=7&pages=715%E2%80%93725&doi=10.1038/nri2155)\] \[ [CrossRef](https://dx.doi.org/10.1038/nri2155) \]

5.科勒（G. Milstein，C。分泌预定特异性抗体的融合细胞的连续培养。*自然* ****1975年****，*256*，495-497。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=Continuous+cultures+of+fused+cells+secreting+antibody+of+predefined+specificity&author=Kohler,+G.&author=Milstein,+C.&publication_year=1975&journal=Nature&volume=256&pages=495%E2%80%93497&doi=10.1038/256495a0)\] \[ [CrossRef](https://dx.doi.org/10.1038/256495a0) \]

6.邱ML; 博士古雷（Douule）特普利亚科夫 Gilliland，GL抗体的结构和功能：工程治疗学的基础。*抗体* ****2019****，*8*，55[谷歌学术](https://scholar.google.com/scholar_lookup?title=Antibody+Structure+and+Function:+The+Basis+for+Engineering+Therapeutics&author=Chiu,+M.L.&author=Goulet,+D.R.&author=Teplyakov,+A.&author=Gilliland,+G.L.&publication_year=2019&journal=Antibodies&volume=8&pages=55&doi=10.3390/antib8040055)\] \[[交叉引用](https://dx.doi.org/10.3390/antib8040055)\]

7.合资公司Ravetch；Bolland，S.IgG Fc受体。*安努* *免疫牧师* ****2001年****，*19*，275-290。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=IgG+Fc+receptors&author=Ravetch,+J.V.&author=Bolland,+S.&publication_year=2001&journal=Annu.+Rev.+Immunol.&volume=19&pages=275%E2%80%93290&doi=10.1146/annurev.immunol.19.1.275)\] \[ [CrossRef](https://dx.doi.org/10.1146/annurev.immunol.19.1.275) \]

8.Taka，T .；李敏 西尔维斯特（Sylvestre）；克莱恩河; Ravetch，JV FcRγ链缺失导致多营养型效应细胞缺陷。*细胞* ****1994****，*76*，519-529。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=FcR+gamma+chain+deletion+results+in+pleiotrophic+effector+cell+defects&author=Takai,+T.&author=Li,+M.&author=Sylvestre,+D.&author=Clynes,+R.&author=Ravetch,+J.V.&publication_year=1994&journal=Cell&volume=76&pages=519%E2%80%93529&doi=10.1016/0092-8674%2894%2990115-5 "https://scholar.google.com/scholar_lookup?title=FcR+gamma+chain+deletion+results+in+pleiotrophic+effector+cell+defects&author=Takai,+T.&author=Li,+M.&author=Sylvestre,+D.&author=Clynes,+R.&author=Ravetch,+J.V.&publication_year=1994&journal=Cell&volume=76&pages=519%E2%80%93529&doi=10.1016/0092-8674(94)90115-5")\] \[ [CrossRef](https://dx.doi.org/10.1016/0092-8674%2894%2990115-5 "https://dx.doi.org/10.1016/0092-8674(94)90115-5") \]

9.JE，鲑鱼；密勒德（Sill）荷兰布洛格；金伯利（Kimberly），RP Fcγ受体IIIb以氧化剂依赖性和等位基因敏感的方式增强Fcγ受体IIa的功能。\*J.临床。\**调查。* ****1995年****，*95*，2877年至2885年。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=Fc+gamma+receptor+IIIb+enhances+Fc+gamma+receptor+IIa+function+in+an+oxidant-dependent+and+allele-sensitive+manner&author=Salmon,+J.E.&author=Millard,+S.S.&author=Brogle,+N.L.&author=Kimberly,+R.P.&publication_year=1995&journal=J.+Clin.+Investig.&volume=95&pages=2877%E2%80%932885&doi=10.1172/JCI117994)\] \[ [CrossRef](https://dx.doi.org/10.1172/JCI117994) \]

10.范德普尔（CE）；RM Spaapen; 范·德·温克尔（JG）Leusen，JH高亲和力IgG受体FcgammaRI的功能特征。*J.免疫。* ****2011****，*186*，2699年至2704年。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=Functional+characteristics+of+the+high+affinity+IgG+receptor,+FcgammaRI&author=van+der+Poel,+C.E.&author=Spaapen,+R.M.&author=van+de+Winkel,+J.G.&author=Leusen,+J.H.&publication_year=2011&journal=J.+Immunol.&volume=186&pages=2699%E2%80%932704&doi=10.4049/jimmunol.1003526)\] \[ [CrossRef](https://dx.doi.org/10.4049/jimmunol.1003526) \]

11.Mancardi，D .；Daëron，免疫应答中的Fc受体。可在线获得：[https](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157464/)：[//www.ncbi.nlm.nih.gov/pmc/articles/PMC7157464/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157464/)（于2020年8月30日访问）。

12.Nimmerjahn，F。Ravetch，JV通过选择性Fc受体结合，产生不同的免疫球蛋白g亚类活性。*科学* ****2005****，*310*，1510-1512。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=Divergent+immunoglobulin+g+subclass+activity+through+selective+Fc+receptor+binding&author=Nimmerjahn,+F.&author=Ravetch,+J.V.&publication_year=2005&journal=Science&volume=310&pages=1510%E2%80%931512&doi=10.1126/science.1118948)\] \[ [CrossRef](https://dx.doi.org/10.1126/science.1118948) \]

13.路易斯安那州达哈尔；窦升; 侯赛因，K .；刘荣; 埃里（A.）吉隆坡考克斯 Murinello，S。特雷西，我。F.福科尼；斯蒂尔（AJ）；等。STING激活可逆转淋巴瘤介导的对抗体免疫疗法的抵抗。*癌症研究。* ****2017年****，*77*，3619-3631。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=STING+Activation+Reverses+Lymphoma-Mediated+Resistance+to+Antibody+Immunotherapy&author=Dahal,+L.N.&author=Dou,+L.&author=Hussain,+K.&author=Liu,+R.&author=Earley,+A.&author=Cox,+K.L.&author=Murinello,+S.&author=Tracy,+I.&author=Forconi,+F.&author=Steele,+A.J.&publication_year=2017&journal=Cancer+Res.&volume=77&pages=3619%E2%80%933631&doi=10.1158/0008-5472.CAN-16-2784)\] \[ [CrossRef](https://dx.doi.org/10.1158/0008-5472.CAN-16-2784) \]

14.布鲁恩斯，P .；Iannascoli，B .；英格兰，P .；宾夕法尼亚州曼卡迪；费尔南德斯（N. Jorieux，S .；Daëron，M.人Fcγ受体及其多态性变体对人IgG亚类的特异性和亲和力。*血* ****2009年****，*113*，3716-3725。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=Specificity+and+affinity+of+human+Fc%CE%B3+receptors+and+their+polymorphic+variants+for+human+IgG+subclasses&author=Bruhns,+P.&author=Iannascoli,+B.&author=England,+P.&author=Mancardi,+D.A.&author=Fernandez,+N.&author=Jorieux,+S.&author=Da%C3%ABron,+M.&publication_year=2009&journal=Blood&volume=113&pages=3716%E2%80%933725&doi=10.1182/blood-2008-09-179754)\] \[ [CrossRef](https://dx.doi.org/10.1182/blood-2008-09-179754) \]

15.CE哈格里夫斯；密西西比州Rose-Zerilli；LR马查多；饭山市; EJ Hollox；克雷格，MS；Strefford，JCFcγ受体：遗传变异，功能和疾病。*免疫* *牧师* ****2015年****，*268*，6-24。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=Fc%CE%B3+receptors:+Genetic+variation,+function,+and+disease&author=Hargreaves,+C.E.&author=Rose-Zerilli,+M.J.&author=Machado,+L.R.&author=Iriyama,+C.&author=Hollox,+E.J.&author=Cragg,+M.S.&author=Strefford,+J.C.&publication_year=2015&journal=Immunol.+Rev.&volume=268&pages=6%E2%80%9324&doi=10.1111/imr.12341)\] \[ [CrossRef](https://dx.doi.org/10.1111/imr.12341) \]

16.路易斯安那州达哈尔；Roghanian，A .; SA，比尔斯；Cragg，MSFcγR需求导致成功的免疫治疗。*免疫* *牧师* ****2015年****，*268*，104-122。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=Fc%CE%B3R+requirements+leading+to+successful+immunotherapy&author=Dahal,+L.N.&author=Roghanian,+A.&author=Beers,+S.A.&author=Cragg,+M.S.&publication_year=2015&journal=Immunol.+Rev.&volume=268&pages=104%E2%80%93122&doi=10.1111/imr.12342)\] \[ [CrossRef](https://dx.doi.org/10.1111/imr.12342) \]

17.吴建 JC Edberg；PB，Redecha；Bansal，V .; 总理古雷（Guyre）；科尔曼，K。JE，鲑鱼；金伯利，RPFcγRIIIa（CD16）的新型多态性改变受体功能，并易患自身免疫性疾病。\*J.临床。\**投资。* ****1997年****，*100*，1059年至1070年。\[ [Google学术搜索](https://scholar.google.com/scholar_lookup?title=A+novel+polymorphism+of+FcgammaRIIIa+%28CD16%29+alters+receptor+function+and+predisposes+to+autoimmune+disease&author=Wu,+J.&author=Edberg,+J.C.&author=Redecha,+P.B.&author=Bansal,+V.&author=Guyre,+P.M.&author=Coleman,+K.&author=Salmon,+J.E.&author=Kimberly,+R.P.&publication_year=1997&journal=J.+Clin.+Invest.&volume=100&pages=1059%E2%80%931070&doi=10.1172/JCI119616 "https://scholar.google.com/scholar_lookup?title=A+novel+polymorphism+of+FcgammaRIIIa+(CD16)+alters+receptor+function+and+predisposes+to+autoimmune+disease&author=Wu,+J.&author=Edberg,+J.C.&author=Redecha,+P.B.&author=Bansal,+V.&author=Guyre,+P.M.&author=Coleman,+K.&author=Salmon,+J.E.&author=Kimberly,+R.P.&publication_year=1997&journal=J.+Clin.+Invest.&volume=100&pages=1059%E2%80%931070&doi=10.1172/JCI119616")\] \[ [CrossRef](https://dx.doi.org/10.1172/JCI119616) \]

18.Lo Nigro, C.; Macagno, M.; Sangiolo, D.; Bertolaccini, L.; Aglietta, M.; Merlano, M.C. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: Biological evidence and clinical perspectives. *Ann. Transl. Med.* **2019**, *7*, 105\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=NK-mediated+antibody-dependent+cell-mediated+cytotoxicity+in+solid+tumors:+Biological+evidence+and+clinical+perspectives&author=Lo+Nigro,+C.&author=Macagno,+M.&author=Sangiolo,+D.&author=Bertolaccini,+L.&author=Aglietta,+M.&author=Merlano,+M.C.&publication_year=2019&journal=Ann.+Transl.+Med.&volume=7&pages=105&doi=10.21037/atm.2019.01.42)\] \[[CrossRef](https://dx.doi.org/10.21037/atm.2019.01.42)\]

19.Parham, P. *The Immune System*, 4th ed.; Garland Science: New York, NY, USA, 2014; 532p. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+Immune+System&author=Parham,+P.&publication_year=2014)\]

20.Herter, S.; Birk, M.C.; Klein, C.; Gerdes, C.; Umana, P.; Bacac, M. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. *J. Immunol.* **2014**, *192*, 2252–2260. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Glycoengineering+of+therapeutic+antibodies+enhances+monocyte/macrophage-mediated+phagocytosis+and+cytotoxicity&author=Herter,+S.&author=Birk,+M.C.&author=Klein,+C.&author=Gerdes,+C.&author=Umana,+P.&author=Bacac,+M.&publication_year=2014&journal=J.+Immunol.&volume=192&pages=2252%E2%80%932260&doi=10.4049/jimmunol.1301249)\] \[[CrossRef](https://dx.doi.org/10.4049/jimmunol.1301249)\]

21.Oflazoglu, E.; Stone, I.J.; Gordon, K.A.; Grewal, I.S.; van Rooijen, N.; Law, C.L.; Gerber, H.P. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. *Blood* **2007**, *110*, 4370–4372. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Macrophages+contribute+to+the+antitumor+activity+of+the+anti-CD30+antibody+SGN-30&author=Oflazoglu,+E.&author=Stone,+I.J.&author=Gordon,+K.A.&author=Grewal,+I.S.&author=van+Rooijen,+N.&author=Law,+C.L.&author=Gerber,+H.P.&publication_year=2007&journal=Blood&volume=110&pages=4370%E2%80%934372&doi=10.1182/blood-2007-06-097014)\] \[[CrossRef](https://dx.doi.org/10.1182/blood-2007-06-097014)\]

22.Cheney, C.M.; Stephens, D.M.; Mo, X.; Rafiq, S.; Butchar, J.; Flynn, J.M.; Jones, J.A.; Maddocks, K.; O’Reilly, A.; Ramachandran, A. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. *MAbs* **2014**, *6*, 749–755. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Ocaratuzumab,+an+Fc-engineered+antibody+demonstrates+enhanced+antibody-dependent+cell-mediated+cytotoxicity+in+chronic+lymphocytic+leukemia&author=Cheney,+C.M.&author=Stephens,+D.M.&author=Mo,+X.&author=Rafiq,+S.&author=Butchar,+J.&author=Flynn,+J.M.&author=Jones,+J.A.&author=Maddocks,+K.&author=O%E2%80%99Reilly,+A.&author=Ramachandran,+A.&publication_year=2014&journal=MAbs&volume=6&pages=749%E2%80%93755&doi=10.4161/mabs.28282)\] \[[CrossRef](https://dx.doi.org/10.4161/mabs.28282)\]

23.Oflazoglu, E.; Audoly, L.P. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. *MAbs* **2010**, *2*, 14–19. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Evolution+of+anti-CD20+monoclonal+antibody+therapeutics+in+oncology&author=Oflazoglu,+E.&author=Audoly,+L.P.&publication_year=2010&journal=MAbs&volume=2&pages=14%E2%80%9319&doi=10.4161/mabs.2.1.10789)\] \[[CrossRef](https://dx.doi.org/10.4161/mabs.2.1.10789)\]

24.Derer, S.; Beurskens, F.J.; Rosner, T.; Peipp, M.; Valerius, T. Complement in antibody-based tumor therapy. *Crit. Rev. Immunol.* **2014**, *34*, 199–214. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Complement+in+antibody-based+tumor+therapy&author=Derer,+S.&author=Beurskens,+F.J.&author=Rosner,+T.&author=Peipp,+M.&author=Valerius,+T.&publication_year=2014&journal=Crit.+Rev.+Immunol.&volume=34&pages=199%E2%80%93214&doi=10.1615/CritRevImmunol.2014009761)\] \[[CrossRef](https://dx.doi.org/10.1615/CritRevImmunol.2014009761)\]

25.Macor, P.; Tripodo, C.; Zorzet, S.; Piovan, E.; Bossi, F.; Marzari, R.; Amadori, A.; Tedesco, F. In Vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. *Cancer Res.* **2007**, *67*, 10556–10563. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=In+Vivo+targeting+of+human+neutralizing+antibodies+against+CD55+and+CD59+to+lymphoma+cells+increases+the+antitumor+activity+of+rituximab&author=Macor,+P.&author=Tripodo,+C.&author=Zorzet,+S.&author=Piovan,+E.&author=Bossi,+F.&author=Marzari,+R.&author=Amadori,+A.&author=Tedesco,+F.&publication_year=2007&journal=Cancer+Res.&volume=67&pages=10556%E2%80%9310563&doi=10.1158/0008-5472.CAN-07-1811)\] \[[CrossRef](https://dx.doi.org/10.1158/0008-5472.CAN-07-1811)\]

26.Kennedy, A.D.; Beum, P.V.; Solga, M.D.; DiLillo, D.J.; Lindorfer, M.A.; Hess, C.E.; Densmore, J.J.; Williams, M.E.; Taylor, R.P. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. *J. Immunol.* **2004**, *172*, 3280–3288. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Rituximab+infusion+promotes+rapid+complement+depletion+and+acute+CD20+loss+in+chronic+lymphocytic+leukemia&author=Kennedy,+A.D.&author=Beum,+P.V.&author=Solga,+M.D.&author=DiLillo,+D.J.&author=Lindorfer,+M.A.&author=Hess,+C.E.&author=Densmore,+J.J.&author=Williams,+M.E.&author=Taylor,+R.P.&publication_year=2004&journal=J.+Immunol.&volume=172&pages=3280%E2%80%933288&doi=10.4049/jimmunol.172.5.3280)\] \[[CrossRef](https://dx.doi.org/10.4049/jimmunol.172.5.3280)\]

27.Di Gaetano, N.; Cittera, E.; Nota, R.; Vecchi, A.; Grieco, V.; Scanziani, E.; Botto, M.; Introna, M.; Golay, J. Complement activation determines the therapeutic activity of rituximab In Vivo. *J. Immunol.* **2003**, *171*, 1581–1587. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Complement+activation+determines+the+therapeutic+activity+of+rituximab+In+Vivo&author=Di+Gaetano,+N.&author=Cittera,+E.&author=Nota,+R.&author=Vecchi,+A.&author=Grieco,+V.&author=Scanziani,+E.&author=Botto,+M.&author=Introna,+M.&author=Golay,+J.&publication_year=2003&journal=J.+Immunol.&volume=171&pages=1581%E2%80%931587&doi=10.4049/jimmunol.171.3.1581)\] \[[CrossRef](https://dx.doi.org/10.4049/jimmunol.171.3.1581)\]

28.Meier, R.P.H.; Muller, Y.D.; Balaphas, A.; Morel, P.; Pascual, M.; Seebach, J.D.; Buhler, L.H. Xenotransplantation: Back to the future? *Transpl. Int.* **2018**, *31*, 465–477. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Xenotransplantation:+Back+to+the+future?&author=Meier,+R.P.H.&author=Muller,+Y.D.&author=Balaphas,+A.&author=Morel,+P.&author=Pascual,+M.&author=Seebach,+J.D.&author=Buhler,+L.H.&publication_year=2018&journal=Transpl.+Int.&volume=31&pages=465%E2%80%93477&doi=10.1111/tri.13104)\] \[[CrossRef](https://dx.doi.org/10.1111/tri.13104)\]

29.Cascalho, M.; Platt, J.L. Challenges and potentials of xenotransplantation. *Clin. Immunol.* **2008**, *81*, 1215–1222. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Challenges+and+potentials+of+xenotransplantation&author=Cascalho,+M.&author=Platt,+J.L.&publication_year=2008&journal=Clin.+Immunol.&volume=81&pages=1215%E2%80%931222)\]

30.Beers, S.A.; Chan, C.H.; James, S.; French, R.R.; Attfield, K.E.; Brennan, C.M.; Ahuja, A.; Shlomchik, M.J.; Cragg, M.S.; Glennie, M.J. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. *Blood* **2008**, *112*, 4170–4177. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Type+II+%28tositumomab%29+anti-CD20+monoclonal+antibody+out+performs+type+I+%28rituximab-like%29+reagents+in+B-cell+depletion+regardless+of+complement+activation&author=Beers,+S.A.&author=Chan,+C.H.&author=James,+S.&author=French,+R.R.&author=Attfield,+K.E.&author=Brennan,+C.M.&author=Ahuja,+A.&author=Shlomchik,+M.J.&author=Cragg,+M.S.&author=Glennie,+M.J.&publication_year=2008&journal=Blood&volume=112&pages=4170%E2%80%934177&doi=10.1182/blood-2008-04-149161 "https://scholar.google.com/scholar_lookup?title=Type+II+(tositumomab)+anti-CD20+monoclonal+antibody+out+performs+type+I+(rituximab-like)+reagents+in+B-cell+depletion+regardless+of+complement+activation&author=Beers,+S.A.&author=Chan,+C.H.&author=James,+S.&author=French,+R.R.&author=Attfield,+K.E.&author=Brennan,+C.M.&author=Ahuja,+A.&author=Shlomchik,+M.J.&author=Cragg,+M.S.&author=Glennie,+M.J.&publication_year=2008&journal=Blood&volume=112&pages=4170%E2%80%934177&doi=10.1182/blood-2008-04-149161")\] \[[CrossRef](https://dx.doi.org/10.1182/blood-2008-04-149161)\]

31.Beers, S.A.; Chan, C.H.; French, R.R.; Cragg, M.S.; Glennie, M.J. CD20 as a target for therapeutic type I and II monoclonal antibodies. *Semin. Hematol.* **2010**, *47*, 107–114. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=CD20+as+a+target+for+therapeutic+type+I+and+II+monoclonal+antibodies&author=Beers,+S.A.&author=Chan,+C.H.&author=French,+R.R.&author=Cragg,+M.S.&author=Glennie,+M.J.&publication_year=2010&journal=Semin.+Hematol.&volume=47&pages=107%E2%80%93114&doi=10.1053/j.seminhematol.2010.01.001)\] \[[CrossRef](https://dx.doi.org/10.1053/j.seminhematol.2010.01.001)\]

32.Weng, W.K.; Levy, R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. *Blood* **2001**, *98*, 1352–1357. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Expression+of+complement+inhibitors+CD46,+CD55,+and+CD59+on+tumor+cells+does+not+predict+clinical+outcome+after+rituximab+treatment+in+follicular+non-Hodgkin+lymphoma&author=Weng,+W.K.&author=Levy,+R.&publication_year=2001&journal=Blood&volume=98&pages=1352%E2%80%931357&doi=10.1182/blood.V98.5.1352)\] \[[CrossRef](https://dx.doi.org/10.1182/blood.V98.5.1352)\]

33.Burmeister, W.P.; Gastinel, L.N.; Simister, N.E.; Blum, M.L.; Bjorkman, P.J. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. *Nature* **1994**, *372*, 336–343. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Crystal+structure+at+2.2+A+resolution+of+the+MHC-related+neonatal+Fc+receptor&author=Burmeister,+W.P.&author=Gastinel,+L.N.&author=Simister,+N.E.&author=Blum,+M.L.&author=Bjorkman,+P.J.&publication_year=1994&journal=Nature&volume=372&pages=336%E2%80%93343&doi=10.1038/372336a0&pmid=7969491)\] \[[CrossRef](https://dx.doi.org/10.1038/372336a0)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7969491)\]

34.Leach, J.L.; Sedmak, D.D.; Osborne, J.M.; Rahill, B.; Lairmore, M.D.; Anderson, C.L. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: Implications for maternal-fetal antibody transport. *J. Immunol.* **1996**, *157*, 3317–3322. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Isolation+from+human+placenta+of+the+IgG+transporter,+FcRn,+and+localization+to+the+syncytiotrophoblast:+Implications+for+maternal-fetal+antibody+transport&author=Leach,+J.L.&author=Sedmak,+D.D.&author=Osborne,+J.M.&author=Rahill,+B.&author=Lairmore,+M.D.&author=Anderson,+C.L.&publication_year=1996&journal=J.+Immunol.&volume=157&pages=3317%E2%80%933322)\]

35.Kristoffersen, E.K. Human placental Fc gamma-binding proteins in the maternofetal transfer of IgG. *APMIS Suppl.* **1996**, *64*, 5–36. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Human+placental+Fc+gamma-binding+proteins+in+the+maternofetal+transfer+of+IgG&author=Kristoffersen,+E.K.&publication_year=1996&journal=APMIS+Suppl.&volume=64&pages=5%E2%80%9336&doi=10.1111/j.1600-0463.1996.tb05583.x&pmid=8944053)\] \[[CrossRef](https://dx.doi.org/10.1111/j.1600-0463.1996.tb05583.x)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8944053)\]

36.Roopenian, D.C.; Christianson, G.J.; Sproule, T.J.; Brown, A.C.; Akilesh, S.; Jung, N.; Petkova, S.; Avanessian, L.; Choi, E.Y.; Shaffer, D.J.; et al. The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs. *J. Immunol.* **2003**, *170*, 3528–3533. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+MHC+Class+I-Like+IgG+Receptor+Controls+Perinatal+IgG+Transport,+IgG+Homeostasis,+and+Fate+of+IgG-Fc-Coupled+Drugs&author=Roopenian,+D.C.&author=Christianson,+G.J.&author=Sproule,+T.J.&author=Brown,+A.C.&author=Akilesh,+S.&author=Jung,+N.&author=Petkova,+S.&author=Avanessian,+L.&author=Choi,+E.Y.&author=Shaffer,+D.J.&publication_year=2003&journal=J.+Immunol.&volume=170&pages=3528%E2%80%933533&doi=10.4049/jimmunol.170.7.3528&pmid=12646614)\] \[[CrossRef](https://dx.doi.org/10.4049/jimmunol.170.7.3528)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12646614)\]

37.Lobo, E.D.; Hansen, R.J.; Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. *J. Pharm. Sci.* **2004**, *93*, 2645–2668. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Antibody+pharmacokinetics+and+pharmacodynamics&author=Lobo,+E.D.&author=Hansen,+R.J.&author=Balthasar,+J.P.&publication_year=2004&journal=J.+Pharm.+Sci.&volume=93&pages=2645%E2%80%932668&doi=10.1002/jps.20178)\] \[[CrossRef](https://dx.doi.org/10.1002/jps.20178)\]

38.Raghavan, M.; Bonagura, V.R.; Morrison, S.L.; Bjorkman, P.J. Analysis of the pH Dependence of the Neonatal Fc Receptor/Immunoglobulin G Interaction Using Antibody and Receptor Variants. *Biochemistry* **1995**, *34*, 14649–14657. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Analysis+of+the+pH+Dependence+of+the+Neonatal+Fc+Receptor/Immunoglobulin+G+Interaction+Using+Antibody+and+Receptor+Variants&author=Raghavan,+M.&author=Bonagura,+V.R.&author=Morrison,+S.L.&author=Bjorkman,+P.J.&publication_year=1995&journal=Biochemistry&volume=34&pages=14649%E2%80%9314657&doi=10.1021/bi00045a005)\] \[[CrossRef](https://dx.doi.org/10.1021/bi00045a005)\]

39.Kim, J.K.; Firan, M.; Radu, C.G.; Kim, C.H.; Ghetie, V.; Ward, E.S. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. *Eur. J. Immunol.* **1999**, *29*, 2819–2825. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Mapping+the+site+on+human+IgG+for+binding+of+the+MHC+class+I-related+receptor,+FcRn&author=Kim,+J.K.&author=Firan,+M.&author=Radu,+C.G.&author=Kim,+C.H.&author=Ghetie,+V.&author=Ward,+E.S.&publication_year=1999&journal=Eur.+J.+Immunol.&volume=29&pages=2819%E2%80%932825&doi=10.1002/%28SICI%291521-4141%28199909%2929:09%3C2819::AID-IMMU2819%3E3.0.CO;2-6 "https://scholar.google.com/scholar_lookup?title=Mapping+the+site+on+human+IgG+for+binding+of+the+MHC+class+I-related+receptor,+FcRn&author=Kim,+J.K.&author=Firan,+M.&author=Radu,+C.G.&author=Kim,+C.H.&author=Ghetie,+V.&author=Ward,+E.S.&publication_year=1999&journal=Eur.+J.+Immunol.&volume=29&pages=2819%E2%80%932825&doi=10.1002/(SICI)1521-4141(199909)29:09%3C2819::AID-IMMU2819%3E3.0.CO;2-6")\] \[[CrossRef](https://dx.doi.org/10.1002/%28SICI%291521-4141%28199909%2929:09%3C2819::AID-IMMU2819%3E3.0.CO;2-6 "https://dx.doi.org/10.1002/(SICI)1521-4141(199909)29:09%3C2819::AID-IMMU2819%3E3.0.CO;2-6")\]

40.Shields, R.L.; Namenuk, A.K.; Hong, K.; Meng, Y.G.; Rae, J.; Briggs, J.; Xie, D.; Lai, J.; Stadlen, A.; Li, B.; et al. High resolution mapping of the binding site on human IgG1 for Fc gamma, R.I.; Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma, R. *J. Biol. Chem.* **2001**, *276*, 6591–6604. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=High+resolution+mapping+of+the+binding+site+on+human+IgG1+for+Fc+gamma,+R.I.;+Fc+gamma+RII,+Fc+gamma+RIII,+and+FcRn+and+design+of+IgG1+variants+with+improved+binding+to+the+Fc+gamma,+R&author=Shields,+R.L.&author=Namenuk,+A.K.&author=Hong,+K.&author=Meng,+Y.G.&author=Rae,+J.&author=Briggs,+J.&author=Xie,+D.&author=Lai,+J.&author=Stadlen,+A.&author=Li,+B.&publication_year=2001&journal=J.+Biol.+Chem.&volume=276&pages=6591%E2%80%936604&doi=10.1074/jbc.M009483200)\] \[[CrossRef](https://dx.doi.org/10.1074/jbc.M009483200)\]

41.Yamane-Ohnuki, N.; Kinoshita, S.; Inoue-Urakubo, M.; Kusunoki, M.; Iida, S.; Nakano, R.; Wakitani, M.; Niwa, R.; Sakurada, M.; Uchida, K.; et al. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. *Biotechnol. Bioeng.* **2004**, *87*, 614–622. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Establishment+of+FUT8+knockout+Chinese+hamster+ovary+cells:+An+ideal+host+cell+line+for+producing+completely+defucosylated+antibodies+with+enhanced+antibody-dependent+cellular+cytotoxicity&author=Yamane-Ohnuki,+N.&author=Kinoshita,+S.&author=Inoue-Urakubo,+M.&author=Kusunoki,+M.&author=Iida,+S.&author=Nakano,+R.&author=Wakitani,+M.&author=Niwa,+R.&author=Sakurada,+M.&author=Uchida,+K.&publication_year=2004&journal=Biotechnol.+Bioeng.&volume=87&pages=614%E2%80%93622&doi=10.1002/bit.20151)\] \[[CrossRef](https://dx.doi.org/10.1002/bit.20151)\]

42.Lazar, G.A.; Dang, W.; Karki, S.; Vafa, O.; Peng, J.S.; Hyun, L.; Chan, C.; Chung, H.S.; Eivazi, A.; Yoder, S.C.; et al. Engineered antibody Fc variants with enhanced effector function. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 4005–4010. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+antibody+Fc+variants+with+enhanced+effector+function&author=Lazar,+G.A.&author=Dang,+W.&author=Karki,+S.&author=Vafa,+O.&author=Peng,+J.S.&author=Hyun,+L.&author=Chan,+C.&author=Chung,+H.S.&author=Eivazi,+A.&author=Yoder,+S.C.&publication_year=2006&journal=Proc.+Natl.+Acad.+Sci.+USA&volume=103&pages=4005%E2%80%934010&doi=10.1073/pnas.0508123103)\] \[[CrossRef](https://dx.doi.org/10.1073/pnas.0508123103)\]

43.Richards, J.O.; Karki, S.; Lazar, G.A.; Chen, H.; Dang, W.; Desjarlais, J.R. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. *Mol. Cancer Ther.* **2008**, *7*, 2517–2527. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Optimization+of+antibody+binding+to+FcgammaRIIa+enhances+macrophage+phagocytosis+of+tumor+cells&author=Richards,+J.O.&author=Karki,+S.&author=Lazar,+G.A.&author=Chen,+H.&author=Dang,+W.&author=Desjarlais,+J.R.&publication_year=2008&journal=Mol.+Cancer+Ther.&volume=7&pages=2517%E2%80%932527&doi=10.1158/1535-7163.MCT-08-0201)\] \[[CrossRef](https://dx.doi.org/10.1158/1535-7163.MCT-08-0201)\]

44.Ravetch, J.V.; Bournazos, S. Human IgG Fc Domain Variants with Improved Effector Function. Patent Application No. WO/2019/125846, 27 June 2019. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Human+IgG+Fc+Domain+Variants+with+Improved+Effector+Function&author=Ravetch,+J.V.&author=Bournazos,+S.&publication_year=2019)\]

45.Ahmed, A.A.; Keremane, S.R.; Vielmetter, J.; Bjorkman, P.J. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcgammaRIIIa. *J. Struct. Biol.* **2016**, *194*, 78–89. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Structural+characterization+of+GASDALIE+Fc+bound+to+the+activating+Fc+receptor+FcgammaRIIIa&author=Ahmed,+A.A.&author=Keremane,+S.R.&author=Vielmetter,+J.&author=Bjorkman,+P.J.&publication_year=2016&journal=J.+Struct.+Biol.&volume=194&pages=78%E2%80%9389&doi=10.1016/j.jsb.2016.02.001)\] \[[CrossRef](https://dx.doi.org/10.1016/j.jsb.2016.02.001)\]

46.Stavenhagen, J.B.; Gorlatov, S.; Tuaillon, N.; Rankin, C.T.; Li, H.; Burke, S.; Huang, L.; Vijh, S.; Johnson, S.; Bonvini, E.; et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells In Vitro and controls tumor expansion In Vivo via low-affinity activating Fcgamma receptors. *Cancer Res.* **2007**, *67*, 8882–8890. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Fc+optimization+of+therapeutic+antibodies+enhances+their+ability+to+kill+tumor+cells+In+Vitro+and+controls+tumor+expansion+In+Vivo+via+low-affinity+activating+Fcgamma+receptors&author=Stavenhagen,+J.B.&author=Gorlatov,+S.&author=Tuaillon,+N.&author=Rankin,+C.T.&author=Li,+H.&author=Burke,+S.&author=Huang,+L.&author=Vijh,+S.&author=Johnson,+S.&author=Bonvini,+E.&publication_year=2007&journal=Cancer+Res.&volume=67&pages=8882%E2%80%938890&doi=10.1158/0008-5472.CAN-07-0696)\] \[[CrossRef](https://dx.doi.org/10.1158/0008-5472.CAN-07-0696)\]

47.Nordstrom, J.L.; Gorlatov, S.; Zhang, W.; Yang, Y.; Huang, L.; Burke, S.; Li, H.; Ciccarone, V.; Zhang, T.; Stavenhagen, J.; et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. *Breast Cancer Res.* **2011**, *13*, R123. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Anti-tumor+activity+and+toxicokinetics+analysis+of+MGAH22,+an+anti-HER2+monoclonal+antibody+with+enhanced+Fcgamma+receptor+binding+properties&author=Nordstrom,+J.L.&author=Gorlatov,+S.&author=Zhang,+W.&author=Yang,+Y.&author=Huang,+L.&author=Burke,+S.&author=Li,+H.&author=Ciccarone,+V.&author=Zhang,+T.&author=Stavenhagen,+J.&publication_year=2011&journal=Breast+Cancer+Res.&volume=13&pages=R123&doi=10.1186/bcr3069)\] \[[CrossRef](https://dx.doi.org/10.1186/bcr3069)\]

48.Mimoto, F.; Igawa, T.; Kuramochi, T.; Katada, H.; Kadono, S.; Kamikawa, T.; Kawazoe-Shida, M.; Hattori, K. Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant. *MAbs* **2013**, *5*, 229–236. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Novel+asymmetrically+engineered+antibody+Fc+variant+with+superior+FcgammaR+binding+affinity+and+specificity+compared+with+afucosylated+Fc+variant&author=Mimoto,+F.&author=Igawa,+T.&author=Kuramochi,+T.&author=Katada,+H.&author=Kadono,+S.&author=Kamikawa,+T.&author=Kawazoe-Shida,+M.&author=Hattori,+K.&publication_year=2013&journal=MAbs&volume=5&pages=229%E2%80%93236&doi=10.4161/mabs.23452)\] \[[CrossRef](https://dx.doi.org/10.4161/mabs.23452)\]

49.Matsumiya, S.; Yamaguchi, Y.; Saito, J.; Nagano, M.; Sasakawa, H.; Otaki, S.; Satoh, M.; Shitara, K.; Kato, K. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. *J. Mol. Biol.* **2007**, *368*, 767–779. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Structural+comparison+of+fucosylated+and+nonfucosylated+Fc+fragments+of+human+immunoglobulin+G1&author=Matsumiya,+S.&author=Yamaguchi,+Y.&author=Saito,+J.&author=Nagano,+M.&author=Sasakawa,+H.&author=Otaki,+S.&author=Satoh,+M.&author=Shitara,+K.&author=Kato,+K.&publication_year=2007&journal=J.+Mol.+Biol.&volume=368&pages=767%E2%80%93779&doi=10.1016/j.jmb.2007.02.034)\] \[[CrossRef](https://dx.doi.org/10.1016/j.jmb.2007.02.034)\]

50.Matsumiya, K.; Yamaguchi, Y.; Saito, J.; Nagano, K.; Sasakawa, H.; Otaki, S.; Satoh, M.; Shitara, K.; Kato, K. Corrigendum to “Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1” \[J. Mol. Biol. 386/3 (2007) 767–779\]. *J. Mol. Biol.* **2011**, *408*, 1001\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Corrigendum+to+%E2%80%9CStructural+Comparison+of+Fucosylated+and+Nonfucosylated+Fc+Fragments+of+Human+Immunoglobulin+G1%E2%80%9D+%5BJ.+Mol.+Biol.+386/3+%282007%29+767%E2%80%93779%5D&author=Matsumiya,+K.&author=Yamaguchi,+Y.&author=Saito,+J.&author=Nagano,+K.&author=Sasakawa,+H.&author=Otaki,+S.&author=Satoh,+M.&author=Shitara,+K.&author=Kato,+K.&publication_year=2011&journal=J.+Mol.+Biol.&volume=408&pages=1001&doi=10.1016/j.jmb.2011.03.031 "https://scholar.google.com/scholar_lookup?title=Corrigendum+to+%E2%80%9CStructural+Comparison+of+Fucosylated+and+Nonfucosylated+Fc+Fragments+of+Human+Immunoglobulin+G1%E2%80%9D+%5BJ.+Mol.+Biol.+386/3+(2007)+767%E2%80%93779%5D&author=Matsumiya,+K.&author=Yamaguchi,+Y.&author=Saito,+J.&author=Nagano,+K.&author=Sasakawa,+H.&author=Otaki,+S.&author=Satoh,+M.&author=Shitara,+K.&author=Kato,+K.&publication_year=2011&journal=J.+Mol.+Biol.&volume=408&pages=1001&doi=10.1016/j.jmb.2011.03.031")\] \[[CrossRef](https://dx.doi.org/10.1016/j.jmb.2011.03.031)\]

51.Lazar, G.A.; Chirino, A.J.; Dang, W.; Desjarlais, J.R.; Doberstein, S.K.; Hayes, R.J.; Karki, S.; Vafa, O. Optimized Fc Variants and Methods for Their Generation. U.S. Patent 2008O181890A1, 31 July 2008. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Optimized+Fc+Variants+and+Methods+for+Their+Generation&author=Lazar,+G.A.&author=Chirino,+A.J.&author=Dang,+W.&author=Desjarlais,+J.R.&author=Doberstein,+S.K.&author=Hayes,+R.J.&author=Karki,+S.&author=Vafa,+O.&publication_year=2008)\]

52.DiLillo, D.J.; Ravetch, J.V. Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. *Cell* **2015**, *161*, 1035–1045. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Differential+Fc-Receptor+Engagement+Drives+an+Anti-tumor+Vaccinal+Effect&author=DiLillo,+D.J.&author=Ravetch,+J.V.&publication_year=2015&journal=Cell&volume=161&pages=1035%E2%80%931045&doi=10.1016/j.cell.2015.04.016)\] \[[CrossRef](https://dx.doi.org/10.1016/j.cell.2015.04.016)\]

53.Arnold, J.N.; Wormald, M.R.; Sim, R.B.; Rudd, P.M.; Dwek, R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. *Annu. Rev. Immunol.* **2007**, *25*, 21–50. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+impact+of+glycosylation+on+the+biological+function+and+structure+of+human+immunoglobulins&author=Arnold,+J.N.&author=Wormald,+M.R.&author=Sim,+R.B.&author=Rudd,+P.M.&author=Dwek,+R.A.&publication_year=2007&journal=Annu.+Rev.+Immunol.&volume=25&pages=21%E2%80%9350&doi=10.1146/annurev.immunol.25.022106.141702)\] \[[CrossRef](https://dx.doi.org/10.1146/annurev.immunol.25.022106.141702)\]

54.Jefferis, R.; Lund, J.; Pound, J.D. IgG-Fc-mediated effector functions: Molecular definition of interaction sites for effector ligands and the role of glycosylation. *Immunol. Rev.* **1998**, *163*, 59–76. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=IgG-Fc-mediated+effector+functions:+Molecular+definition+of+interaction+sites+for+effector+ligands+and+the+role+of+glycosylation&author=Jefferis,+R.&author=Lund,+J.&author=Pound,+J.D.&publication_year=1998&journal=Immunol.+Rev.&volume=163&pages=59%E2%80%9376&doi=10.1111/j.1600-065X.1998.tb01188.x)\] \[[CrossRef](https://dx.doi.org/10.1111/j.1600-065X.1998.tb01188.x)\]

55.Mimura, Y.; Sondermann, P.; Ghirlando, R.; Lund, J.; Young, S.P.; Goodall, M.; Jefferis, R. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. *J. Biol. Chem.* **2001**, *276*, 45539–45547. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Role+of+oligosaccharide+residues+of+IgG1-Fc+in+Fc+gamma+RIIb+binding&author=Mimura,+Y.&author=Sondermann,+P.&author=Ghirlando,+R.&author=Lund,+J.&author=Young,+S.P.&author=Goodall,+M.&author=Jefferis,+R.&publication_year=2001&journal=J.+Biol.+Chem.&volume=276&pages=45539%E2%80%9345547&doi=10.1074/jbc.M107478200)\] \[[CrossRef](https://dx.doi.org/10.1074/jbc.M107478200)\]

56.Nose, M.; Wigzell, H. Biological significance of carbohydrate chains on monoclonal antibodies. *Proc. Natl. Acad. Sci. USA* **1983**, *80*, 6632–6636. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Biological+significance+of+carbohydrate+chains+on+monoclonal+antibodies&author=Nose,+M.&author=Wigzell,+H.&publication_year=1983&journal=Proc.+Natl.+Acad.+Sci.+USA&volume=80&pages=6632%E2%80%936636&doi=10.1073/pnas.80.21.6632&pmid=6579549)\] \[[CrossRef](https://dx.doi.org/10.1073/pnas.80.21.6632)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/6579549)\]

57.Walker, M.R.; Lund, J.; Thompson, K.M.; Jefferis, R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. *Biochem. J.* **1989**, *259*, 347–353. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Aglycosylation+of+human+IgG1+and+IgG3+monoclonal+antibodies+can+eliminate+recognition+by+human+cells+expressing+Fc+gamma+RI+and/or+Fc+gamma+RII+receptors&author=Walker,+M.R.&author=Lund,+J.&author=Thompson,+K.M.&author=Jefferis,+R.&publication_year=1989&journal=Biochem.+J.&volume=259&pages=347%E2%80%93353&doi=10.1042/bj2590347&pmid=2524188)\] \[[CrossRef](https://dx.doi.org/10.1042/bj2590347)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2524188)\]

58.Subedi, G.P.; Barb, A.W. The Structural Role of Antibody N-Glycosylation in Receptor Interactions. *Structure* **2015**, *23*, 1573–1583. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+Structural+Role+of+Antibody+N-Glycosylation+in+Receptor+Interactions&author=Subedi,+G.P.&author=Barb,+A.W.&publication_year=2015&journal=Structure&volume=23&pages=1573%E2%80%931583&doi=10.1016/j.str.2015.06.015&pmid=26211613)\] \[[CrossRef](https://dx.doi.org/10.1016/j.str.2015.06.015)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26211613)\]

59.Epp, A.; Sullivan, K.C.; Herr, A.B.; Strait, R.T. Immunoglobulin Glycosylation Effects in Allergy and Immunity. *Curr. Allergy Asthma Rep.* **2016**, *16*, 79\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Immunoglobulin+Glycosylation+Effects+in+Allergy+and+Immunity&author=Epp,+A.&author=Sullivan,+K.C.&author=Herr,+A.B.&author=Strait,+R.T.&publication_year=2016&journal=Curr.+Allergy+Asthma+Rep.&volume=16&pages=79&doi=10.1007/s11882-016-0658-x)\] \[[CrossRef](https://dx.doi.org/10.1007/s11882-016-0658-x)\]

60.Almagro, J.C.; Daniels-Wells, T.R.; Perez-Tapia, S.M.; Penichet, M.L. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. *Front. Immunol.* **2017**, *8*, 1751\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Progress+and+Challenges+in+the+Design+and+Clinical+Development+of+Antibodies+for+Cancer+Therapy&author=Almagro,+J.C.&author=Daniels-Wells,+T.R.&author=Perez-Tapia,+S.M.&author=Penichet,+M.L.&publication_year=2017&journal=Front.+Immunol.&volume=8&pages=1751&doi=10.3389/fimmu.2017.01751)\] \[[CrossRef](https://dx.doi.org/10.3389/fimmu.2017.01751)\]

61.Umana, P.; Jean-Mairet, J.; Moudry, R.; Amstutz, H.; Bailey, J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. *Nat. Biotechnol.* **1999**, *17*, 176–180. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+glycoforms+of+an+antineuroblastoma+IgG1+with+optimized+antibody-dependent+cellular+cytotoxic+activity&author=Umana,+P.&author=Jean-Mairet,+J.&author=Moudry,+R.&author=Amstutz,+H.&author=Bailey,+J.E.&publication_year=1999&journal=Nat.+Biotechnol.&volume=17&pages=176%E2%80%93180&doi=10.1038/6179)\] \[[CrossRef](https://dx.doi.org/10.1038/6179)\]

62.Evans, J.B.; Syed, B.A. From the analyst’s couch: Next-generation antibodies. *Nat. Rev. Drug Discov.* **2014**, *13*, 413–414. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=From+the+analyst%E2%80%99s+couch:+Next-generation+antibodies&author=Evans,+J.B.&author=Syed,+B.A.&publication_year=2014&journal=Nat.+Rev.+Drug+Discov.&volume=13&pages=413%E2%80%93414&doi=10.1038/nrd4255)\] \[[CrossRef](https://dx.doi.org/10.1038/nrd4255)\]

63.Shinkawa, T.; Nakamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakurada, M.; Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M.; et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. *J. Biol. Chem.* **2003**, *278*, 3466–3473. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+absence+of+fucose+but+not+the+presence+of+galactose+or+bisecting+N-acetylglucosamine+of+human+IgG1+complex-type+oligosaccharides+shows+the+critical+role+of+enhancing+antibody-dependent+cellular+cytotoxicity&author=Shinkawa,+T.&author=Nakamura,+K.&author=Yamane,+N.&author=Shoji-Hosaka,+E.&author=Kanda,+Y.&author=Sakurada,+M.&author=Uchida,+K.&author=Anazawa,+H.&author=Satoh,+M.&author=Yamasaki,+M.&publication_year=2003&journal=J.+Biol.+Chem.&volume=278&pages=3466%E2%80%933473&doi=10.1074/jbc.M210665200)\] \[[CrossRef](https://dx.doi.org/10.1074/jbc.M210665200)\]

64.Matsushita, T. Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent(R) Technology. *Korean J. Hematol.* **2011**, *46*, 148–150. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+therapeutic+antibodies+with+enhanced+effector+functions:+Clinical+application+of+the+Potelligent%28R%29+Technology&author=Matsushita,+T.&publication_year=2011&journal=Korean+J.+Hematol.&volume=46&pages=148%E2%80%93150&doi=10.5045/kjh.2011.46.3.148 "https://scholar.google.com/scholar_lookup?title=Engineered+therapeutic+antibodies+with+enhanced+effector+functions:+Clinical+application+of+the+Potelligent(R)+Technology&author=Matsushita,+T.&publication_year=2011&journal=Korean+J.+Hematol.&volume=46&pages=148%E2%80%93150&doi=10.5045/kjh.2011.46.3.148")\] \[[CrossRef](https://dx.doi.org/10.5045/kjh.2011.46.3.148)\]

65.Niwa, R.; Shoji-Hosaka, E.; Sakurada, M.; Shinkawa, T.; Uchida, K.; Nakamura, K.; Matsushima, K.; Ueda, R.; Hanai, N.; Shitara, K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. *Cancer Res.* **2004**, *64*, 2127–2133. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Defucosylated+chimeric+anti-CC+chemokine+receptor+4+IgG1+with+enhanced+antibody-dependent+cellular+cytotoxicity+shows+potent+therapeutic+activity+to+T-cell+leukemia+and+lymphoma&author=Niwa,+R.&author=Shoji-Hosaka,+E.&author=Sakurada,+M.&author=Shinkawa,+T.&author=Uchida,+K.&author=Nakamura,+K.&author=Matsushima,+K.&author=Ueda,+R.&author=Hanai,+N.&author=Shitara,+K.&publication_year=2004&journal=Cancer+Res.&volume=64&pages=2127%E2%80%932133&doi=10.1158/0008-5472.CAN-03-2068&pmid=15026353)\] \[[CrossRef](https://dx.doi.org/10.1158/0008-5472.CAN-03-2068)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15026353)\]

66.Yu, X.; Marshall, M.J.E.; Cragg, M.S.; Crispin, M. Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. *BioDrugs* **2017**, *31*, 151–166. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Improving+Antibody-Based+Cancer+Therapeutics+Through+Glycan+Engineering&author=Yu,+X.&author=Marshall,+M.J.E.&author=Cragg,+M.S.&author=Crispin,+M.&publication_year=2017&journal=BioDrugs&volume=31&pages=151%E2%80%93166&doi=10.1007/s40259-017-0223-8&pmid=28466278)\] \[[CrossRef](https://dx.doi.org/10.1007/s40259-017-0223-8)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28466278)\]

67.Li, T.; DiLillo, D.J.; Bournazos, S.; Giddens, J.P.; Ravetch, J.V.; Wang, L.X. Modulating IgG effector function by Fc glycan engineering. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 3485–3490. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Modulating+IgG+effector+function+by+Fc+glycan+engineering&author=Li,+T.&author=DiLillo,+D.J.&author=Bournazos,+S.&author=Giddens,+J.P.&author=Ravetch,+J.V.&author=Wang,+L.X.&publication_year=2017&journal=Proc.+Natl.+Acad.+Sci.+USA&volume=114&pages=3485%E2%80%933490&doi=10.1073/pnas.1702173114&pmid=28289219)\] \[[CrossRef](https://dx.doi.org/10.1073/pnas.1702173114)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28289219)\]

68.The Antibody Society. Antibody therapeutics approved or in regulatory review in the EU or US. Available online: https://www.antibodysociety.org/resources/approved-antibodies/ (accessed on 13 August 2020).

69.Goede, V.; Fischer, K.; Busch, R.; Engelke, A.; Eichhorst, B.; Wendtner, C.M.; Chagorova, T.; De La Serna, J.; Dilhuydy, M.-S.; Illmer, T.; et al. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. *N. Engl. J. Med.* **2014**, *370*, 1101–1110. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Obinutuzumab+plus+Chlorambucil+in+Patients+with+CLL+and+Coexisting+Conditions&author=Goede,+V.&author=Fischer,+K.&author=Busch,+R.&author=Engelke,+A.&author=Eichhorst,+B.&author=Wendtner,+C.M.&author=Chagorova,+T.&author=De+La+Serna,+J.&author=Dilhuydy,+M.-S.&author=Illmer,+T.&publication_year=2014&journal=N.+Engl.+J.+Med.&volume=370&pages=1101%E2%80%931110&doi=10.1056/NEJMoa1313984)\] \[[CrossRef](https://dx.doi.org/10.1056/NEJMoa1313984)\]

70.Marcus, R.; Davies, A.; Ando, K.; Klapper, W.; Opat, S.; Owen, C.; Phillips, E.; Sangha, R.; Schlag, R.; Seymour, J.F.; et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. *N. Engl. J. Med.* **2017**, *377*, 1331–1344. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Obinutuzumab+for+the+First-Line+Treatment+of+Follicular+Lymphoma&author=Marcus,+R.&author=Davies,+A.&author=Ando,+K.&author=Klapper,+W.&author=Opat,+S.&author=Owen,+C.&author=Phillips,+E.&author=Sangha,+R.&author=Schlag,+R.&author=Seymour,+J.F.&publication_year=2017&journal=N.+Engl.+J.+Med.&volume=377&pages=1331%E2%80%931344&doi=10.1056/NEJMoa1614598)\] \[[CrossRef](https://dx.doi.org/10.1056/NEJMoa1614598)\]

71.Sehn, L.H.; Martelli, M.; Trneny, M.; Liu, W.; Bolen, C.R.; Knapp, A.; Sahin, D.; Sellam, G.; Vitolo, U. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: Final analysis of GOYA. *J. Hematol. Oncol.* **2020**, *13*, 71\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=A+randomized,+open-label,+Phase+III+study+of+obinutuzumab+or+rituximab+plus+CHOP+in+patients+with+previously+untreated+diffuse+large+B-Cell+lymphoma:+Final+analysis+of+GOYA&author=Sehn,+L.H.&author=Martelli,+M.&author=Trneny,+M.&author=Liu,+W.&author=Bolen,+C.R.&author=Knapp,+A.&author=Sahin,+D.&author=Sellam,+G.&author=Vitolo,+U.&publication_year=2020&journal=J.+Hematol.+Oncol.&volume=13&pages=71&doi=10.1186/s13045-020-00900-7)\] \[[CrossRef](https://dx.doi.org/10.1186/s13045-020-00900-7)\]

72.Vitolo, U.; Trneny, M.; Belada, D.; Burke, J.M.; Carella, A.M.; Chua, N.; Abrisqueta, P.; Demeter, J.; Flinn, I.; Hong, X.; et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. *J. Clin. Oncol.* **2017**, *35*, 3529–3537. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Obinutuzumab+or+Rituximab+Plus+Cyclophosphamide,+Doxorubicin,+Vincristine,+and+Prednisone+in+Previously+Untreated+Diffuse+Large+B-Cell+Lymphoma&author=Vitolo,+U.&author=Trneny,+M.&author=Belada,+D.&author=Burke,+J.M.&author=Carella,+A.M.&author=Chua,+N.&author=Abrisqueta,+P.&author=Demeter,+J.&author=Flinn,+I.&author=Hong,+X.&publication_year=2017&journal=J.+Clin.+Oncol.&volume=35&pages=3529%E2%80%933537&doi=10.1200/JCO.2017.73.3402)\] \[[CrossRef](https://dx.doi.org/10.1200/JCO.2017.73.3402)\]

73.Oldham, R.J.; Cleary, K.L.S.; Cragg, M.S. CD20 and Its Antibodies: Past, Present, and Future. *Forum Immunopathol. Dis. Ther.* **2014**, *5*, 7–23. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=CD20+and+Its+Antibodies:+Past,+Present,+and+Future&author=Oldham,+R.J.&author=Cleary,+K.L.S.&author=Cragg,+M.S.&publication_year=2014&journal=Forum+Immunopathol.+Dis.+Ther.&volume=5&pages=7%E2%80%9323&doi=10.1615/ForumImmunDisTher.2015014073)\] \[[CrossRef](https://dx.doi.org/10.1615/ForumImmunDisTher.2015014073)\]

74.Vaughan, A.T.; Iriyama, C.; Beers, S.A.; Chan, C.H.T.; Lim, S.H.; Williams, E.L.; Shah, V.; Roghanian, A.; Frendéus, B.; Glennie, M.J.; et al. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. *Blood* **2014**, *123*, 669–677. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Inhibitory+Fc%CE%B3RIIb+%28CD32b%29+becomes+activated+by+therapeutic+mAb+in+both+cis+and+trans+and+drives+internalization+according+to+antibody+specificity&author=Vaughan,+A.T.&author=Iriyama,+C.&author=Beers,+S.A.&author=Chan,+C.H.T.&author=Lim,+S.H.&author=Williams,+E.L.&author=Shah,+V.&author=Roghanian,+A.&author=Frend%C3%A9us,+B.&author=Glennie,+M.J.&publication_year=2014&journal=Blood&volume=123&pages=669%E2%80%93677&doi=10.1182/blood-2013-04-490821 "https://scholar.google.com/scholar_lookup?title=Inhibitory+Fc%CE%B3RIIb+(CD32b)+becomes+activated+by+therapeutic+mAb+in+both+cis+and+trans+and+drives+internalization+according+to+antibody+specificity&author=Vaughan,+A.T.&author=Iriyama,+C.&author=Beers,+S.A.&author=Chan,+C.H.T.&author=Lim,+S.H.&author=Williams,+E.L.&author=Shah,+V.&author=Roghanian,+A.&author=Frend%C3%A9us,+B.&author=Glennie,+M.J.&publication_year=2014&journal=Blood&volume=123&pages=669%E2%80%93677&doi=10.1182/blood-2013-04-490821")\] \[[CrossRef](https://dx.doi.org/10.1182/blood-2013-04-490821)\]

75.Lim, S.H.; Vaughan, A.T.; Ashton-Key, M.; Williams, E.L.; Dixon, S.V.; Chan, H.T.C.; Beers, S.A.; French, R.R.; Cox, K.L.; Davies, A.J.; et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. *Blood* **2011**, *118*, 2530–2540. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Fc+gamma+receptor+IIb+on+target+B+cells+promotes+rituximab+internalization+and+reduces+clinical+efficacy&author=Lim,+S.H.&author=Vaughan,+A.T.&author=Ashton-Key,+M.&author=Williams,+E.L.&author=Dixon,+S.V.&author=Chan,+H.T.C.&author=Beers,+S.A.&author=French,+R.R.&author=Cox,+K.L.&author=Davies,+A.J.&publication_year=2011&journal=Blood&volume=118&pages=2530%E2%80%932540&doi=10.1182/blood-2011-01-330357)\] \[[CrossRef](https://dx.doi.org/10.1182/blood-2011-01-330357)\]

76.Sharman, J.P.; Farber, C.M.; Mahadevan, D.; Schreeder, M.T.; Brooks, H.D.; Kolibaba, K.S.; Fanning, S.; Klein, L.; Greenwald, D.R.; Sportelli, P.; et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: Results of a phase 2 trial. *Br. J. Haematol.* **2017**, *176*, 412–420. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Ublituximab+%28TG-1101%29,+a+novel+glycoengineered+anti-CD20+antibody,+in+combination+with+ibrutinib+is+safe+and+highly+active+in+patients+with+relapsed+and/or+refractory+chronic+lymphocytic+leukaemia:+Results+of+a+phase+2+trial&author=Sharman,+J.P.&author=Farber,+C.M.&author=Mahadevan,+D.&author=Schreeder,+M.T.&author=Brooks,+H.D.&author=Kolibaba,+K.S.&author=Fanning,+S.&author=Klein,+L.&author=Greenwald,+D.R.&author=Sportelli,+P.&publication_year=2017&journal=Br.+J.+Haematol.&volume=176&pages=412%E2%80%93420&doi=10.1111/bjh.14447&pmid=27982425 "https://scholar.google.com/scholar_lookup?title=Ublituximab+(TG-1101),+a+novel+glycoengineered+anti-CD20+antibody,+in+combination+with+ibrutinib+is+safe+and+highly+active+in+patients+with+relapsed+and/or+refractory+chronic+lymphocytic+leukaemia:+Results+of+a+phase+2+trial&author=Sharman,+J.P.&author=Farber,+C.M.&author=Mahadevan,+D.&author=Schreeder,+M.T.&author=Brooks,+H.D.&author=Kolibaba,+K.S.&author=Fanning,+S.&author=Klein,+L.&author=Greenwald,+D.R.&author=Sportelli,+P.&publication_year=2017&journal=Br.+J.+Haematol.&volume=176&pages=412%E2%80%93420&doi=10.1111/bjh.14447&pmid=27982425")\] \[[CrossRef](https://dx.doi.org/10.1111/bjh.14447)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27982425)\]

77.Burger, J.A.; Sivina, M.; Jain, N.; Kim, E.; Kadia, T.; Estrov, Z.; Nogueras-González, G.M.; Huang, X.; Jorgensen, J.; Li, J.; et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. *Blood* **2019**, *133*, 1011–1019. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Randomized+trial+of+ibrutinib+vs+ibrutinib+plus+rituximab+in+patients+with+chronic+lymphocytic+leukemia&author=Burger,+J.A.&author=Sivina,+M.&author=Jain,+N.&author=Kim,+E.&author=Kadia,+T.&author=Estrov,+Z.&author=Nogueras-Gonz%C3%A1lez,+G.M.&author=Huang,+X.&author=Jorgensen,+J.&author=Li,+J.&publication_year=2019&journal=Blood&volume=133&pages=1011%E2%80%931019&doi=10.1182/blood-2018-10-879429&pmid=30530801)\] \[[CrossRef](https://dx.doi.org/10.1182/blood-2018-10-879429)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30530801)\]

78.Therapeutics, T. TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia. Available online: http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-positive-topline-results-unity-cll (accessed on 25 August 2020).

79.Chenoweth, A.M.; Wines, B.D.; Anania, J.C.; Mark Hogarth, P. Harnessing the immune system via FcγR function in immune therapy: A pathway to next-gen MAbs. *Immunol. Cell Biol.* **2020**, *98*, 287–304. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Harnessing+the+immune+system+via+Fc%CE%B3R+function+in+immune+therapy:+A+pathway+to+next-gen+MAbs&author=Chenoweth,+A.M.&author=Wines,+B.D.&author=Anania,+J.C.&author=Mark+Hogarth,+P.&publication_year=2020&journal=Immunol.+Cell+Biol.&volume=98&pages=287%E2%80%93304&doi=10.1111/imcb.12326&pmid=32157732)\] \[[CrossRef](https://dx.doi.org/10.1111/imcb.12326)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32157732)\]

80.Ollila, T.A.; Sahin, I.; Olszewski, A.J. Mogamulizumab: A new tool for management of cutaneous T-cell lymphoma. *OncoTargets Ther.* **2019**, *12*, 1085–1094. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Mogamulizumab:+A+new+tool+for+management+of+cutaneous+T-cell+lymphoma&author=Ollila,+T.A.&author=Sahin,+I.&author=Olszewski,+A.J.&publication_year=2019&journal=OncoTargets+Ther.&volume=12&pages=1085%E2%80%931094&doi=10.2147/OTT.S165615)\] \[[CrossRef](https://dx.doi.org/10.2147/OTT.S165615)\]

81.Kim, Y.H.; Bagot, M.; Pinter-Brown, L.; Rook, A.H.; Porcu, P.; Horwitz, S.M.; Whittaker, S.; Tokura, Y.; Vermeer, M.; Zinzani, P.L.; et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial. *Lancet Oncol.* **2018**, *19*, 1192–1204. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Mogamulizumab+versus+vorinostat+in+previously+treated+cutaneous+T-cell+lymphoma+%28MAVORIC%29:+An+international,+open-label,+randomised,+controlled+phase+3+trial&author=Kim,+Y.H.&author=Bagot,+M.&author=Pinter-Brown,+L.&author=Rook,+A.H.&author=Porcu,+P.&author=Horwitz,+S.M.&author=Whittaker,+S.&author=Tokura,+Y.&author=Vermeer,+M.&author=Zinzani,+P.L.&publication_year=2018&journal=Lancet+Oncol.&volume=19&pages=1192%E2%80%931204&doi=10.1016/S1470-2045%2818%2930379-6 "https://scholar.google.com/scholar_lookup?title=Mogamulizumab+versus+vorinostat+in+previously+treated+cutaneous+T-cell+lymphoma+(MAVORIC):+An+international,+open-label,+randomised,+controlled+phase+3+trial&author=Kim,+Y.H.&author=Bagot,+M.&author=Pinter-Brown,+L.&author=Rook,+A.H.&author=Porcu,+P.&author=Horwitz,+S.M.&author=Whittaker,+S.&author=Tokura,+Y.&author=Vermeer,+M.&author=Zinzani,+P.L.&publication_year=2018&journal=Lancet+Oncol.&volume=19&pages=1192%E2%80%931204&doi=10.1016/S1470-2045(18)30379-6")\] \[[CrossRef](https://dx.doi.org/10.1016/S1470-2045%2818%2930379-6 "https://dx.doi.org/10.1016/S1470-2045(18)30379-6")\]

82.Phillips, A.; Fields, P.; Hermine, O.; Ramos, J.C.; Beltran, B.E.; Pereira, J.; Brites, C.; Wandroo, F.A.; Lill, M.; Feldman, T.A.; et al. A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator’s Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival. *Blood* **2016**, *128*, 4159\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=A+Prospective,+Multicenter,+Randomized+Study+of+Anti-CCR4+Monoclonal+Antibody+Mogamulizumab+Versus+Investigator%E2%80%99s+Choice+in+the+Treatment+of+Patients+with+Relapsed/Refractory+Adult+T-Cell+Leukemia-Lymphoma:+Overall+Response+Rate,+Progression-Free+Survival,+and+Overall+Survival&author=Phillips,+A.&author=Fields,+P.&author=Hermine,+O.&author=Ramos,+J.C.&author=Beltran,+B.E.&author=Pereira,+J.&author=Brites,+C.&author=Wandroo,+F.A.&author=Lill,+M.&author=Feldman,+T.A.&publication_year=2016&journal=Blood&volume=128&pages=4159)\]

83.Ishida, T.; Utsunomiya, A.; Jo, T.; Yamamoto, K.; Kato, K.; Yoshida, S.; Takemoto, S.; Suzushima, H.; Kobayashi, Y.; Imaizumi, Y.; et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. *Cancer Sci.* **2017**, *108*, 2022–2029. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Mogamulizumab+for+relapsed+adult+T-cell+leukemia-lymphoma:+Updated+follow-up+analysis+of+phase+I+and+II+studies&author=Ishida,+T.&author=Utsunomiya,+A.&author=Jo,+T.&author=Yamamoto,+K.&author=Kato,+K.&author=Yoshida,+S.&author=Takemoto,+S.&author=Suzushima,+H.&author=Kobayashi,+Y.&author=Imaizumi,+Y.&publication_year=2017&journal=Cancer+Sci.&volume=108&pages=2022%E2%80%932029&doi=10.1111/cas.13343)\] \[[CrossRef](https://dx.doi.org/10.1111/cas.13343)\]

84.Salles, G.; Duell, J.; Gonzalez Barca, E.; Tournilhac, O.; Jurczak, W.; Liberati, A.M.; Nagy, Z.; Obr, A.; Gaidano, G.; André, M.; et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. *Lancet Oncol.* **2020**, *21*, 978–988. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Tafasitamab+plus+lenalidomide+in+relapsed+or+refractory+diffuse+large+B-cell+lymphoma+%28L-MIND%29:+A+multicentre,+prospective,+single-arm,+phase+2+study&author=Salles,+G.&author=Duell,+J.&author=Gonzalez+Barca,+E.&author=Tournilhac,+O.&author=Jurczak,+W.&author=Liberati,+A.M.&author=Nagy,+Z.&author=Obr,+A.&author=Gaidano,+G.&author=Andr%C3%A9,+M.&publication_year=2020&journal=Lancet+Oncol.&volume=21&pages=978%E2%80%93988&doi=10.1016/S1470-2045%2820%2930225-4 "https://scholar.google.com/scholar_lookup?title=Tafasitamab+plus+lenalidomide+in+relapsed+or+refractory+diffuse+large+B-cell+lymphoma+(L-MIND):+A+multicentre,+prospective,+single-arm,+phase+2+study&author=Salles,+G.&author=Duell,+J.&author=Gonzalez+Barca,+E.&author=Tournilhac,+O.&author=Jurczak,+W.&author=Liberati,+A.M.&author=Nagy,+Z.&author=Obr,+A.&author=Gaidano,+G.&author=Andr%C3%A9,+M.&publication_year=2020&journal=Lancet+Oncol.&volume=21&pages=978%E2%80%93988&doi=10.1016/S1470-2045(20)30225-4")\] \[[CrossRef](https://dx.doi.org/10.1016/S1470-2045%2820%2930225-4 "https://dx.doi.org/10.1016/S1470-2045(20)30225-4")\]

85.Morphosys. MorphoSys’ Tafasitamab B-MIND DLBCL Study Successfully Passed Futility Analysis. Available online: https://www.morphosys.com/media-investors/media-center/morphosys-tafasitamab-b-mind-dlbcl-study-successfully-passed-futility (accessed on 25 August 2020).

86.Klein, C.; Lammens, A.; Schäfer, W.; Georges, G.; Schwaiger, M.; Mössner, E.; Hopfner, K.-P.; Umaña, P.; Niederfellner, G. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. *MAbs* **2013**, *5*, 22–33. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Epitope+interactions+of+monoclonal+antibodies+targeting+CD20+and+their+relationship+to+functional+properties&author=Klein,+C.&author=Lammens,+A.&author=Sch%C3%A4fer,+W.&author=Georges,+G.&author=Schwaiger,+M.&author=M%C3%B6ssner,+E.&author=Hopfner,+K.-P.&author=Uma%C3%B1a,+P.&author=Niederfellner,+G.&publication_year=2013&journal=MAbs&volume=5&pages=22%E2%80%9333&doi=10.4161/mabs.22771)\] \[[CrossRef](https://dx.doi.org/10.4161/mabs.22771)\]

87.Morschhauser, F.; Marlton, P.; Vitolo, U.; Linden, O.; Seymour, J.F.; Crump, M.; Coiffier, B.; Foà, R.; Wassner, E.; Burger, H.-U.; et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. *Ann. Oncol.* **2010**, *21*, 1870–1876. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Results+of+a+phase+I/II+study+of+ocrelizumab,+a+fully+humanized+anti-CD20+mAb,+in+patients+with+relapsed/refractory+follicular+lymphoma&author=Morschhauser,+F.&author=Marlton,+P.&author=Vitolo,+U.&author=Linden,+O.&author=Seymour,+J.F.&author=Crump,+M.&author=Coiffier,+B.&author=Fo%C3%A0,+R.&author=Wassner,+E.&author=Burger,+H.-U.&publication_year=2010&journal=Ann.+Oncol.&volume=21&pages=1870%E2%80%931876&doi=10.1093/annonc/mdq027)\] \[[CrossRef](https://dx.doi.org/10.1093/annonc/mdq027)\]

88.Davis, T.A.; Grillo-Lopez, A.J.; White, C.A.; McLaughlin, P.; Czuczman, M.S.; Link, B.K.; Maloney, D.G.; Weaver, R.L.; Rosenberg, J.; Levy, R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: Safety and efficacy of re-treatment. *J. Clin. Oncol.* **2000**, *18*, 3135–3143. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Rituximab+anti-CD20+monoclonal+antibody+therapy+in+non-Hodgkin%E2%80%99s+lymphoma:+Safety+and+efficacy+of+re-treatment&author=Davis,+T.A.&author=Grillo-Lopez,+A.J.&author=White,+C.A.&author=McLaughlin,+P.&author=Czuczman,+M.S.&author=Link,+B.K.&author=Maloney,+D.G.&author=Weaver,+R.L.&author=Rosenberg,+J.&author=Levy,+R.&publication_year=2000&journal=J.+Clin.+Oncol.&volume=18&pages=3135%E2%80%933143&doi=10.1200/JCO.2000.18.17.3135&pmid=10963642)\] \[[CrossRef](https://dx.doi.org/10.1200/JCO.2000.18.17.3135)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10963642)\]

89.Keilholz, U.; Kawecki, A.; Dietz, A.; Zurawski, B.; Schenker, M.; Kukielka-Budny, B.; Schafhausen, P.; Mihailov, A.C.; Ochenduszko, S.; Imarisio, I.; et al. Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study. *J. Clin. Oncol.* **2018**, *36* (Suppl. S5), 59. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+CetuGEX+in+recurrent/metastatic+squamous+cell+carcinoma+of+the+head+and+neck+%28RM-HNSCC%29:+Results+from+the+randomized+phase+II+RESGEX+study&author=Keilholz,+U.&author=Kawecki,+A.&author=Dietz,+A.&author=Zurawski,+B.&author=Schenker,+M.&author=Kukielka-Budny,+B.&author=Schafhausen,+P.&author=Mihailov,+A.C.&author=Ochenduszko,+S.&author=Imarisio,+I.&publication_year=2018&journal=J.+Clin.+Oncol.&volume=36&pages=59&doi=10.1200/JCO.2018.36.5_suppl.59 "https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+CetuGEX+in+recurrent/metastatic+squamous+cell+carcinoma+of+the+head+and+neck+(RM-HNSCC):+Results+from+the+randomized+phase+II+RESGEX+study&author=Keilholz,+U.&author=Kawecki,+A.&author=Dietz,+A.&author=Zurawski,+B.&author=Schenker,+M.&author=Kukielka-Budny,+B.&author=Schafhausen,+P.&author=Mihailov,+A.C.&author=Ochenduszko,+S.&author=Imarisio,+I.&publication_year=2018&journal=J.+Clin.+Oncol.&volume=36&pages=59&doi=10.1200/JCO.2018.36.5_suppl.59")\] \[[CrossRef](https://dx.doi.org/10.1200/JCO.2018.36.5_suppl.59)\]

90.Rugo, H.S.; Im, S.-A.; Cardoso, F.; Cortes, J.; Curigliano, G.; Pegram, M.D.; Musolino, A.; Bachelot, T.; Wright, G.S.; De Laurentiis, M.; et al. Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Second interim overall survival analysis. *Cancer Res.* **2020**, *80* (Suppl. S4), GS1-02. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Abstract+GS1-02:+Phase+3+SOPHIA+study+of+margetuximab+++chemotherapy+vs+trastuzumab+++chemotherapy+in+patients+with+HER2++metastatic+breast+cancer+after+prior+anti-HER2+therapies:+Second+interim+overall+survival+analysis&author=Rugo,+H.S.&author=Im,+S.-A.&author=Cardoso,+F.&author=Cortes,+J.&author=Curigliano,+G.&author=Pegram,+M.D.&author=Musolino,+A.&author=Bachelot,+T.&author=Wright,+G.S.&author=De+Laurentiis,+M.&publication_year=2020&journal=Cancer+Res.&volume=80&pages=GS1-02)\]

91.Gavin, P.G.; Song, N.; Kim, S.R.; Lipchik, C.; Johnson, N.L.; Bandos, H.; Finnigan, M.; Rastogi, P.; Fehrenbacher, L.; Mamounas, E.P.; et al. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial. *JAMA Oncol.* **2017**, *3*, 335–341. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Association+of+Polymorphisms+in+FCGR2A+and+FCGR3A+With+Degree+of+Trastuzumab+Benefit+in+the+Adjuvant+Treatment+of+ERBB2/HER2%E2%80%93Positive+Breast+Cancer:+Analysis+of+the+NSABP+B-31+Trial&author=Gavin,+P.G.&author=Song,+N.&author=Kim,+S.R.&author=Lipchik,+C.&author=Johnson,+N.L.&author=Bandos,+H.&author=Finnigan,+M.&author=Rastogi,+P.&author=Fehrenbacher,+L.&author=Mamounas,+E.P.&publication_year=2017&journal=JAMA+Oncol.&volume=3&pages=335%E2%80%93341&doi=10.1001/jamaoncol.2016.4884)\] \[[CrossRef](https://dx.doi.org/10.1001/jamaoncol.2016.4884)\]

92.Kaplon, H.; Muralidharan, M.; Schneider, Z.; Reichert, J.M. Antibodies to watch in 2020. *MAbs* **2020**, *12*, 1703531\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Antibodies+to+watch+in+2020&author=Kaplon,+H.&author=Muralidharan,+M.&author=Schneider,+Z.&author=Reichert,+J.M.&publication_year=2020&journal=MAbs&volume=12&pages=1703531&doi=10.1080/19420862.2019.1703531)\] \[[CrossRef](https://dx.doi.org/10.1080/19420862.2019.1703531)\]

93.Vargas, F.A.; Furness, A.J.; Litchfield, K.; Joshi, K.; Rosenthal, R.; Ghorani, E.; Solomon, I.; Lesko, M.H.; Ruef, N.; Roddie, C.; et al. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. *Cancer Cell* **2018**, *33*, 649–663. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Fc+Effector+Function+Contributes+to+the+Activity+of+Human+Anti-CTLA-4+Antibodies&author=Vargas,+F.A.&author=Furness,+A.J.&author=Litchfield,+K.&author=Joshi,+K.&author=Rosenthal,+R.&author=Ghorani,+E.&author=Solomon,+I.&author=Lesko,+M.H.&author=Ruef,+N.&author=Roddie,+C.&publication_year=2018&journal=Cancer+Cell&volume=33&pages=649%E2%80%93663&doi=10.1016/j.ccell.2018.02.010)\] \[[CrossRef](https://dx.doi.org/10.1016/j.ccell.2018.02.010)\]

94.Sharma, A.; Subudhi, S.K.; Blando, J.; Vence, L.; Wargo, J.; Allison, J.P.; Ribas, A.; Sharma, P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers-Response. *Clin. Cancer Res.* **2019**, *25*, 3469–3470. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Anti-CTLA-4+Immunotherapy+Does+Not+Deplete+FOXP3%28+%29+Regulatory+T+Cells+%28Tregs%29+in+Human+Cancers-Response&author=Sharma,+A.&author=Subudhi,+S.K.&author=Blando,+J.&author=Vence,+L.&author=Wargo,+J.&author=Allison,+J.P.&author=Ribas,+A.&author=Sharma,+P.&publication_year=2019&journal=Clin.+Cancer+Res.&volume=25&pages=3469%E2%80%933470&doi=10.1158/1078-0432.CCR-19-0402 "https://scholar.google.com/scholar_lookup?title=Anti-CTLA-4+Immunotherapy+Does+Not+Deplete+FOXP3(+)+Regulatory+T+Cells+(Tregs)+in+Human+Cancers-Response&author=Sharma,+A.&author=Subudhi,+S.K.&author=Blando,+J.&author=Vence,+L.&author=Wargo,+J.&author=Allison,+J.P.&author=Ribas,+A.&author=Sharma,+P.&publication_year=2019&journal=Clin.+Cancer+Res.&volume=25&pages=3469%E2%80%933470&doi=10.1158/1078-0432.CCR-19-0402")\] \[[CrossRef](https://dx.doi.org/10.1158/1078-0432.CCR-19-0402)\]

95.Gombos, R.B.; González, A.; Manrique, M.; Chand, D.; Savitsky, D.; Morin, B.; Breous-Nystrom, E.; Dupont, C.; Ward, R.A.; Mundt, C.; et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. *PLoS ONE* **2018**, *13*, e0191926. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Toxicological+and+pharmacological+assessment+of+AGEN1884,+a+novel+human+IgG1+anti-CTLA-4+antibody&author=Gombos,+R.B.&author=Gonz%C3%A1lez,+A.&author=Manrique,+M.&author=Chand,+D.&author=Savitsky,+D.&author=Morin,+B.&author=Breous-Nystrom,+E.&author=Dupont,+C.&author=Ward,+R.A.&author=Mundt,+C.&publication_year=2018&journal=PLoS+ONE&volume=13&pages=e0191926&doi=10.1371/journal.pone.0191926)\] \[[CrossRef](https://dx.doi.org/10.1371/journal.pone.0191926)\]

96.Pena, A. Early Data Support Agenus’ 2 Lead Immunotherapies for Advanced Cervical Cancer. Available online: https://immuno-oncologynews.com/2020/03/04/balstilimab-zalifrelimab-and-agen1181-show-early-signs-of-efficacy-and-safety-in-advanced-cervical-cancer-and-other-solid-tumors/ (accessed on 25 August 2020).

97.Lee, C.H.; Romain, G.; Yan, W.; Watanabe, M.; Charab, W.; Todorova, B.; Lee, J.; Triplett, K.; Donkor, M.; Lungu, O.I.; et al. Corrigendum: IgG Fc domains that bind C1q but not effector Fcgamma receptors delineate the importance of complement-mediated effector functions. *Nat. Immunol.* **2017**, *18*, 1173\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Corrigendum:+IgG+Fc+domains+that+bind+C1q+but+not+effector+Fcgamma+receptors+delineate+the+importance+of+complement-mediated+effector+functions&author=Lee,+C.H.&author=Romain,+G.&author=Yan,+W.&author=Watanabe,+M.&author=Charab,+W.&author=Todorova,+B.&author=Lee,+J.&author=Triplett,+K.&author=Donkor,+M.&author=Lungu,+O.I.&publication_year=2017&journal=Nat.+Immunol.&volume=18&pages=1173&doi=10.1038/ni1017-1173c)\] \[[CrossRef](https://dx.doi.org/10.1038/ni1017-1173c)\]

98.Ugurlar, D.; Howes, S.C.; De Kreuk, B.-J.; Koning, R.I.; De Jong, R.N.; Beurskens, F.J.; Schuurman, J.; Koster, A.J.; Sharp, T.H.; Parren, P.W.H.I.; et al. Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. *Science* **2018**, *359*, 794–797. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Structures+of+C1-IgG1+provide+insights+into+how+danger+pattern+recognition+activates+complement&author=Ugurlar,+D.&author=Howes,+S.C.&author=De+Kreuk,+B.-J.&author=Koning,+R.I.&author=De+Jong,+R.N.&author=Beurskens,+F.J.&author=Schuurman,+J.&author=Koster,+A.J.&author=Sharp,+T.H.&author=Parren,+P.W.H.I.&publication_year=2018&journal=Science&volume=359&pages=794%E2%80%93797&doi=10.1126/science.aao4988)\] \[[CrossRef](https://dx.doi.org/10.1126/science.aao4988)\]

99.Cragg, M.S.; Morgan, S.M.; Chan, H.T.C.; Morgan, B.P.; Filatov, A.V.; Johnson, P.W.M.; French, R.R.; Glennie, M.J. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. *Blood* **2003**, *101*, 1045–1052. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Complement-mediated+lysis+by+anti-CD20+mAb+correlates+with+segregation+into+lipid+rafts&author=Cragg,+M.S.&author=Morgan,+S.M.&author=Chan,+H.T.C.&author=Morgan,+B.P.&author=Filatov,+A.V.&author=Johnson,+P.W.M.&author=French,+R.R.&author=Glennie,+M.J.&publication_year=2003&journal=Blood&volume=101&pages=1045%E2%80%931052&doi=10.1182/blood-2002-06-1761&pmid=12393541)\] \[[CrossRef](https://dx.doi.org/10.1182/blood-2002-06-1761)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12393541)\]

100.Natsume, A.; In, M.; Takamura, H.; Nakagawa, T.; Shimizu, Y.; Kitajima, K.; Wakitani, M.; Ohta, S.; Satoh, M.; Shitara, K.; et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. *Cancer Res.* **2008**, *68*, 3863–3872. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+antibodies+of+IgG1/IgG3+mixed+isotype+with+enhanced+cytotoxic+activities&author=Natsume,+A.&author=In,+M.&author=Takamura,+H.&author=Nakagawa,+T.&author=Shimizu,+Y.&author=Kitajima,+K.&author=Wakitani,+M.&author=Ohta,+S.&author=Satoh,+M.&author=Shitara,+K.&publication_year=2008&journal=Cancer+Res.&volume=68&pages=3863%E2%80%933872&doi=10.1158/0008-5472.CAN-07-6297)\] \[[CrossRef](https://dx.doi.org/10.1158/0008-5472.CAN-07-6297)\]

101.Idusogie, E.E.; Wong, P.Y.; Presta, L.G.; Gazzano-Santoro, H.; Totpal, K.; Ultsch, M.; Mulkerrin, M.G. Engineered antibodies with increased activity to recruit complement. *J. Immunol.* **2001**, *166*, 2571–2575. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+antibodies+with+increased+activity+to+recruit+complement&author=Idusogie,+E.E.&author=Wong,+P.Y.&author=Presta,+L.G.&author=Gazzano-Santoro,+H.&author=Totpal,+K.&author=Ultsch,+M.&author=Mulkerrin,+M.G.&publication_year=2001&journal=J.+Immunol.&volume=166&pages=2571%E2%80%932575&doi=10.4049/jimmunol.166.4.2571&pmid=11160318)\] \[[CrossRef](https://dx.doi.org/10.4049/jimmunol.166.4.2571)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11160318)\]

102.Moore, G.L.; Chen, H.; Karki, S.; Lazar, G.A. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. *MAbs* **2010**, *2*, 181–189. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+Fc+variant+antibodies+with+enhanced+ability+to+recruit+complement+and+mediate+effector+functions&author=Moore,+G.L.&author=Chen,+H.&author=Karki,+S.&author=Lazar,+G.A.&publication_year=2010&journal=MAbs&volume=2&pages=181%E2%80%93189&doi=10.4161/mabs.2.2.11158&pmid=20150767)\] \[[CrossRef](https://dx.doi.org/10.4161/mabs.2.2.11158)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20150767)\]

103.Saunders, K.O. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. *Front. Immunol.* **2019**, *10*, 1296\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Conceptual+Approaches+to+Modulating+Antibody+Effector+Functions+and+Circulation+Half-Life&author=Saunders,+K.O.&publication_year=2019&journal=Front.+Immunol.&volume=10&pages=1296&doi=10.3389/fimmu.2019.01296)\] \[[CrossRef](https://dx.doi.org/10.3389/fimmu.2019.01296)\]

104.Kellner, C.; Otte, A.; Cappuzzello, E.; Klausz, K.; Peipp, M. Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy. *Transfus. Med. Hemother.* **2017**, *44*, 327–336. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Modulating+Cytotoxic+Effector+Functions+by+Fc+Engineering+to+Improve+Cancer+Therapy&author=Kellner,+C.&author=Otte,+A.&author=Cappuzzello,+E.&author=Klausz,+K.&author=Peipp,+M.&publication_year=2017&journal=Transfus.+Med.+Hemother.&volume=44&pages=327%E2%80%93336&doi=10.1159/000479980&pmid=29070978)\] \[[CrossRef](https://dx.doi.org/10.1159/000479980)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29070978)\]

105.Wang, X.; Mathieu, M.; Brezski, R.J. IgG Fc engineering to modulate antibody effector functions. *Protein Cell* **2018**, *9*, 63–73. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=IgG+Fc+engineering+to+modulate+antibody+effector+functions&author=Wang,+X.&author=Mathieu,+M.&author=Brezski,+R.J.&publication_year=2018&journal=Protein+Cell&volume=9&pages=63%E2%80%9373&doi=10.1007/s13238-017-0473-8&pmid=28986820)\] \[[CrossRef](https://dx.doi.org/10.1007/s13238-017-0473-8)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28986820)\]

106.Clynes, R.; Maizes, J.S.; Guinamard, R.; Ono, M.; Takai, T.; Ravetch, J.V. Modulation of immune complex-induced inflammation In Vivo by the coordinate expression of activation and inhibitory Fc receptors. *J. Exp. Med.* **1999**, *189*, 179–185. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Modulation+of+immune+complex-induced+inflammation+In+Vivo+by+the+coordinate+expression+of+activation+and+inhibitory+Fc+receptors&author=Clynes,+R.&author=Maizes,+J.S.&author=Guinamard,+R.&author=Ono,+M.&author=Takai,+T.&author=Ravetch,+J.V.&publication_year=1999&journal=J.+Exp.+Med.&volume=189&pages=179%E2%80%93185&doi=10.1084/jem.189.1.179)\] \[[CrossRef](https://dx.doi.org/10.1084/jem.189.1.179)\]

107.Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory Fc receptors modulate In Vivo cytotoxicity against tumor targets. *Nat. Med.* **2000**, *6*, 443–446. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Inhibitory+Fc+receptors+modulate+In+Vivo+cytotoxicity+against+tumor+targets&author=Clynes,+R.A.&author=Towers,+T.L.&author=Presta,+L.G.&author=Ravetch,+J.V.&publication_year=2000&journal=Nat.+Med.&volume=6&pages=443%E2%80%93446&doi=10.1038/74704)\] \[[CrossRef](https://dx.doi.org/10.1038/74704)\]

108.Beers, S.A.; Glennie, M.J.; White, A.L. Influence of immunoglobulin isotype on therapeutic antibody function. *Blood* **2016**, *127*, 1097–1101. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Influence+of+immunoglobulin+isotype+on+therapeutic+antibody+function&author=Beers,+S.A.&author=Glennie,+M.J.&author=White,+A.L.&publication_year=2016&journal=Blood&volume=127&pages=1097%E2%80%931101&doi=10.1182/blood-2015-09-625343)\] \[[CrossRef](https://dx.doi.org/10.1182/blood-2015-09-625343)\]

109.White, A.L.; Dou, L.; Chan, H.T.; Field, V.L.; Mockridge, C.I.; Moss, K.; Williams, E.L.; Booth, S.G.; French, R.R.; Potter, E.A.; et al. Fcgamma receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. *J. Immunol.* **2014**, *193*, 1828–1835. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Fcgamma+receptor+dependency+of+agonistic+CD40+antibody+in+lymphoma+therapy+can+be+overcome+through+antibody+multimerization&author=White,+A.L.&author=Dou,+L.&author=Chan,+H.T.&author=Field,+V.L.&author=Mockridge,+C.I.&author=Moss,+K.&author=Williams,+E.L.&author=Booth,+S.G.&author=French,+R.R.&author=Potter,+E.A.&publication_year=2014&journal=J.+Immunol.&volume=193&pages=1828%E2%80%931835&doi=10.4049/jimmunol.1303204&pmid=25024386)\] \[[CrossRef](https://dx.doi.org/10.4049/jimmunol.1303204)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25024386)\]

110.Li, F.; Ravetch, J.V. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. *Science* **2011**, *333*, 1030–1034. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Inhibitory+Fcgamma+receptor+engagement+drives+adjuvant+and+anti-tumor+activities+of+agonistic+CD40+antibodies&author=Li,+F.&author=Ravetch,+J.V.&publication_year=2011&journal=Science&volume=333&pages=1030%E2%80%931034&doi=10.1126/science.1206954&pmid=21852502)\] \[[CrossRef](https://dx.doi.org/10.1126/science.1206954)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21852502)\]

111.White, A.L.; Beers, S.A.; Cragg, M.S. FcgammaRIIB as a key determinant of agonistic antibody efficacy. *Curr. Top. Microbiol. Immunol.* **2014**, *382*, 355–372. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=FcgammaRIIB+as+a+key+determinant+of+agonistic+antibody+efficacy&author=White,+A.L.&author=Beers,+S.A.&author=Cragg,+M.S.&publication_year=2014&journal=Curr.+Top.+Microbiol.+Immunol.&volume=382&pages=355%E2%80%93372&pmid=25116108)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25116108)\]

112.White, A.L.; Chan, H.T.; Roghanian, A.; French, R.R.; Mockridge, C.I.; Tutt, A.L.; Dixon, S.V.; Daniel Ajona, D.; Verbeek, J.S.; Al-Shamkhani, A.; et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. *J. Immunol.* **2011**, *187*, 1754–1763. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Interaction+with+FcgammaRIIB+is+critical+for+the+agonistic+activity+of+anti-CD40+monoclonal+antibody&author=White,+A.L.&author=Chan,+H.T.&author=Roghanian,+A.&author=French,+R.R.&author=Mockridge,+C.I.&author=Tutt,+A.L.&author=Dixon,+S.V.&author=Daniel+Ajona,+D.&author=Verbeek,+J.S.&author=Al-Shamkhani,+A.&publication_year=2011&journal=J.+Immunol.&volume=187&pages=1754%E2%80%931763&doi=10.4049/jimmunol.1101135&pmid=21742972)\] \[[CrossRef](https://dx.doi.org/10.4049/jimmunol.1101135)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21742972)\]

113.Wilson, N.S.; Yang, B.; Yang, A.; Loeser, S.; Marsters, S.; Lawrence, D.; Li, Y.; Pitti, R.; Totpal, K.; Yee, S.; et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. *Cancer Cell* **2011**, *19*, 101–113. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=An+Fcgamma+receptor-dependent+mechanism+drives+antibody-mediated+target-receptor+signaling+in+cancer+cells&author=Wilson,+N.S.&author=Yang,+B.&author=Yang,+A.&author=Loeser,+S.&author=Marsters,+S.&author=Lawrence,+D.&author=Li,+Y.&author=Pitti,+R.&author=Totpal,+K.&author=Yee,+S.&publication_year=2011&journal=Cancer+Cell&volume=19&pages=101%E2%80%93113&doi=10.1016/j.ccr.2010.11.012)\] \[[CrossRef](https://dx.doi.org/10.1016/j.ccr.2010.11.012)\]

114.Mayes, P.A.; Hance, K.W.; Hoos, A. The promise and challenges of immune agonist antibody development in cancer. *Nat. Rev. Drug Discov.* **2018**, *17*, 509–527. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+promise+and+challenges+of+immune+agonist+antibody+development+in+cancer&author=Mayes,+P.A.&author=Hance,+K.W.&author=Hoos,+A.&publication_year=2018&journal=Nat.+Rev.+Drug+Discov.&volume=17&pages=509%E2%80%93527&doi=10.1038/nrd.2018.75)\] \[[CrossRef](https://dx.doi.org/10.1038/nrd.2018.75)\]

115.Chu, S.Y.; Vostiar, I.; Karki, S.; Moore, G.L.; Lazar, G.A.; Pong, E.; Joyce, P.F.; Szymkowski, D.E.; Desjarlais, J.D. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. *Mol. Immunol.* **2008**, *45*, 3926–3933. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Inhibition+of+B+cell+receptor-mediated+activation+of+primary+human+B+cells+by+coengagement+of+CD19+and+FcgammaRIIb+with+Fc-engineered+antibodies&author=Chu,+S.Y.&author=Vostiar,+I.&author=Karki,+S.&author=Moore,+G.L.&author=Lazar,+G.A.&author=Pong,+E.&author=Joyce,+P.F.&author=Szymkowski,+D.E.&author=Desjarlais,+J.D.&publication_year=2008&journal=Mol.+Immunol.&volume=45&pages=3926%E2%80%933933&doi=10.1016/j.molimm.2008.06.027)\] \[[CrossRef](https://dx.doi.org/10.1016/j.molimm.2008.06.027)\]

116.Zhang, D.; Goldberg, M.V.; Chiu, M.L. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody. *J. Biol. Chem.* **2016**, *291*, 27134–27146. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Fc+Engineering+Approaches+to+Enhance+the+Agonism+and+Effector+Functions+of+an+Anti-OX40+Antibody&author=Zhang,+D.&author=Goldberg,+M.V.&author=Chiu,+M.L.&publication_year=2016&journal=J.+Biol.+Chem.&volume=291&pages=27134%E2%80%9327146&doi=10.1074/jbc.M116.757773)\] \[[CrossRef](https://dx.doi.org/10.1074/jbc.M116.757773)\]

117.Dahan, R.; Barnhart, B.C.; Li, F.; Yamniuk, A.P.; Korman, A.J.; Ravetch, J.V. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcgammaR Engagement. *Cancer Cell* **2016**, *29*, 820–831. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Therapeutic+Activity+of+Agonistic,+Human+Anti-CD40+Monoclonal+Antibodies+Requires+Selective+FcgammaR+Engagement&author=Dahan,+R.&author=Barnhart,+B.C.&author=Li,+F.&author=Yamniuk,+A.P.&author=Korman,+A.J.&author=Ravetch,+J.V.&publication_year=2016&journal=Cancer+Cell&volume=29&pages=820%E2%80%93831&doi=10.1016/j.ccell.2016.05.001)\] \[[CrossRef](https://dx.doi.org/10.1016/j.ccell.2016.05.001)\]

118.Mimoto, F.; Katada, H.; Kadono, S.; Igawa, T.; Kuramochi, T.; Muraoka, M.; Wada, Y.; Haraya, K.; Miyazaki, T.; Hattori, K. Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa(R131) and FcgammaRIIa(H131). *Protein Eng. Des. Sel.* **2013**, *26*, 589–598. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+antibody+Fc+variant+with+selectively+enhanced+FcgammaRIIb+binding+over+both+FcgammaRIIa%28R131%29+and+FcgammaRIIa%28H131%29&author=Mimoto,+F.&author=Katada,+H.&author=Kadono,+S.&author=Igawa,+T.&author=Kuramochi,+T.&author=Muraoka,+M.&author=Wada,+Y.&author=Haraya,+K.&author=Miyazaki,+T.&author=Hattori,+K.&publication_year=2013&journal=Protein+Eng.+Des.+Sel.&volume=26&pages=589%E2%80%93598&doi=10.1093/protein/gzt022 "https://scholar.google.com/scholar_lookup?title=Engineered+antibody+Fc+variant+with+selectively+enhanced+FcgammaRIIb+binding+over+both+FcgammaRIIa(R131)+and+FcgammaRIIa(H131)&author=Mimoto,+F.&author=Katada,+H.&author=Kadono,+S.&author=Igawa,+T.&author=Kuramochi,+T.&author=Muraoka,+M.&author=Wada,+Y.&author=Haraya,+K.&author=Miyazaki,+T.&author=Hattori,+K.&publication_year=2013&journal=Protein+Eng.+Des.+Sel.&volume=26&pages=589%E2%80%93598&doi=10.1093/protein/gzt022")\] \[[CrossRef](https://dx.doi.org/10.1093/protein/gzt022)\]

119.Yu, X.; Chan, H.C.; Orr, C.M.; Dadas, O.; Booth, S.G.; Dahal, L.N.; Penfold, C.A.; O’Brien, L.; Mockridge, C.I.; French, R.R.; et al. Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. *Cancer Cell* **2018**, *33*, 664–675. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Complex+Interplay+between+Epitope+Specificity+and+Isotype+Dictates+the+Biological+Activity+of+Anti-human+CD40+Antibodies&author=Yu,+X.&author=Chan,+H.C.&author=Orr,+C.M.&author=Dadas,+O.&author=Booth,+S.G.&author=Dahal,+L.N.&author=Penfold,+C.A.&author=O%E2%80%99Brien,+L.&author=Mockridge,+C.I.&author=French,+R.R.&publication_year=2018&journal=Cancer+Cell&volume=33&pages=664%E2%80%93675&doi=10.1016/j.ccell.2018.02.009&pmid=29576376)\] \[[CrossRef](https://dx.doi.org/10.1016/j.ccell.2018.02.009)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29576376)\]

120.Knorr, D.A.; Dahan, R.; Ravetch, J.V. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 11048\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Toxicity+of+an+Fc-engineered+anti-CD40+antibody+is+abrogated+by+intratumoral+injection+and+results+in+durable+antitumor+immunity&author=Knorr,+D.A.&author=Dahan,+R.&author=Ravetch,+J.V.&publication_year=2018&journal=Proc.+Natl.+Acad.+Sci.+USA&volume=115&pages=11048&doi=10.1073/pnas.1810566115&pmid=30297432)\] \[[CrossRef](https://dx.doi.org/10.1073/pnas.1810566115)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30297432)\]

121.Buchan, S.L.; Dou, L.; Remer, M.; Booth, S.G.; Dunn, S.N.; Lai, C.; Semmrich, M.; Teige, I.; Mårtensson, L.; Penfold, C.A.; et al. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. *Immunity* **2018**, *49*, 958–970. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Antibodies+to+Costimulatory+Receptor+4-1BB+Enhance+Anti-tumor+Immunity+via+T+Regulatory+Cell+Depletion+and+Promotion+of+CD8+T+Cell+Effector+Function&author=Buchan,+S.L.&author=Dou,+L.&author=Remer,+M.&author=Booth,+S.G.&author=Dunn,+S.N.&author=Lai,+C.&author=Semmrich,+M.&author=Teige,+I.&author=M%C3%A5rtensson,+L.&author=Penfold,+C.A.&publication_year=2018&journal=Immunity&volume=49&pages=958%E2%80%93970&doi=10.1016/j.immuni.2018.09.014&pmid=30446386)\] \[[CrossRef](https://dx.doi.org/10.1016/j.immuni.2018.09.014)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30446386)\]

122.Qi, X.; Li, F.; Wu, Y.; Cheng, C.; Han, P.; Wang, J.; Yang, X. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. *Nat. Commun.* **2019**, *10*, 2141\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Optimization+of+4-1BB+antibody+for+cancer+immunotherapy+by+balancing+agonistic+strength+with+Fc%CE%B3R+affinity&author=Qi,+X.&author=Li,+F.&author=Wu,+Y.&author=Cheng,+C.&author=Han,+P.&author=Wang,+J.&author=Yang,+X.&publication_year=2019&journal=Nat.+Commun.&volume=10&pages=2141&doi=10.1038/s41467-019-10088-1&pmid=31105267)\] \[[CrossRef](https://dx.doi.org/10.1038/s41467-019-10088-1)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31105267)\]

123.Claus, C.; Ferrara, C.; Xu, W.; Sam, J.; Lang, S.; Uhlenbrock, F.; Albrecht, R.; Herter, S.; Schlenker, R.; Hüsser, T.; et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. *Sci. Transl. Med.* **2019**, *11*, eaav5989. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Tumor-targeted+4-1BB+agonists+for+combination+with+T+cell+bispecific+antibodies+as+off-the-shelf+therapy&author=Claus,+C.&author=Ferrara,+C.&author=Xu,+W.&author=Sam,+J.&author=Lang,+S.&author=Uhlenbrock,+F.&author=Albrecht,+R.&author=Herter,+S.&author=Schlenker,+R.&author=H%C3%BCsser,+T.&publication_year=2019&journal=Sci.+Transl.+Med.&volume=11&pages=eaav5989&pmid=31189721)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31189721)\]

124.Sazinsky, S.L.; Ott, R.G.; Silver, N.W.; Tidor, B.; Ravetch, J.V.; Wittrup, K.D. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 20167–20172. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Aglycosylated+immunoglobulin+G1+variants+productively+engage+activating+Fc+receptors&author=Sazinsky,+S.L.&author=Ott,+R.G.&author=Silver,+N.W.&author=Tidor,+B.&author=Ravetch,+J.V.&author=Wittrup,+K.D.&publication_year=2008&journal=Proc.+Natl.+Acad.+Sci.+USA&volume=105&pages=20167%E2%80%9320172&doi=10.1073/pnas.0809257105)\] \[[CrossRef](https://dx.doi.org/10.1073/pnas.0809257105)\]

125.Jo, M.; Kwon, H.S.; Lee, K.H.; Lee, J.C.; Jung, S.T. Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcgammaRIIIa binding and tumor cell clearance. *MAbs* **2018**, *10*, 278–289. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+aglycosylated+full-length+IgG+Fc+variants+exhibiting+improved+FcgammaRIIIa+binding+and+tumor+cell+clearance&author=Jo,+M.&author=Kwon,+H.S.&author=Lee,+K.H.&author=Lee,+J.C.&author=Jung,+S.T.&publication_year=2018&journal=MAbs&volume=10&pages=278%E2%80%93289&doi=10.1080/19420862.2017.1402995)\] \[[CrossRef](https://dx.doi.org/10.1080/19420862.2017.1402995)\]

126.Bolt, S.; Routledge, E.; Lloyd, I.; Chatenoud, L.; Pope, H.; Gorman, S.D.; Clark, M.; Waldmann, H. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains In Vitro immunosuppressive properties. *Eur. J. Immunol.* **1993**, *23*, 403–411. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+generation+of+a+humanized,+non-mitogenic+CD3+monoclonal+antibody+which+retains+In+Vitro+immunosuppressive+properties&author=Bolt,+S.&author=Routledge,+E.&author=Lloyd,+I.&author=Chatenoud,+L.&author=Pope,+H.&author=Gorman,+S.D.&author=Clark,+M.&author=Waldmann,+H.&publication_year=1993&journal=Eur.+J.+Immunol.&volume=23&pages=403%E2%80%93411&doi=10.1002/eji.1830230216)\] \[[CrossRef](https://dx.doi.org/10.1002/eji.1830230216)\]

127.Hutchins, J.T.; Kull, F.C.; Bynum, J.; Knick, V.C.; Thurmond, L.M.; Ray, P. Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 11980–11984. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Improved+biodistribution,+tumor+targeting,+and+reduced+immunogenicity+in+mice+with+a+gamma+4+variant+of+Campath-1H&author=Hutchins,+J.T.&author=Kull,+F.C.&author=Bynum,+J.&author=Knick,+V.C.&author=Thurmond,+L.M.&author=Ray,+P.&publication_year=1995&journal=Proc.+Natl.+Acad.+Sci.+USA&volume=92&pages=11980%E2%80%9311984&doi=10.1073/pnas.92.26.11980)\] \[[CrossRef](https://dx.doi.org/10.1073/pnas.92.26.11980)\]

128.Xu, D.; Alegre, M.-L.; Varga, S.S.; Rothermel, A.L.; Collins, A.M.; Pulito, V.L.; Hanna, L.S.; Dolan, K.P.; Parren, P.W.; Bluestone, J.A.; et al. In Vitro characterization of five humanized OKT3 effector function variant antibodies. *Cell Immunol.* **2000**, *200*, 16–26. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=In+Vitro+characterization+of+five+humanized+OKT3+effector+function+variant+antibodies&author=Xu,+D.&author=Alegre,+M.-L.&author=Varga,+S.S.&author=Rothermel,+A.L.&author=Collins,+A.M.&author=Pulito,+V.L.&author=Hanna,+L.S.&author=Dolan,+K.P.&author=Parren,+P.W.&author=Bluestone,+J.A.&publication_year=2000&journal=Cell+Immunol.&volume=200&pages=16%E2%80%9326&doi=10.1006/cimm.2000.1617)\] \[[CrossRef](https://dx.doi.org/10.1006/cimm.2000.1617)\]

129.Hezareh, M.; Hessell, A.J.; Jensen, R.C.; van de Winkel, J.G.; Parren, P.W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. *J. Virol.* **2001**, *75*, 12161–12168. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Effector+function+activities+of+a+panel+of+mutants+of+a+broadly+neutralizing+antibody+against+human+immunodeficiency+virus+type+1&author=Hezareh,+M.&author=Hessell,+A.J.&author=Jensen,+R.C.&author=van+de+Winkel,+J.G.&author=Parren,+P.W.&publication_year=2001&journal=J.+Virol.&volume=75&pages=12161%E2%80%9312168&doi=10.1128/JVI.75.24.12161-12168.2001&pmid=11711607)\] \[[CrossRef](https://dx.doi.org/10.1128/JVI.75.24.12161-12168.2001)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11711607)\]

130.Schlothauer, T.; Herter, S.; Koller, C.F.; Grau-Richards, S.; Steinhart, V.; Spick, C.; Kubbies, M.; Klein, C.; Umaña, P.; Moessner, E. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. *Protein Eng. Des. Sel.* **2016**, *29*, 457–466. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Novel+human+IgG1+and+IgG4+Fc-engineered+antibodies+with+completely+abolished+immune+effector+functions&author=Schlothauer,+T.&author=Herter,+S.&author=Koller,+C.F.&author=Grau-Richards,+S.&author=Steinhart,+V.&author=Spick,+C.&author=Kubbies,+M.&author=Klein,+C.&author=Uma%C3%B1a,+P.&author=Moessner,+E.&publication_year=2016&journal=Protein+Eng.+Des.+Sel.&volume=29&pages=457%E2%80%93466&doi=10.1093/protein/gzw040&pmid=27578889)\] \[[CrossRef](https://dx.doi.org/10.1093/protein/gzw040)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27578889)\]

131.Oganesyan, V.; Gao, C.; Shirinian, L.; Wu, H.; Dall’Acqua, W.F. Structural characterization of a human Fc fragment engineered for lack of effector functions. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **2008**, *64* *Pt 6*, 700–704. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Structural+characterization+of+a+human+Fc+fragment+engineered+for+lack+of+effector+functions&author=Oganesyan,+V.&author=Gao,+C.&author=Shirinian,+L.&author=Wu,+H.&author=Dall%E2%80%99Acqua,+W.F.&publication_year=2008&journal=Acta+Crystallogr.+Sect.+D+Biol.+Crystallogr.&volume=64&issue=Pt+6&pages=700%E2%80%93704&doi=10.1107/S0907444908007877&pmid=18560159)\] \[[CrossRef](https://dx.doi.org/10.1107/S0907444908007877)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18560159)\]

132.An, Z.; Forrest, G.; Moore, R.; Cukan, M.; Haytko, P.; Huang, L.; Vitelli, S.; Zhao, J.Z.; Lu, P.; Hua, J.; et al. IgG2m4, an engineered antibody isotype with reduced Fc function. *MAbs* **2009**, *1*, 572–579. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=IgG2m4,+an+engineered+antibody+isotype+with+reduced+Fc+function&author=An,+Z.&author=Forrest,+G.&author=Moore,+R.&author=Cukan,+M.&author=Haytko,+P.&author=Huang,+L.&author=Vitelli,+S.&author=Zhao,+J.Z.&author=Lu,+P.&author=Hua,+J.&publication_year=2009&journal=MAbs&volume=1&pages=572%E2%80%93579&doi=10.4161/mabs.1.6.10185)\] \[[CrossRef](https://dx.doi.org/10.4161/mabs.1.6.10185)\]

133.Moore, G.L.; Bernett, M.J.; Rashid, R.; Pong, E.W.; Nguyen, D.-H.T.; Jacinto, J.; Eivazi, A.; Nisthal, A.; Diaz, J.E.; Chu, S.Y.; et al. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats. *Methods* **2019**, *154*, 38–50. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=A+robust+heterodimeric+Fc+platform+engineered+for+efficient+development+of+bispecific+antibodies+of+multiple+formats&author=Moore,+G.L.&author=Bernett,+M.J.&author=Rashid,+R.&author=Pong,+E.W.&author=Nguyen,+D.-H.T.&author=Jacinto,+J.&author=Eivazi,+A.&author=Nisthal,+A.&author=Diaz,+J.E.&author=Chu,+S.Y.&publication_year=2019&journal=Methods&volume=154&pages=38%E2%80%9350&doi=10.1016/j.ymeth.2018.10.006)\] \[[CrossRef](https://dx.doi.org/10.1016/j.ymeth.2018.10.006)\]

134.Strohl, W.; Vafa, O. Antibody Fc Mutants with Ablated Effector Functions. U.S. Patent 20150337053A1, 26 November 2015. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Antibody+Fc+Mutants+with+Ablated+Effector+Functions&author=Strohl,+W.&author=Vafa,+O.&publication_year=2015)\]

135.Engelberts, P.J.; Hiemstra, I.H.; De Jong, B.; Schuurhuis, D.H.; Meesters, J.; Hernandez, I.B.; Oostindie, S.C.; Neijssen, J.; Brink, E.N.V.D.; Horbach, G.J.; et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. *EBioMedicine* **2020**, *52*, 102625\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=DuoBody-CD3xCD20+induces+potent+T-cell-mediated+killing+of+malignant+B+cells+in+preclinical+models+and+provides+opportunities+for+subcutaneous+dosing&author=Engelberts,+P.J.&author=Hiemstra,+I.H.&author=De+Jong,+B.&author=Schuurhuis,+D.H.&author=Meesters,+J.&author=Hernandez,+I.B.&author=Oostindie,+S.C.&author=Neijssen,+J.&author=Brink,+E.N.V.D.&author=Horbach,+G.J.&publication_year=2020&journal=EBioMedicine&volume=52&pages=102625&doi=10.1016/j.ebiom.2019.102625)\] \[[CrossRef](https://dx.doi.org/10.1016/j.ebiom.2019.102625)\]

136.Newman, R.; Hariharan, K.; Reff, M.; Anderson, D.R.; Braslawsky, G.; Santoro, D.; Hanna, N.; Bugelski, P.J.; Brigham-Burke, M.; Crysler, C.; et al. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. *Clin. Immunol.* **2001**, *98*, 164–174. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Modification+of+the+Fc+region+of+a+primatized+IgG+antibody+to+human+CD4+retains+its+ability+to+modulate+CD4+receptors+but+does+not+deplete+CD4%28+%29+T+cells+in+chimpanzees&author=Newman,+R.&author=Hariharan,+K.&author=Reff,+M.&author=Anderson,+D.R.&author=Braslawsky,+G.&author=Santoro,+D.&author=Hanna,+N.&author=Bugelski,+P.J.&author=Brigham-Burke,+M.&author=Crysler,+C.&publication_year=2001&journal=Clin.+Immunol.&volume=98&pages=164%E2%80%93174&doi=10.1006/clim.2000.4975 "https://scholar.google.com/scholar_lookup?title=Modification+of+the+Fc+region+of+a+primatized+IgG+antibody+to+human+CD4+retains+its+ability+to+modulate+CD4+receptors+but+does+not+deplete+CD4(+)+T+cells+in+chimpanzees&author=Newman,+R.&author=Hariharan,+K.&author=Reff,+M.&author=Anderson,+D.R.&author=Braslawsky,+G.&author=Santoro,+D.&author=Hanna,+N.&author=Bugelski,+P.J.&author=Brigham-Burke,+M.&author=Crysler,+C.&publication_year=2001&journal=Clin.+Immunol.&volume=98&pages=164%E2%80%93174&doi=10.1006/clim.2000.4975")\] \[[CrossRef](https://dx.doi.org/10.1006/clim.2000.4975)\]

137.Duncan, A.R.; Winter, G. The binding site for C1q on IgG. *Nature* **1988**, *332*, 738–740. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+binding+site+for+C1q+on+IgG&author=Duncan,+A.R.&author=Winter,+G.&publication_year=1988&journal=Nature&volume=332&pages=738%E2%80%93740&doi=10.1038/332738a0)\] \[[CrossRef](https://dx.doi.org/10.1038/332738a0)\]

138.Armour, K.L.; Clark, M.R.; Hadley, A.G.; Williamson, L.M. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. *Eur. J. Immunol.* **1999**, *29*, 2613–2624. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Recombinant+human+IgG+molecules+lacking+Fcgamma+receptor+I+binding+and+monocyte+triggering+activities&author=Armour,+K.L.&author=Clark,+M.R.&author=Hadley,+A.G.&author=Williamson,+L.M.&publication_year=1999&journal=Eur.+J.+Immunol.&volume=29&pages=2613%E2%80%932624&doi=10.1002/%28SICI%291521-4141%28199908%2929:08%3C2613::AID-IMMU2613%3E3.0.CO;2-J "https://scholar.google.com/scholar_lookup?title=Recombinant+human+IgG+molecules+lacking+Fcgamma+receptor+I+binding+and+monocyte+triggering+activities&author=Armour,+K.L.&author=Clark,+M.R.&author=Hadley,+A.G.&author=Williamson,+L.M.&publication_year=1999&journal=Eur.+J.+Immunol.&volume=29&pages=2613%E2%80%932624&doi=10.1002/(SICI)1521-4141(199908)29:08%3C2613::AID-IMMU2613%3E3.0.CO;2-J")\] \[[CrossRef](https://dx.doi.org/10.1002/%28SICI%291521-4141%28199908%2929:08%3C2613::AID-IMMU2613%3E3.0.CO;2-J "https://dx.doi.org/10.1002/(SICI)1521-4141(199908)29:08%3C2613::AID-IMMU2613%3E3.0.CO;2-J")\]

139.Ferrara, C.; Grau, S.; Jager, C.; Sondermann, P.; Brunker, P.; Waldhauer, I.; Hennig, M.; Ruf, A.; Rufer, A.C.; Stihle, M.; et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 12669–12674. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Unique+carbohydrate-carbohydrate+interactions+are+required+for+high+affinity+binding+between+FcgammaRIII+and+antibodies+lacking+core+fucose&author=Ferrara,+C.&author=Grau,+S.&author=Jager,+C.&author=Sondermann,+P.&author=Brunker,+P.&author=Waldhauer,+I.&author=Hennig,+M.&author=Ruf,+A.&author=Rufer,+A.C.&author=Stihle,+M.&publication_year=2011&journal=Proc.+Natl.+Acad.+Sci.+USA&volume=108&pages=12669%E2%80%9312674&doi=10.1073/pnas.1108455108)\] \[[CrossRef](https://dx.doi.org/10.1073/pnas.1108455108)\]

140.Bruhns, P.; Jonsson, F. Mouse and human FcR effector functions. *Immunol. Rev.* **2015**, *268*, 25–51. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Mouse+and+human+FcR+effector+functions&author=Bruhns,+P.&author=Jonsson,+F.&publication_year=2015&journal=Immunol.+Rev.&volume=268&pages=25%E2%80%9351&doi=10.1111/imr.12350&pmid=26497511)\] \[[CrossRef](https://dx.doi.org/10.1111/imr.12350)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26497511)\]

141.Lux, A.; Yu, X.; Scanlan, C.N.; Nimmerjahn, F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. *J. Immunol.* **2013**, *190*, 4315–4323. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Impact+of+immune+complex+size+and+glycosylation+on+IgG+binding+to+human+FcgammaRs&author=Lux,+A.&author=Yu,+X.&author=Scanlan,+C.N.&author=Nimmerjahn,+F.&publication_year=2013&journal=J.+Immunol.&volume=190&pages=4315%E2%80%934323&doi=10.4049/jimmunol.1200501&pmid=23509345)\] \[[CrossRef](https://dx.doi.org/10.4049/jimmunol.1200501)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23509345)\]

142.Brüggemann, M.; Williams, G.T.; Bindon, C.I.; Clark, M.R.; Walker, M.R.; Jefferis, R.; Waldmann, H.; Neuberger, M.S. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. *J. Exp. Med.* **1987**, *166*, 1351–1361. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Comparison+of+the+effector+functions+of+human+immunoglobulins+using+a+matched+set+of+chimeric+antibodies&author=Br%C3%BCggemann,+M.&author=Williams,+G.T.&author=Bindon,+C.I.&author=Clark,+M.R.&author=Walker,+M.R.&author=Jefferis,+R.&author=Waldmann,+H.&author=Neuberger,+M.S.&publication_year=1987&journal=J.+Exp.+Med.&volume=166&pages=1351%E2%80%931361&doi=10.1084/jem.166.5.1351)\] \[[CrossRef](https://dx.doi.org/10.1084/jem.166.5.1351)\]

143.Bindon, C.I.; Hale, G.; Bruggemann, M.; Waldmann, H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. *J. Exp. Med.* **1988**, *168*, 127–142. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Human+monoclonal+IgG+isotypes+differ+in+complement+activating+function+at+the+level+of+C4+as+well+as+C1q&author=Bindon,+C.I.&author=Hale,+G.&author=Bruggemann,+M.&author=Waldmann,+H.&publication_year=1988&journal=J.+Exp.+Med.&volume=168&pages=127%E2%80%93142&doi=10.1084/jem.168.1.127&pmid=3260935)\] \[[CrossRef](https://dx.doi.org/10.1084/jem.168.1.127)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/3260935)\]

144.Kretschmer, A.; Schwanbeck, R.; Valerius, T.; Rosner, T. Antibody Isotypes for Tumor Immunotherapy. *Transfus. Med. Hemother.* **2017**, *44*, 320–326. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Antibody+Isotypes+for+Tumor+Immunotherapy&author=Kretschmer,+A.&author=Schwanbeck,+R.&author=Valerius,+T.&author=Rosner,+T.&publication_year=2017&journal=Transfus.+Med.+Hemother.&volume=44&pages=320%E2%80%93326&doi=10.1159/000479240&pmid=29070977)\] \[[CrossRef](https://dx.doi.org/10.1159/000479240)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29070977)\]

145.Bloom, J.W.; Madanat, M.S.; Marriott, D.; Wong, T.; Chan, S.Y. Intrachain disulfide bond in the core hinge region of human IgG4. *Protein Sci.* **1997**, *6*, 407–415. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Intrachain+disulfide+bond+in+the+core+hinge+region+of+human+IgG4&author=Bloom,+J.W.&author=Madanat,+M.S.&author=Marriott,+D.&author=Wong,+T.&author=Chan,+S.Y.&publication_year=1997&journal=Protein+Sci.&volume=6&pages=407%E2%80%93415&doi=10.1002/pro.5560060217&pmid=9041643)\] \[[CrossRef](https://dx.doi.org/10.1002/pro.5560060217)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9041643)\]

146.Angal, S.; King, D.; Bodmer, M.; Turner, A.; Lawson, A.; Roberts, G.; Pedley, B.; Adair, J. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. *Mol. Immunol.* **1993**, *30*, 105–108. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=A+single+amino+acid+substitution+abolishes+the+heterogeneity+of+chimeric+mouse/human+%28IgG4%29+antibody&author=Angal,+S.&author=King,+D.&author=Bodmer,+M.&author=Turner,+A.&author=Lawson,+A.&author=Roberts,+G.&author=Pedley,+B.&author=Adair,+J.&publication_year=1993&journal=Mol.+Immunol.&volume=30&pages=105%E2%80%93108&doi=10.1016/0161-5890%2893%2990432-B "https://scholar.google.com/scholar_lookup?title=A+single+amino+acid+substitution+abolishes+the+heterogeneity+of+chimeric+mouse/human+(IgG4)+antibody&author=Angal,+S.&author=King,+D.&author=Bodmer,+M.&author=Turner,+A.&author=Lawson,+A.&author=Roberts,+G.&author=Pedley,+B.&author=Adair,+J.&publication_year=1993&journal=Mol.+Immunol.&volume=30&pages=105%E2%80%93108&doi=10.1016/0161-5890(93)90432-B")\] \[[CrossRef](https://dx.doi.org/10.1016/0161-5890%2893%2990432-B "https://dx.doi.org/10.1016/0161-5890(93)90432-B")\]

147.Arlauckas, S.P.; Garris, C.S.; Kohler, R.H.; Kitaoka, M.; Cuccarese, M.F.; Yang, K.S.; Miller, M.A.; Carlson, J.C.; Freeman, G.J.; Anthony, R.M.; et al. In Vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy. *Sci. Transl. Med.* **2017**, *9*, eaal3604. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=In+Vivo+imaging+reveals+a+tumor-associated+macrophage%E2%80%93mediated+resistance+pathway+in+anti%E2%80%93PD-1+therapy&author=Arlauckas,+S.P.&author=Garris,+C.S.&author=Kohler,+R.H.&author=Kitaoka,+M.&author=Cuccarese,+M.F.&author=Yang,+K.S.&author=Miller,+M.A.&author=Carlson,+J.C.&author=Freeman,+G.J.&author=Anthony,+R.M.&publication_year=2017&journal=Sci.+Transl.+Med.&volume=9&pages=eaal3604&doi=10.1126/scitranslmed.aal3604)\] \[[CrossRef](https://dx.doi.org/10.1126/scitranslmed.aal3604)\]

148.Darvin, P.; Toor, S.M.; Sasidharan Nair, V.; Elkord, E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. *Exp. Mol. Med.* **2018**, *50*, 1–11. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Immune+checkpoint+inhibitors:+Recent+progress+and+potential+biomarkers&author=Darvin,+P.&author=Toor,+S.M.&author=Sasidharan+Nair,+V.&author=Elkord,+E.&publication_year=2018&journal=Exp.+Mol.+Med.&volume=50&pages=1%E2%80%9311&doi=10.1038/s12276-018-0191-1)\] \[[CrossRef](https://dx.doi.org/10.1038/s12276-018-0191-1)\]

149.Silva, J.-P.; Vetterlein, O.; Jose, J.; Peters, S.; Kirby, H. The S228P mutation prevents In Vivo and In Vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. *J. Biol. Chem.* **2015**, *290*, 5462–5469. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+S228P+mutation+prevents+In+Vivo+and+In+Vitro+IgG4+Fab-arm+exchange+as+demonstrated+using+a+combination+of+novel+quantitative+immunoassays+and+physiological+matrix+preparation&author=Silva,+J.-P.&author=Vetterlein,+O.&author=Jose,+J.&author=Peters,+S.&author=Kirby,+H.&publication_year=2015&journal=J.+Biol.+Chem.&volume=290&pages=5462%E2%80%935469&doi=10.1074/jbc.M114.600973)\] \[[CrossRef](https://dx.doi.org/10.1074/jbc.M114.600973)\]

150.Zhang, T.; Song, X.; Xu, L.; Ma, J.; Zhang, Y.; Gong, W.; Zhang, Y.; Zhou, X.; Wang, Z.; Wang, Y.; et al. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. *Cancer Immunol. Immunother.* **2018**, *67*, 1079–1090. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+binding+of+an+anti-PD-1+antibody+to+Fc%CE%B3R%CE%99+has+a+profound+impact+on+its+biological+functions&author=Zhang,+T.&author=Song,+X.&author=Xu,+L.&author=Ma,+J.&author=Zhang,+Y.&author=Gong,+W.&author=Zhang,+Y.&author=Zhou,+X.&author=Wang,+Z.&author=Wang,+Y.&publication_year=2018&journal=Cancer+Immunol.+Immunother.&volume=67&pages=1079%E2%80%931090&doi=10.1007/s00262-018-2160-x&pmid=29687231)\] \[[CrossRef](https://dx.doi.org/10.1007/s00262-018-2160-x)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29687231)\]

151.Beigene. Available online: https://www.globenewswire.com/news-release/2019/06/14/1868811/0/en/BeiGene-Announces-Updated-Results-from-a-Pivotal-Phase-2-Study-of-Tislelizumab-in-Chinese-Patients-with-Relapsed-or-Refractory-Classical-Hodgkin-Lymphoma-at-the-24th-Congress-of-th.html (accessed on 25 August 2020).

152.Zinzani, P.L.; Lee, H.J.; Armand, P.; Johnson, N.; Brice, P.; Radford, J.; Ribrag, V.; Molin, D.; Vassilakopoulos, T.P.; Tomita, A.; et al. Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma. *Blood* **2019**, *134* (Suppl. S1), 240. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Three-Year+Follow-up+of+Keynote-087:+Pembrolizumab+Monotherapy+in+Relapsed/Refractory+Classic+Hodgkin+Lymphoma&author=Zinzani,+P.L.&author=Lee,+H.J.&author=Armand,+P.&author=Johnson,+N.&author=Brice,+P.&author=Radford,+J.&author=Ribrag,+V.&author=Molin,+D.&author=Vassilakopoulos,+T.P.&author=Tomita,+A.&publication_year=2019&journal=Blood&volume=134&pages=240&doi=10.1182/blood-2019-127280)\] \[[CrossRef](https://dx.doi.org/10.1182/blood-2019-127280)\]

153.Beigene. BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. Available online: http://ir.beigene.com/news-releases/news-release-details/beigene-presents-phase-3-data-tislelizumab-combined-chemotherapy?loc=US (accessed on 25 August 2020).

154.Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Şenler, F.Ç.; Csőszi, T.; Fülöp, A.; et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* **2018**, *379*, 2040–2051. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+Chemotherapy+for+Squamous+Non%E2%80%93Small-Cell+Lung+Cancer&author=Paz-Ares,+L.&author=Luft,+A.&author=Vicente,+D.&author=Tafreshi,+A.&author=G%C3%BCm%C3%BC%C5%9F,+M.&author=Mazi%C3%A8res,+J.&author=Hermes,+B.&author=%C5%9Eenler,+F.%C3%87.&author=Cs%C5%91szi,+T.&author=F%C3%BCl%C3%B6p,+A.&publication_year=2018&journal=N.+Engl.+J.+Med.&volume=379&pages=2040%E2%80%932051&doi=10.1056/NEJMoa1810865)\] \[[CrossRef](https://dx.doi.org/10.1056/NEJMoa1810865)\]

155.Paz-Ares, L.; Ciuleanu, T.E.; Yu, X. First-Line Nivolumab Plus Chemotherapy Did Not Meet the Primary Endpoint of Overall Survival in Non-Squamous Nsclc 2019. Available online: https://www.esmo.org/meetings/past-meetings/esmo-immuno-oncology-congress-2019/congress-coverage/news-press-releases/first-line-nivolumab-plus-chemotherapy-did-not-meet-the-primary-endpoint-of-overall-survival-in-non-squamous-nsclc (accessed on 25 August 2020).

156.Akinleye, A.; Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. *J. Hematol. Oncol.* **2019**, *12*, 92\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Immune+checkpoint+inhibitors+of+PD-L1+as+cancer+therapeutics&author=Akinleye,+A.&author=Rasool,+Z.&publication_year=2019&journal=J.+Hematol.+Oncol.&volume=12&pages=92&doi=10.1186/s13045-019-0779-5)\] \[[CrossRef](https://dx.doi.org/10.1186/s13045-019-0779-5)\]

157.Inman, B.A.; Longo, T.A.; Ramalingam, S.; Harrison, M.R. Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer. *Clin. Cancer Res.* **2017**, *23*, 1886\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Atezolizumab:+A+PD-L1%E2%80%93Blocking+Antibody+for+Bladder+Cancer&author=Inman,+B.A.&author=Longo,+T.A.&author=Ramalingam,+S.&author=Harrison,+M.R.&publication_year=2017&journal=Clin.+Cancer+Res.&volume=23&pages=1886&doi=10.1158/1078-0432.CCR-16-1417)\] \[[CrossRef](https://dx.doi.org/10.1158/1078-0432.CCR-16-1417)\]

158.Stewart, R.; Morrow, M.; Hammond, S.A.; Mulgrew, K.; Marcus, D.; Poon, E.; Watkins, A.; Mullins, S.; Chodorge, M.; Andrews, J.; et al. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody. *Cancer Immunol. Res.* **2015**, *3*, 1052\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Identification+and+Characterization+of+MEDI4736,+an+Antagonistic+Anti%E2%80%93PD-L1+Monoclonal+Antibody&author=Stewart,+R.&author=Morrow,+M.&author=Hammond,+S.A.&author=Mulgrew,+K.&author=Marcus,+D.&author=Poon,+E.&author=Watkins,+A.&author=Mullins,+S.&author=Chodorge,+M.&author=Andrews,+J.&publication_year=2015&journal=Cancer+Immunol.+Res.&volume=3&pages=1052&doi=10.1158/2326-6066.CIR-14-0191&pmid=25943534)\] \[[CrossRef](https://dx.doi.org/10.1158/2326-6066.CIR-14-0191)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25943534)\]

159.Paz-Ares, L.; Dvorkin, M.; Chen, Y.; Reinmuth, N.; Hotta, K.; Trukhin, D.; Statsenko, G.; Hochmair, M.J.; Özgüroğlu, M.; Ji, J.H.; et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. *Lancet* **2019**, *394*, 1929–1939. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Durvalumab+plus+platinum-etoposide+versus+platinum-etoposide+in+first-line+treatment+of+extensive-stage+small-cell+lung+cancer+%28CASPIAN%29:+A+randomised,+controlled,+open-label,+phase+3+trial&author=Paz-Ares,+L.&author=Dvorkin,+M.&author=Chen,+Y.&author=Reinmuth,+N.&author=Hotta,+K.&author=Trukhin,+D.&author=Statsenko,+G.&author=Hochmair,+M.J.&author=%C3%96zg%C3%BCro%C4%9Flu,+M.&author=Ji,+J.H.&publication_year=2019&journal=Lancet&volume=394&pages=1929%E2%80%931939&doi=10.1016/S0140-6736%2819%2932222-6 "https://scholar.google.com/scholar_lookup?title=Durvalumab+plus+platinum-etoposide+versus+platinum-etoposide+in+first-line+treatment+of+extensive-stage+small-cell+lung+cancer+(CASPIAN):+A+randomised,+controlled,+open-label,+phase+3+trial&author=Paz-Ares,+L.&author=Dvorkin,+M.&author=Chen,+Y.&author=Reinmuth,+N.&author=Hotta,+K.&author=Trukhin,+D.&author=Statsenko,+G.&author=Hochmair,+M.J.&author=%C3%96zg%C3%BCro%C4%9Flu,+M.&author=Ji,+J.H.&publication_year=2019&journal=Lancet&volume=394&pages=1929%E2%80%931939&doi=10.1016/S0140-6736(19)32222-6")\] \[[CrossRef](https://dx.doi.org/10.1016/S0140-6736%2819%2932222-6 "https://dx.doi.org/10.1016/S0140-6736(19)32222-6")\]

160.Horn, L.; Mansfield, A.S.; Szczęsna, A.; Havel, L.; Krzakowski, M.; Hochmair, M.J.; Huemer, F.; Losonczy, G.; Johnson, M.L.; Nishio, M.; et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N. Engl. J. Med.* **2018**, *379*, 2220–2229. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=First-Line+Atezolizumab+plus+Chemotherapy+in+Extensive-Stage+Small-Cell+Lung+Cancer&author=Horn,+L.&author=Mansfield,+A.S.&author=Szcz%C4%99sna,+A.&author=Havel,+L.&author=Krzakowski,+M.&author=Hochmair,+M.J.&author=Huemer,+F.&author=Losonczy,+G.&author=Johnson,+M.L.&author=Nishio,+M.&publication_year=2018&journal=N.+Engl.+J.+Med.&volume=379&pages=2220%E2%80%932229&doi=10.1056/NEJMoa1809064&pmid=30280641)\] \[[CrossRef](https://dx.doi.org/10.1056/NEJMoa1809064)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30280641)\]

161.Barlesi, F.; Vansteenkiste, J.; Spigel, D.; Ishii, H.; Garassino, M.; De Marinis, F.; Özgüroğlu, M.; Szczesna, A.; Polychronis, A.; Uslu, R.; et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): An open-label, randomised, phase 3 study. *Lancet Oncol.* **2018**, *19*, 1468–1479. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Avelumab+versus+docetaxel+in+patients+with+platinum-treated+advanced+non-small-cell+lung+cancer+%28JAVELIN+Lung+200%29:+An+open-label,+randomised,+phase+3+study&author=Barlesi,+F.&author=Vansteenkiste,+J.&author=Spigel,+D.&author=Ishii,+H.&author=Garassino,+M.&author=De+Marinis,+F.&author=%C3%96zg%C3%BCro%C4%9Flu,+M.&author=Szczesna,+A.&author=Polychronis,+A.&author=Uslu,+R.&publication_year=2018&journal=Lancet+Oncol.&volume=19&pages=1468%E2%80%931479&doi=10.1016/S1470-2045%2818%2930673-9 "https://scholar.google.com/scholar_lookup?title=Avelumab+versus+docetaxel+in+patients+with+platinum-treated+advanced+non-small-cell+lung+cancer+(JAVELIN+Lung+200):+An+open-label,+randomised,+phase+3+study&author=Barlesi,+F.&author=Vansteenkiste,+J.&author=Spigel,+D.&author=Ishii,+H.&author=Garassino,+M.&author=De+Marinis,+F.&author=%C3%96zg%C3%BCro%C4%9Flu,+M.&author=Szczesna,+A.&author=Polychronis,+A.&author=Uslu,+R.&publication_year=2018&journal=Lancet+Oncol.&volume=19&pages=1468%E2%80%931479&doi=10.1016/S1470-2045(18)30673-9")\] \[[CrossRef](https://dx.doi.org/10.1016/S1470-2045%2818%2930673-9 "https://dx.doi.org/10.1016/S1470-2045(18)30673-9")\]

162.Dall’Acqua, W.F.; Woods, R.M.; Ward, E.S.; Palaszynski, S.R.; Patel, N.K.; Brewah, Y.A.; Wu, H.; Kiener, P.A.; Langermann, S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences. *J. Immunol.* **2002**, *169*, 5171–5180. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Increasing+the+affinity+of+a+human+IgG1+for+the+neonatal+Fc+receptor:+Biological+consequences&author=Dall%E2%80%99Acqua,+W.F.&author=Woods,+R.M.&author=Ward,+E.S.&author=Palaszynski,+S.R.&author=Patel,+N.K.&author=Brewah,+Y.A.&author=Wu,+H.&author=Kiener,+P.A.&author=Langermann,+S.&publication_year=2002&journal=J.+Immunol.&volume=169&pages=5171%E2%80%935180)\]

163.Dall’Acqua, W.F.; Kiener, P.A.; Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). *J. Biol. Chem.* **2006**, *281*, 23514–23524. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Properties+of+human+IgG1s+engineered+for+enhanced+binding+to+the+neonatal+Fc+receptor+%28FcRn%29&author=Dall%E2%80%99Acqua,+W.F.&author=Kiener,+P.A.&author=Wu,+H.&publication_year=2006&journal=J.+Biol.+Chem.&volume=281&pages=23514%E2%80%9323524&doi=10.1074/jbc.M604292200&pmid=16793771 "https://scholar.google.com/scholar_lookup?title=Properties+of+human+IgG1s+engineered+for+enhanced+binding+to+the+neonatal+Fc+receptor+(FcRn)&author=Dall%E2%80%99Acqua,+W.F.&author=Kiener,+P.A.&author=Wu,+H.&publication_year=2006&journal=J.+Biol.+Chem.&volume=281&pages=23514%E2%80%9323524&doi=10.1074/jbc.M604292200&pmid=16793771")\] \[[CrossRef](https://dx.doi.org/10.1074/jbc.M604292200)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16793771)\]

164.Hinton, P.R.; Johlfs, M.G.; Xiong, J.M.; Hanestad, K.; Ong, K.C.; Bullock, C.; Keller, S.; Tang, M.T.; Tso, J.Y.; Vasquez, M.; et al. Engineered human IgG antibodies with longer serum half-lives in primates. *J. Biol. Chem.* **2004**, *279*, 6213–6216. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+human+IgG+antibodies+with+longer+serum+half-lives+in+primates&author=Hinton,+P.R.&author=Johlfs,+M.G.&author=Xiong,+J.M.&author=Hanestad,+K.&author=Ong,+K.C.&author=Bullock,+C.&author=Keller,+S.&author=Tang,+M.T.&author=Tso,+J.Y.&author=Vasquez,+M.&publication_year=2004&journal=J.+Biol.+Chem.&volume=279&pages=6213%E2%80%936216&doi=10.1074/jbc.C300470200&pmid=14699147)\] \[[CrossRef](https://dx.doi.org/10.1074/jbc.C300470200)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/14699147)\]

165.Vaccaro, C.; Zhou, J.; Ober, R.J.; Ward, E.S. Engineering the Fc region of immunoglobulin G to modulate In Vivo antibody levels. *Nat. Biotechnol.* **2005**, *23*, 1283–1288. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineering+the+Fc+region+of+immunoglobulin+G+to+modulate+In+Vivo+antibody+levels&author=Vaccaro,+C.&author=Zhou,+J.&author=Ober,+R.J.&author=Ward,+E.S.&publication_year=2005&journal=Nat.+Biotechnol.&volume=23&pages=1283%E2%80%931288&doi=10.1038/nbt1143&pmid=16186811)\] \[[CrossRef](https://dx.doi.org/10.1038/nbt1143)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16186811)\]

166.Ward, E.S. Iggl Antibodies with Mutated Fc Portion for Increased Binding to Fcrn Receptor and Uses Thereof. U.S. Patent Application No. WO/2006/130,834, 12 July 2006. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Iggl+Antibodies+with+Mutated+Fc+Portion+for+Increased+Binding+to+Fcrn+Receptor+and+Uses+Thereof&author=Ward,+E.S.&publication_year=2006)\]

167.Vaccaro, C.; Bawdon, R.; Wanjie, S.; Ober, R.J.; Ward, E.S. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 18709–18714. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Divergent+activities+of+an+engineered+antibody+in+murine+and+human+systems+have+implications+for+therapeutic+antibodies&author=Vaccaro,+C.&author=Bawdon,+R.&author=Wanjie,+S.&author=Ober,+R.J.&author=Ward,+E.S.&publication_year=2006&journal=Proc.+Natl.+Acad.+Sci.+USA&volume=103&pages=18709%E2%80%9318714&doi=10.1073/pnas.0606304103&pmid=17116867)\] \[[CrossRef](https://dx.doi.org/10.1073/pnas.0606304103)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17116867)\]

168.Zalevsky, J.; Chamberlain, A.K.; Horton, H.M.; Karki, S.; Leung, I.W.; Sproule, T.J.; Lazar, G.A.; Roopenian, D.C.; Desjarlais, J.R. Enhanced antibody half-life improves In Vivo activity. *Nat. Biotechnol.* **2010**, *28*, 157–159. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Enhanced+antibody+half-life+improves+In+Vivo+activity&author=Zalevsky,+J.&author=Chamberlain,+A.K.&author=Horton,+H.M.&author=Karki,+S.&author=Leung,+I.W.&author=Sproule,+T.J.&author=Lazar,+G.A.&author=Roopenian,+D.C.&author=Desjarlais,+J.R.&publication_year=2010&journal=Nat.+Biotechnol.&volume=28&pages=157%E2%80%93159&doi=10.1038/nbt.1601&pmid=20081867)\] \[[CrossRef](https://dx.doi.org/10.1038/nbt.1601)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20081867)\]

169.Datta-Mannan, A.; Chow, C.-K.; Dickinson, C.; Driver, D.; Lu, J.; Witcher, D.R.; Wroblewski, V.J. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved In Vitro FcRn binding properties in cynomolgus monkeys. *Drug Metab. Dispos.* **2012**, *40*, 1545–1555. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=FcRn+affinity-pharmacokinetic+relationship+of+five+human+IgG4+antibodies+engineered+for+improved+In+Vitro+FcRn+binding+properties+in+cynomolgus+monkeys&author=Datta-Mannan,+A.&author=Chow,+C.-K.&author=Dickinson,+C.&author=Driver,+D.&author=Lu,+J.&author=Witcher,+D.R.&author=Wroblewski,+V.J.&publication_year=2012&journal=Drug+Metab.+Dispos.&volume=40&pages=1545%E2%80%931555&doi=10.1124/dmd.112.045864)\] \[[CrossRef](https://dx.doi.org/10.1124/dmd.112.045864)\]

170.Igawa, T.; Maeda, A.; Haraya, K.; Tachibana, T.; Iwayanagi, Y.; Mimoto, F.; Higuchi, Y.; Ishii, S.; Tamba, S.; Hironiwa, N.; et al. Engineered monoclonal antibody with novel antigen-sweeping activity In Vivo. *PLoS ONE* **2013**, *8*, e63236. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Engineered+monoclonal+antibody+with+novel+antigen-sweeping+activity+In+Vivo&author=Igawa,+T.&author=Maeda,+A.&author=Haraya,+K.&author=Tachibana,+T.&author=Iwayanagi,+Y.&author=Mimoto,+F.&author=Higuchi,+Y.&author=Ishii,+S.&author=Tamba,+S.&author=Hironiwa,+N.&publication_year=2013&journal=PLoS+ONE&volume=8&pages=e63236&doi=10.1371/journal.pone.0063236)\] \[[CrossRef](https://dx.doi.org/10.1371/journal.pone.0063236)\]

171.Booth, B.J.; Ramakrishnan, B.; Narayan, K.; Wollacott, A.M.; Babcock, G.J.; Shriver, Z.; Viswanathan, K. Extending human IgG half-life using structure-guided design. *MAbs* **2018**, *10*, 1098–1110. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Extending+human+IgG+half-life+using+structure-guided+design&author=Booth,+B.J.&author=Ramakrishnan,+B.&author=Narayan,+K.&author=Wollacott,+A.M.&author=Babcock,+G.J.&author=Shriver,+Z.&author=Viswanathan,+K.&publication_year=2018&journal=MAbs&volume=10&pages=1098%E2%80%931110&doi=10.1080/19420862.2018.1490119)\] \[[CrossRef](https://dx.doi.org/10.1080/19420862.2018.1490119)\]

172.Lee, C.-H.; Kang, T.H.; Godon, O.; Watanabe, M.; Delidakis, G.; Gillis, C.M.; Sterlin, D.; Hardy, D.; Cogné, M.; Macdonald, L.E.; et al. Publisher Correction: An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence. *Nat. Commun.* **2019**, *10*, 5461\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Publisher+Correction:+An+engineered+human+Fc+domain+that+behaves+like+a+pH-toggle+switch+for+ultra-long+circulation+persistence&author=Lee,+C.-H.&author=Kang,+T.H.&author=Godon,+O.&author=Watanabe,+M.&author=Delidakis,+G.&author=Gillis,+C.M.&author=Sterlin,+D.&author=Hardy,+D.&author=Cogn%C3%A9,+M.&author=Macdonald,+L.E.&publication_year=2019&journal=Nat.+Commun.&volume=10&pages=5461&doi=10.1038/s41467-019-13458-x)\] \[[CrossRef](https://dx.doi.org/10.1038/s41467-019-13458-x)\]

173.Salles, G.; Seymour, J.F.; Offner, F.; López-Guillermo, A.; Belada, D.; Xerri, L.; Feugier, P.; Bouabdallah, R.; Catalano, J.V.; Brice, P.; et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. *Lancet* **2011**, *377*, 42–51. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Rituximab+maintenance+for+2+years+in+patients+with+high+tumour+burden+follicular+lymphoma+responding+to+rituximab+plus+chemotherapy+%28PRIMA%29:+A+phase+3,+randomised+controlled+trial&author=Salles,+G.&author=Seymour,+J.F.&author=Offner,+F.&author=L%C3%B3pez-Guillermo,+A.&author=Belada,+D.&author=Xerri,+L.&author=Feugier,+P.&author=Bouabdallah,+R.&author=Catalano,+J.V.&author=Brice,+P.&publication_year=2011&journal=Lancet&volume=377&pages=42%E2%80%9351&doi=10.1016/S0140-6736%2810%2962175-7 "https://scholar.google.com/scholar_lookup?title=Rituximab+maintenance+for+2+years+in+patients+with+high+tumour+burden+follicular+lymphoma+responding+to+rituximab+plus+chemotherapy+(PRIMA):+A+phase+3,+randomised+controlled+trial&author=Salles,+G.&author=Seymour,+J.F.&author=Offner,+F.&author=L%C3%B3pez-Guillermo,+A.&author=Belada,+D.&author=Xerri,+L.&author=Feugier,+P.&author=Bouabdallah,+R.&author=Catalano,+J.V.&author=Brice,+P.&publication_year=2011&journal=Lancet&volume=377&pages=42%E2%80%9351&doi=10.1016/S0140-6736(10)62175-7")\] \[[CrossRef](https://dx.doi.org/10.1016/S0140-6736%2810%2962175-7 "https://dx.doi.org/10.1016/S0140-6736(10)62175-7")\]

174.Roschewski, M.; Hill, B.T. One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma? *Am. Soc. Clin. Oncol. Educ. Book* **2019**, *39*, 467–476. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=One+Size+Does+Not+Fit+All:+Who+Benefits+From+Maintenance+After+Frontline+Therapy+for+Follicular+Lymphoma?&author=Roschewski,+M.&author=Hill,+B.T.&publication_year=2019&journal=Am.+Soc.+Clin.+Oncol.+Educ.+Book&volume=39&pages=467%E2%80%93476&doi=10.1200/EDBK_239065&pmid=31099693)\] \[[CrossRef](https://dx.doi.org/10.1200/EDBK_239065)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31099693)\]

175.Attarwala, H. TGN1412: From Discovery to Disaster. *J. Young Pharm.* **2010**, *2*, 332–336. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=TGN1412:+From+Discovery+to+Disaster&author=Attarwala,+H.&publication_year=2010&journal=J.+Young+Pharm.&volume=2&pages=332%E2%80%93336&doi=10.4103/0975-1483.66810&pmid=21042496)\] \[[CrossRef](https://dx.doi.org/10.4103/0975-1483.66810)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21042496)\]

176.Centanni, M.; Moes, D.; Troconiz, I.F.; Ciccolini, J.; van Hasselt, J.G.C. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. *Clin. Pharm.* **2019**, *58*, 835–857. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Clinical+Pharmacokinetics+and+Pharmacodynamics+of+Immune+Checkpoint+Inhibitors&author=Centanni,+M.&author=Moes,+D.&author=Troconiz,+I.F.&author=Ciccolini,+J.&author=van+Hasselt,+J.G.C.&publication_year=2019&journal=Clin.+Pharm.&volume=58&pages=835%E2%80%93857&doi=10.1007/s40262-019-00748-2&pmid=30815848)\] \[[CrossRef](https://dx.doi.org/10.1007/s40262-019-00748-2)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30815848)\]

177.Petkova, S.B.; Akilesh, S.; Sproule, T.J.; Christianson, G.J.; Al Khabbaz, H.; Brown, A.C.; Presta, L.G.; Meng, Y.G.; Roopenian, D.C. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease. *Int. Immunol.* **2006**, *18*, 1759–1769. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Enhanced+half-life+of+genetically+engineered+human+IgG1+antibodies+in+a+humanized+FcRn+mouse+model:+Potential+application+in+humorally+mediated+autoimmune+disease&author=Petkova,+S.B.&author=Akilesh,+S.&author=Sproule,+T.J.&author=Christianson,+G.J.&author=Al+Khabbaz,+H.&author=Brown,+A.C.&author=Presta,+L.G.&author=Meng,+Y.G.&author=Roopenian,+D.C.&publication_year=2006&journal=Int.+Immunol.&volume=18&pages=1759%E2%80%931769&doi=10.1093/intimm/dxl110)\] \[[CrossRef](https://dx.doi.org/10.1093/intimm/dxl110)\]

178.Martin, W.L.; West, A.P., Jr.; Gan, L.; Bjorkman, P.J. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: Mechanism of pH-dependent binding. *Mol. Cell* **2001**, *7*, 867–877. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Crystal+structure+at+2.8+A+of+an+FcRn/heterodimeric+Fc+complex:+Mechanism+of+pH-dependent+binding&author=Martin,+W.L.&author=West,+A.P.,+Jr.&author=Gan,+L.&author=Bjorkman,+P.J.&publication_year=2001&journal=Mol.+Cell&volume=7&pages=867%E2%80%93877&doi=10.1016/S1097-2765%2801%2900230-1 "https://scholar.google.com/scholar_lookup?title=Crystal+structure+at+2.8+A+of+an+FcRn/heterodimeric+Fc+complex:+Mechanism+of+pH-dependent+binding&author=Martin,+W.L.&author=West,+A.P.,+Jr.&author=Gan,+L.&author=Bjorkman,+P.J.&publication_year=2001&journal=Mol.+Cell&volume=7&pages=867%E2%80%93877&doi=10.1016/S1097-2765(01)00230-1")\] \[[CrossRef](https://dx.doi.org/10.1016/S1097-2765%2801%2900230-1 "https://dx.doi.org/10.1016/S1097-2765(01)00230-1")\]

179.Oganesyan, V.; Damschroder, M.M.; Cook, K.E.; Li, Q.; Gao, C.; Wu, H.; Dall’Acqua, W.F. Structural insights into neonatal Fc receptor-based recycling mechanisms. *J. Biol. Chem.* **2014**, *289*, 7812–7824. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Structural+insights+into+neonatal+Fc+receptor-based+recycling+mechanisms&author=Oganesyan,+V.&author=Damschroder,+M.M.&author=Cook,+K.E.&author=Li,+Q.&author=Gao,+C.&author=Wu,+H.&author=Dall%E2%80%99Acqua,+W.F.&publication_year=2014&journal=J.+Biol.+Chem.&volume=289&pages=7812%E2%80%937824&doi=10.1074/jbc.M113.537563)\] \[[CrossRef](https://dx.doi.org/10.1074/jbc.M113.537563)\]

180.Qiu, H.; Mackness, B. Fc Variants with Enhanced Binding to Fcrn and Prolonged Half-Life. U.S. Patent Patent Application No. 20190263934, 1 August 2019. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Fc+Variants+with+Enhanced+Binding+to+Fcrn+and+Prolonged+Half-Life&author=Qiu,+H.&author=Mackness,+B.&publication_year=2019)\]

181.Cooper, P.R.; Kliwinski, C.M.; Perkinson, R.A.; Ragwan, E.; Mabus, J.R.; Powers, G.D.; Dorai, H.; Giles-Komar, J.; Hornby, P.J. The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups. *Front. Pharmacol.* **2014**, *5*, 225\. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=The+contribution+of+cell+surface+FcRn+in+monoclonal+antibody+serum+uptake+from+the+intestine+in+suckling+rat+pups&author=Cooper,+P.R.&author=Kliwinski,+C.M.&author=Perkinson,+R.A.&author=Ragwan,+E.&author=Mabus,+J.R.&author=Powers,+G.D.&author=Dorai,+H.&author=Giles-Komar,+J.&author=Hornby,+P.J.&publication_year=2014&journal=Front.+Pharmacol.&volume=5&pages=225&doi=10.3389/fphar.2014.00225)\] \[[CrossRef](https://dx.doi.org/10.3389/fphar.2014.00225)\]

182.Davda, J.P.; Hansen, R.J. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. *MAbs* **2010**, *2*, 576–588. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Properties+of+a+general+PK/PD+model+of+antibody-ligand+interactions+for+therapeutic+antibodies+that+bind+to+soluble+endogenous+targets&author=Davda,+J.P.&author=Hansen,+R.J.&publication_year=2010&journal=MAbs&volume=2&pages=576%E2%80%93588&doi=10.4161/mabs.2.5.12833)\] \[[CrossRef](https://dx.doi.org/10.4161/mabs.2.5.12833)\]

183.Haringman, J.J.; Gerlag, D.M.; Smeets, T.J.M.; Baeten, D.; Bosch, F.V.D.; Bresnihan, B.; Breedveld, F.C.; Dinant, H.J.; Legay, F.; Gram, H.; et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. *Arthritis Rheum.* **2006**, *54*, 2387–2392. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=A+randomized+controlled+trial+with+an+anti-CCL2+%28anti-monocyte+chemotactic+protein+1%29+monoclonal+antibody+in+patients+with+rheumatoid+arthritis&author=Haringman,+J.J.&author=Gerlag,+D.M.&author=Smeets,+T.J.M.&author=Baeten,+D.&author=Bosch,+F.V.D.&author=Bresnihan,+B.&author=Breedveld,+F.C.&author=Dinant,+H.J.&author=Legay,+F.&author=Gram,+H.&publication_year=2006&journal=Arthritis+Rheum.&volume=54&pages=2387%E2%80%932392&doi=10.1002/art.21975 "https://scholar.google.com/scholar_lookup?title=A+randomized+controlled+trial+with+an+anti-CCL2+(anti-monocyte+chemotactic+protein+1)+monoclonal+antibody+in+patients+with+rheumatoid+arthritis&author=Haringman,+J.J.&author=Gerlag,+D.M.&author=Smeets,+T.J.M.&author=Baeten,+D.&author=Bosch,+F.V.D.&author=Bresnihan,+B.&author=Breedveld,+F.C.&author=Dinant,+H.J.&author=Legay,+F.&author=Gram,+H.&publication_year=2006&journal=Arthritis+Rheum.&volume=54&pages=2387%E2%80%932392&doi=10.1002/art.21975")\] \[[CrossRef](https://dx.doi.org/10.1002/art.21975)\]

184.Igawa, T.; Haraya, K.; Hattori, K. Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. *Immunol. Rev.* **2016**, *270*, 132–151. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Sweeping+antibody+as+a+novel+therapeutic+antibody+modality+capable+of+eliminating+soluble+antigens+from+circulation&author=Igawa,+T.&author=Haraya,+K.&author=Hattori,+K.&publication_year=2016&journal=Immunol.+Rev.&volume=270&pages=132%E2%80%93151&doi=10.1111/imr.12392)\] \[[CrossRef](https://dx.doi.org/10.1111/imr.12392)\]

185.Berraondo, P.; Sanmamed, M.F.; Ochoa, M.C.; Etxeberria, I.; Aznar, M.A.; Pérez-Gracia, J.L.; Rodríguez-Ruiz, M.E.; Ponz-Sarvise, M.; Castañón, E.; Melero, I. Cytokines in clinical cancer immunotherapy. *Br. J. Cancer* **2019**, *120*, 6–15. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Cytokines+in+clinical+cancer+immunotherapy&author=Berraondo,+P.&author=Sanmamed,+M.F.&author=Ochoa,+M.C.&author=Etxeberria,+I.&author=Aznar,+M.A.&author=P%C3%A9rez-Gracia,+J.L.&author=Rodr%C3%ADguez-Ruiz,+M.E.&author=Ponz-Sarvise,+M.&author=Casta%C3%B1%C3%B3n,+E.&author=Melero,+I.&publication_year=2019&journal=Br.+J.+Cancer&volume=120&pages=6%E2%80%9315&doi=10.1038/s41416-018-0328-y&pmid=30413827)\] \[[CrossRef](https://dx.doi.org/10.1038/s41416-018-0328-y)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30413827)\]

186.Sheridan, D.; Yu, Z.-X.; Zhang, Y.; Patel, R.; Sun, F.; Lasaro, M.A.; Bouchard, K.; Andrien, B.; Marozsan, A.; Wang, Y.; et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. *PLoS ONE* **2018**, *13*, e0195909. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Design+and+preclinical+characterization+of+ALXN1210:+A+novel+anti-C5+antibody+with+extended+duration+of+action&author=Sheridan,+D.&author=Yu,+Z.-X.&author=Zhang,+Y.&author=Patel,+R.&author=Sun,+F.&author=Lasaro,+M.A.&author=Bouchard,+K.&author=Andrien,+B.&author=Marozsan,+A.&author=Wang,+Y.&publication_year=2018&journal=PLoS+ONE&volume=13&pages=e0195909&doi=10.1371/journal.pone.0195909&pmid=29649283)\] \[[CrossRef](https://dx.doi.org/10.1371/journal.pone.0195909)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29649283)\]

187.Kulasekararaj, A.G.; Hill, A.; Rottinghaus, S.T.; Langemeijer, S.; Wells, R.; Gonzalez-Fernandez, F.A.; Gaya, A.; Lee, J.W.; Gutierrez, E.O.; Piatek, C.I.; et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: The 302 study. *Blood* **2019**, *133*, 540–549. \[[Google Scholar](https://scholar.google.com/scholar_lookup?title=Ravulizumab+%28ALXN1210%29+vs+eculizumab+in+C5-inhibitor-experienced+adult+patients+with+PNH:+The+302+study&author=Kulasekararaj,+A.G.&author=Hill,+A.&author=Rottinghaus,+S.T.&author=Langemeijer,+S.&author=Wells,+R.&author=Gonzalez-Fernandez,+F.A.&author=Gaya,+A.&author=Lee,+J.W.&author=Gutierrez,+E.O.&author=Piatek,+C.I.&publication_year=2019&journal=Blood&volume=133&pages=540%E2%80%93549&doi=10.1182/blood-2018-09-876805&pmid=30510079 "https://scholar.google.com/scholar_lookup?title=Ravulizumab+(ALXN1210)+vs+eculizumab+in+C5-inhibitor-experienced+adult+patients+with+PNH:+The+302+study&author=Kulasekararaj,+A.G.&author=Hill,+A.&author=Rottinghaus,+S.T.&author=Langemeijer,+S.&author=Wells,+R.&author=Gonzalez-Fernandez,+F.A.&author=Gaya,+A.&author=Lee,+J.W.&author=Gutierrez,+E.O.&author=Piatek,+C.I.&publication_year=2019&journal=Blood&volume=133&pages=540%E2%80%93549&doi=10.1182/blood-2018-09-876805&pmid=30510079")\] \[[CrossRef](https://dx.doi.org/10.1182/blood-2018-09-876805)\] \[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30510079)\]

|     |     |
| --- | --- |
|     | **Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([http://creativecommons.org/licenses/by/4.0/）。](http://creativecommons.org/licenses/by/4.0/%EF%BC%89%E3%80%82)